var title_f38_29_39376="Pseudoxanthoma elasticum lip";
var content_f38_29_39376=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F70421&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F70421&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Pseudoxanthoma elasticum",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 293px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Yellow papules are present on the inner aspect of the lower lip. Infiltration of the buccal mucosa of the lip is the most common mucous membrane involvement in pseudoxanthoma elasticum.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Copyright &copy; Franziska Ringpfeil, MD, Dermatlas; file://www.dermatlas.org.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_29_39376=[""].join("\n");
var outline_f38_29_39376=null;
var title_f38_29_39377="Patient information: Placental abruption (The Basics)";
var content_f38_29_39377=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/83067\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?7/20/7495\">",
"         Pregnancy terms",
"        </a>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"mobipreview.htm?16/21/16723\">",
"         Patient information: C-section (cesarean delivery) (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?12/13/12499\">",
"         Patient information: Labor and delivery (childbirth) (The Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Placental abruption (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/placental-abruption-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H15588993\">",
"      <span class=\"h1\">",
"       What is placental abruption?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Placental abruption is an uncommon condition that causes bleeding during the last half of pregnancy. It can be dangerous for both the mother and her baby.",
"     </p>",
"     <p>",
"      The placenta is the organ that forms between the mother and her baby during pregnancy. It brings the baby nutrients and oxygen and carries away waste. Placental abruption happens when the placenta separates from the mother&rsquo;s uterus before delivery (",
"      <a class=\"graphic graphic_figure graphicRef82935 \" href=\"mobipreview.htm?7/20/7495\">",
"       figure 1",
"      </a>",
"      ).",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H15589008\">",
"      <span class=\"h1\">",
"       What causes placental abruption?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Doctors don&rsquo;t know why some women have a placental abruption. Women are more likely to have a placental abruption if they:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Smoke",
"       </li>",
"       <li>",
"        Use cocaine",
"       </li>",
"       <li>",
"        Have high blood pressure",
"       </li>",
"       <li>",
"        Have a car accident",
"       </li>",
"       <li>",
"        Fall on their belly or get hit hard in the belly",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H15589023\">",
"      <span class=\"h1\">",
"       What are the symptoms of placental abruption?",
"      </span>",
"      &nbsp;&mdash;&nbsp;The symptoms in the mother include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Bleeding from the vagina",
"       </li>",
"       <li>",
"        Belly pain",
"       </li>",
"       <li>",
"        Back pain",
"       </li>",
"       <li>",
"        Tightening of the uterus (called &ldquo;contractions&rdquo;) &nbsp;",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      In a woman having a placental abruption, the baby&rsquo;s heart rate might also not be normal.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H15589038\">",
"      <span class=\"h1\">",
"       Should I see a doctor or nurse?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Call your doctor or nurse right away if you bleed from your vagina or have belly pain when you are pregnant.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H15589053\">",
"      <span class=\"h1\">",
"       Are there tests for placental abruption?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. Most of the time, your doctor or midwife will be able to tell if you have it by asking about your symptoms and doing an exam.",
"     </p>",
"     <p>",
"      But you will likely need an ultrasound. An ultrasound is a test that uses sound waves to take pictures inside in the body. &nbsp;",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H15589070\">",
"      <span class=\"h1\">",
"       How is placental abruption treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;At the hospital, your doctor or nurse will:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Take some blood from your arm",
"       </li>",
"       <li>",
"        Check the baby&rsquo;s heart rate",
"       </li>",
"       <li>",
"        See if you are having contractions",
"       </li>",
"       <li>",
"        Put a small tube, called an &ldquo;IV,&rdquo; in a vein so you can get fluids and blood, if you need it. &nbsp;",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Depending on how much of the placenta is affected and how long you have been pregnant, your doctor or nurse might want to deliver the baby as soon as possible. You might deliver through the vagina, or the doctor might do surgery to get the baby out (called a &ldquo;c-section&rdquo; or &ldquo;cesarean delivery.&rdquo;)",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H15589085\">",
"      <span class=\"h1\">",
"       Can placental abruption be prevented?",
"      </span>",
"      &nbsp;&mdash;&nbsp;You can lower your chances of having placental abruption by:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Not smoking",
"       </li>",
"       <li>",
"        Not using illegal drugs such as cocaine",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H15589100\">",
"      <span class=\"h1\">",
"       What if I want to get pregnant again?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Women who have had a placental abruption have a higher-than-normal chance of having a placental abruption in future pregnancies.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H15589115\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?12/13/12499?source=see_link\">",
"       Patient information: Labor and delivery (childbirth) (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?16/21/16723?source=see_link\">",
"       Patient information: C-section (cesarean delivery) (The Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"mobipreview.htm?38/29/39377?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 83067 Version 1.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-118.97.94.19-A044F949FA-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_29_39377=[""].join("\n");
var outline_f38_29_39377=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15588993\">",
"      What is placental abruption?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15589008\">",
"      What causes placental abruption?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15589023\">",
"      What are the symptoms of placental abruption?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15589038\">",
"      Should I see a doctor or nurse?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15589053\">",
"      Are there tests for placental abruption?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15589070\">",
"      How is placental abruption treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15589085\">",
"      Can placental abruption be prevented?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15589100\">",
"      What if I want to get pregnant again?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15589115\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/83067\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?7/20/7495\">",
"      Pregnancy terms",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?16/21/16723?source=related_link\">",
"      Patient information: C-section (cesarean delivery) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?12/13/12499?source=related_link\">",
"      Patient information: Labor and delivery (childbirth) (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f38_29_39378="Complementary therapies for rheumatoid arthritis";
var content_f38_29_39378=[" <h1 id=\"patTopicTitle\">",
"  Patient information: Complementary therapies for rheumatoid arthritis (Beyond the Basics)",
" </h1>",
" <div id=\"patTopicContributors\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <table>",
"    <tr>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"mobipreview.htm?38/29/39378/contributors\">",
"       Author",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/29/39378/contributors\" id=\"au5318\">",
"       Richard S Panush, MD, MACP, MACR",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"mobipreview.htm?38/29/39378/contributors\">",
"       Section Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/29/39378/contributors\" id=\"se5073\">",
"       RN Maini, BA, MB BChir, FRCP, FMedSci, FRS",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"mobipreview.htm?38/29/39378/contributors\">",
"       Deputy Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/29/39378/contributors\" id=\"de4792\">",
"       Jerry M Greene, MD",
"      </a>",
"     </td>",
"    </tr>",
"   </table>",
"  </div>",
"  <div class=\"rcBottom\">",
"   <div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"patTopicTool\" id=\"patTopicToolTop\">",
"  <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"   Find",
"  </a>",
"  <a class=\"toolbutton printicon\" href=\"mobipreview.htm?38/29/39378?view=print\" title=\"Print This Topic\">",
"   Print",
"  </a>",
"  <script src=\"file://w.sharethis.com/button/sharethis.js#publisher=357881b8-c7e3-4c31-b7d2-242aeb1528e1&amp;type=website&amp;post_services=care2%2Cfacebook%2Ctwitter%2Cmyspace%2Cdigg%2Cdelicious%2Cfaves%2Creddit%2Cxanga%2Cstumbleupon%2Cblinklist%2Csimpy%2Cyigg%2Ctechnorati%2Cmeneame%2Corkut%2Cmixx%2Cfunp%2Cfresqui%2Cmister_wong%2Cfriendster%2Cfriendfeed%2Clinkedin%2Coknotizie%2Cgoogle_bmarks%2Cyahoo_bmarks%2Cfark%2Cnewsvine%2Clivejournal%2Ctypepad%2Cbus_exchange%2Cpropeller%2Cwordpress%2Cblogger%2Cblogmarks%2Cwindows_live%2Cfurl%2Cybuzz%2Cdiigo\" type=\"text/javascript\">",
"  </script>",
" </div>",
" <div id=\"patTopicMiddle\">",
"  <div id=\"topicContent\">",
"   <div id=\"topicText\">",
"    <p class=\"headingAnchor\" id=\"H1\">",
"     <span class=\"h1\">",
"      COMPLEMENTARY THERAPY OVERVIEW",
"     </span>",
"    </p>",
"    <p>",
"     Rheumatoid arthritis (RA) is a chronic inflammatory condition. The condition can affect many tissues throughout the body, although the joints are usually most severely affected. Medications and other conventional therapies, such as physical therapy, are the mainstays of treatment for people with RA. However, treatment for RA remains far from ideal for many patients, leading them to search for other approaches that might improve outcomes.",
"    </p>",
"    <p>",
"     Complementary and alternative medicine (CAM) has been defined by the National Center for Complementary and Alternative Medicine as &ldquo;a group of diverse medical and healthcare systems, practices, and products that are not presently considered to be part of conventional medicine&rdquo; [",
"     <a class=\"abstract\" href=\"mobipreview.htm?38/29/39378/abstract/1\">",
"      1",
"     </a>",
"     ]. For some CAM practices, there is scientific evidence that a treatment is both beneficial and safe. For many other practices, evidence is lacking or inconclusive [",
"     <a class=\"abstract\" href=\"mobipreview.htm?38/29/39378/abstract/2\">",
"      2",
"     </a>",
"     ].",
"    </p>",
"    <p>",
"     Most patients who use complementary and alternative medicine treatments are not dissatisfied with conventional or established medical treatments but find that complementary medicine appeals to their values and beliefs about health and life. Being diagnosed with RA and living with the disease can be a frightening, exhausting, and demanding experience. CAM appeals to many people because these treatments appear to offer a chance to feel better and to decrease uncomfortable symptoms such as pain and fatigue.",
"    </p>",
"    <p>",
"     A number of other topics about RA are available separately. (See",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?20/61/21463?source=see_link\">",
"      \"Patient information: Rheumatoid arthritis symptoms and diagnosis (Beyond the Basics)\"",
"     </a>",
"     and",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?23/44/24264?source=see_link\">",
"      \"Patient information: Rheumatoid arthritis treatment (Beyond the Basics)\"",
"     </a>",
"     and",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?26/40/27266?source=see_link\">",
"      \"Patient information: Disease-modifying antirheumatic drugs (DMARDs) (Beyond the Basics)\"",
"     </a>",
"     and",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?11/52/12098?source=see_link\">",
"      \"Patient information: Rheumatoid arthritis and pregnancy (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H2\">",
"     <span class=\"h1\">",
"      CONVENTIONAL TREATMENT OF RA",
"     </span>",
"    </p>",
"    <p>",
"     Conventional treatments for RA have improved significantly since the late 1990s, when advances in molecular biology led to a variety of new treatment approaches for RA. These new treatments are known as biologic agents, which interfere with the body's production of inflammatory chemicals. Biologic agents are often used with disease modifying antirheumatic drugs (DMARDs) such as methotrexate. When DMARDs and biologic agents are used in combination, up to 85 percent of patients have a moderate to good response to treatment.",
"    </p>",
"    <p>",
"     Certain experimental treatments such as immunoadsorption and stem cell transplantation are rarely, if ever, considered due to the small potential benefit and the significant potential for harm. However, some complementary treatments such as acupuncture, mind-body techniques, and exercise continue to have a place, alongside conventional treatment, for many people with RA; thus, while they are generally still called &ldquo;complementary,&rdquo; they are really mainstream medical therapy. The inclusion of such approaches together with conventional ones reflects what is now considered &ldquo;integrative&rdquo; medicine.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H3\">",
"     <span class=\"h2\">",
"      Placebo effect",
"     </span>",
"     &nbsp;&mdash;&nbsp;When discussing complementary treatments for RA, it is important to understand the placebo effect. A placebo is an inactive medication or treatment. Well-designed studies usually include a placebo treatment as well as a real treatment so that the two may be compared. The placebo effect is the positive or negative result that occurs when a patient believes they have been given a treatment, when in fact they have been given none (or a look-alike substitute). For example, a complementary treatment that claims to improve symptoms of fatigue in 50 percent of patients is of little benefit if a placebo treatment also improves fatigue in 50 percent of patients.",
"    </p>",
"    <p>",
"     The placebo effect is not well-understood, although it has a strong influence on the results of any research study, whether in conventional or complementary medicine.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H4\">",
"     <span class=\"h1\">",
"      COMPLEMENTARY THERAPIES",
"     </span>",
"    </p>",
"    <p>",
"     Complementary medicine is a treatment, practice, or product that might be used alongside conventional medical treatment. It is not meant to replace conventional RA treatment but may help to alleviate side effects or to improve a patient's sense of well-being.",
"    </p>",
"    <p>",
"     Complementary therapies are attractive because they are perceived to be safe and &ldquo;natural&rdquo; and because conventional medical treatments can have limited effectiveness and significant side effects. However, it is not clear how most complementary treatments work. Many are marketed with unproven claims, and certain therapies have even been proven to be harmful.",
"    </p>",
"    <p>",
"     Several complementary therapies may play a useful role in the treatment of RA, although the safety and effectiveness of most of these therapies are still uncertain. Thus, people with RA who are considering complementary therapies should discuss these therapies with their healthcare provider first. Furthermore, therapies that have proven benefits should only be used to complement, not to replace, conventional medical treatment.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H5\">",
"     <span class=\"h2\">",
"      Exercise",
"     </span>",
"     &nbsp;&mdash;&nbsp;Studies suggest that exercise is both safe and beneficial in people with RA. Regular exercise can build endurance and strength, can preserve muscle and normal joint motion, can minimize bone loss, and can improve pain control. Exercise may also have cardiovascular, psychological, and social benefits. (See",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?27/62/28645?source=see_link\">",
"      \"Patient information: Arthritis and exercise (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     People with rheumatoid arthritis should have an exercise program designed by an experienced physical therapist. The program should be tailored to the severity of the person's condition, body build, and activity level. Exercise should never cause increased pain and should never push the joints past their normal range of motion.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H6\">",
"     <span class=\"h2\">",
"      Foods and diets",
"     </span>",
"     &nbsp;&mdash;&nbsp;There is no evidence that food allergies or sensitivities cause or worsen RA in most people. However, some people notice that their symptoms improve when they fast or eliminate certain foods from their diet, leading the person to believe that an allergy or sensitivity is contributing to arthritis. However, elimination diets are difficult to maintain long-term and can lead to malnutrition. Thus, it is important to involve an experienced healthcare provider in decisions regarding diet. In some cases, a consultation with a dietitian will be recommended.",
"    </p>",
"    <p>",
"     For most people with RA, a healthy, balanced diet is a sensible component of the treatment plan [",
"     <a class=\"abstract\" href=\"mobipreview.htm?38/29/39378/abstract/3\">",
"      3",
"     </a>",
"     ]. (See",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?27/62/28642?source=see_link\">",
"      \"Patient information: Diet and health (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H7\">",
"     <span class=\"h2\">",
"      Fish oils and plant oils",
"     </span>",
"     &nbsp;&mdash;&nbsp;Fish oil contains high amounts of two omega-3 fatty acids, which the body can use to make substances that reduce inflammation. Plant oils (such as primrose oil, borage, black currant, and flaxseed oil) contain omega-3 and omega-6 fatty acids.",
"    </p>",
"    <p>",
"     Both fish and plant oils have been shown to modestly reduce symptoms of rheumatoid arthritis and may be helpful in some people. However, fish oils can interact with blood pressure medications (potentially lowering blood pressure too much) and can increase the risk of bleeding, especially in people who take aspirin or warfarin (Coumadin&reg;). In addition, some fish oils have high levels of contaminants such as mercury.",
"    </p>",
"    <p>",
"     Plant oils also have potentially dangerous side effects, including increased bleeding (with borage seed and primrose oil), interactions with psychiatric medications (with primrose oil), and worsened liver function (with borage seed oil).",
"    </p>",
"    <p>",
"     These might be considered by patients during pregnancy or breast feeding, patients who need but are allergic to or who cannot tolerate nonsteroidal antiinflammatory drugs (NSAIDs), or individuals particularly wishing &ldquo;natural&rdquo; therapy for arthritis symptoms.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H8\">",
"     <span class=\"h2\">",
"      Herbs, vitamins, and dietary supplements",
"     </span>",
"     &nbsp;&mdash;&nbsp;Combinations of herbs (also called botanicals) are often promoted as treatments for medical problems. Herbal medicines may come in the form of a powder, liquid, or pill. Examples of herbal treatments for RA include Thunder god vine (botanical name Tripterygium wilfordii Hook F), valerian, ginger, curcumin, and boswellia [",
"     <a class=\"abstract\" href=\"mobipreview.htm?38/29/39378/abstract/4\">",
"      4",
"     </a>",
"     ].",
"    </p>",
"    <p>",
"     However, the evidence in support of such claims is scant, standardized and high quality preparations are not available, and some of these herbs can cause dangerous side effects. In addition, some herbal products can interact with conventional treatments, making them less effective. We do not recommend the use of herbs, vitamins, or other dietary supplements.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H9\">",
"     <span class=\"h2\">",
"      Homeopathy",
"     </span>",
"     &nbsp;&mdash;&nbsp;Homeopathy is a therapy that uses small quantities of highly diluted substances to relieve symptoms of a condition or illness. A few studies have evaluated the benefit of homeopathy in the treatment of RA, although most studies were small. One well-designed study failed to show a clear benefit of homeopathy, compared with placebo, in reducing the symptoms of RA [",
"     <a class=\"abstract\" href=\"mobipreview.htm?38/29/39378/abstract/5\">",
"      5",
"     </a>",
"     ]. Although there may be a low risk of harm from homeopathic remedies, there is no scientific basis to recommend this for RA or for other rheumatic diseases. More information is available from the National Center for Complementary and Alternative Medicine (",
"     <a class=\"external\" href=\"file://nccam.nih.gov/health/homeopathy/\">",
"      file://nccam.nih.gov/health/homeopathy/",
"     </a>",
"     ).",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H10\">",
"     <span class=\"h2\">",
"      Acupuncture",
"     </span>",
"     &nbsp;&mdash;&nbsp;Acupuncture involves inserting hair-thin, metal needles into the skin at specific points on the body. It causes little to no pain. Electrical stimulation is sometimes applied to the acupuncture needle. There have been a few studies of acupuncture's benefit for RA, most of which were small and poorly designed. Review of these studies showed that acupuncture has no effect on the number of swollen and tender joints, on pain, or on the amount of pain medications required by people with RA [",
"     <a class=\"abstract\" href=\"mobipreview.htm?38/29/39378/abstract/6\">",
"      6",
"     </a>",
"     ].",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H11\">",
"     <span class=\"h2\">",
"      Magnets",
"     </span>",
"     &nbsp;&mdash;&nbsp;Magnets produce a type of energy known as a magnetic field, which is theorized to improve pain caused by a number of conditions, including RA. Magnets have been used in bracelets, body wraps, mattresses, and shoe inserts. Research does not show that people with RA derive much (if any) benefit from magnets, nor have electromagnetic treatments been shown to be helpful [",
"     <a class=\"abstract\" href=\"mobipreview.htm?38/29/39378/abstract/7\">",
"      7",
"     </a>",
"     ].",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H12\">",
"     <span class=\"h2\">",
"      Mind-body techniques",
"     </span>",
"     &nbsp;&mdash;&nbsp;Mind-body techniques include practices such as hypnosis, guided imagery, meditation, yoga, biofeedback, tai-chi, and prayer. Mind-body techniques are based upon the interactions between the body, mind, emotions, and overall state of health. These techniques may be useful to control anxiety or pain. Patients of any age can learn mind-body techniques.",
"    </p>",
"    <p>",
"     Studies of mind-body techniques in people with RA show that most techniques are of some benefit, when used along with conventional treatments, in reducing pain and disability and in improving a person's overall psychological state, ability to cope, and belief in one's ability to handle difficult situations [",
"     <a class=\"abstract\" href=\"mobipreview.htm?38/29/39378/abstract/8\">",
"      8",
"     </a>",
"     ].",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H9383385\">",
"     <span class=\"h2\">",
"      Other complementary therapies",
"     </span>",
"     &nbsp;&mdash;&nbsp;There are many other such therapies (ranging from antibiotics to leeches to sitting in abandoned uranium mines), none of which can be recommended as having been scientifically demonstrated as consistently safe and effective for RA. Not using these complementary treatments does not deprive patients of clinically important or valuable therapy for their disease.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H13\">",
"     <span class=\"h1\">",
"      WHERE TO GET MORE INFORMATION",
"     </span>",
"    </p>",
"    <p>",
"     Your healthcare provider is the best source of information for questions and concerns related to your medical problem.",
"    </p>",
"    <p>",
"     This article will be updated as needed on our web site (",
"     <a class=\"external\" href=\"file://www.uptodate.com/patients\">",
"      www.uptodate.com/patients",
"     </a>",
"     ). Related topics for patients, as well as selected articles written for healthcare professionals, are also available. Some of the most relevant are listed below.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H1804437400\">",
"     <span class=\"h2\">",
"      Patient level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H11480448\">",
"     <span class=\"h3\">",
"      The Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;The Basics patient education pieces answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?16/31/16883?source=see_link\">",
"      Patient information: Rheumatoid arthritis (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?24/33/25105?source=see_link\">",
"      Patient information: Alternative medicine (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?26/62/27618?source=see_link\">",
"      Patient information: Probiotics (The Basics)",
"     </a>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H11480456\">",
"     <span class=\"h3\">",
"      Beyond the Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are best for patients who want in-depth information and are comfortable with some medical jargon.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?20/61/21463?source=see_link\">",
"      Patient information: Rheumatoid arthritis symptoms and diagnosis (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?23/44/24264?source=see_link\">",
"      Patient information: Rheumatoid arthritis treatment (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?26/40/27266?source=see_link\">",
"      Patient information: Disease-modifying antirheumatic drugs (DMARDs) (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?11/52/12098?source=see_link\">",
"      Patient information: Rheumatoid arthritis and pregnancy (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?27/62/28645?source=see_link\">",
"      Patient information: Arthritis and exercise (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?27/62/28642?source=see_link\">",
"      Patient information: Diet and health (Beyond the Basics)",
"     </a>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H14\">",
"     <span class=\"h2\">",
"      Professional level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;Professional level articles are designed to keep doctors and other health professionals up-to-date on the latest medical findings. These articles are thorough, long, and complex, and they contain multiple references to the research on which they are based. Professional level articles are best for people who are comfortable with a lot of medical terminology and who want to read the same materials their doctors are reading.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/27/7607?source=see_link\">",
"      Acupuncture for rheumatic conditions",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/21/7513?source=see_link\">",
"      Complementary and alternative remedies in rheumatic disorders",
"     </a>",
"     <br/>",
"    </p>",
"    <p>",
"     The following organizations also provide reliable health information.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Library of Medicine",
"       <br/>",
"       (",
"       <a class=\"external\" href=\"file://www.nlm.nih.gov/medlineplus/healthtopics.html\">",
"        www.nlm.nih.gov/medlineplus/healthtopics.html",
"       </a>",
"       )",
"      </li>",
"      <li>",
"       National Institute of Arthritis and Musculoskeletal and Skin Diseases",
"       <br/>",
"       (301) 496-8188",
"       <br/>",
"       (",
"       <a class=\"external\" href=\"file://www.nih.gov/niams/\">",
"        www.nih.gov/niams/",
"       </a>",
"       )",
"      </li>",
"      <li>",
"       National Center for Complementary and Alternative Medicine",
"       <br/>",
"       (",
"       <a class=\"external\" href=\"file://nccam.nih.gov/\">",
"        file://nccam.nih.gov/",
"       </a>",
"       )",
"      </li>",
"      <li>",
"       American College of",
"       <span class=\"nowrap\">",
"        Rheumatology/Association",
"       </span>",
"       of Rheumatology",
"       <br/>",
"       (404) 633-3777",
"       <br/>",
"       (",
"       <a class=\"external\" href=\"file://www.rheumatology.org/\">",
"        www.rheumatology.org",
"       </a>",
"       )",
"      </li>",
"      <li>",
"       The Arthritis Foundation",
"       <br/>",
"       (800) 283-7800",
"       <br/>",
"       (",
"       <a class=\"external\" href=\"file://www.arthritis.org/\">",
"        www.arthritis.org",
"       </a>",
"       )",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     [",
"     <a class=\"abstract\" href=\"mobipreview.htm?38/29/39378/abstract/1,3,4,6-9\">",
"      1,3,4,6-9",
"     </a>",
"     ]",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   May 29, 2012.",
"  </div>",
"  <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"   <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"    Find",
"   </a>",
"   <a class=\"toolbutton printicon\" href=\"mobipreview.htm?38/29/39378?view=print\" title=\"Print This Topic\">",
"    Print",
"   </a>",
"  </div>",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <div id=\"patTopicRefHeader\">",
"    <div id=\"patTopicRefHeaderHeader\">",
"     References",
"    </div>",
"    <div id=\"patTopicRefHeaderTop\">",
"     <a href=\"#top\">",
"      <img alt=\"\" src=\"./../images/top_arrow.myextg\">",
"       Top",
"      </img>",
"     </a>",
"    </div>",
"   </div>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/29/39378/abstract/1\">",
"      Rajbhandary R, Bhangle S, Patel S, et al. Perspectives about complementary and alternative medicine in rheumatology. Rheum Dis Clin North Am 2011; 37:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/29/39378/abstract/2\">",
"      Ernst E, Posadzki P. Complementary and alternative medicine for rheumatoid arthritis and osteoarthritis: an overview of systematic reviews. Curr Pain Headache Rep 2011; 15:431.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/29/39378/abstract/3\">",
"      Henderson CJ, Panush RS. Diets, dietary supplements, and nutritional therapies in rheumatic diseases. Rheum Dis Clin North Am 1999; 25:937.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/29/39378/abstract/4\">",
"      Little C, Parsons T. Herbal therapy for treating rheumatoid arthritis. Cochrane Database Syst Rev 2001; :CD002948.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/29/39378/abstract/5\">",
"      Fisher P, Scott DL. A randomized controlled trial of homeopathy in rheumatoid arthritis. Rheumatology (Oxford) 2001; 40:1052.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/29/39378/abstract/6\">",
"      Casimiro L, Barnsley L, Brosseau L, et al. Acupuncture and electroacupuncture for the treatment of rheumatoid arthritis. Cochrane Database Syst Rev 2005; :CD003788.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/29/39378/abstract/7\">",
"      Johnson MT, Waite LR, Nindl G. Noninvasive treatment of inflammation using electromagnetic fields: current and emerging therapeutic potential. Biomed Sci Instrum 2004; 40:469.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/29/39378/abstract/8\">",
"      Astin JA, Beckner W, Soeken K, et al. Psychological interventions for rheumatoid arthritis: a meta-analysis of randomized controlled trials. Arthritis Rheum 2002; 47:291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/29/39378/abstract/9\">",
"      Rose G. Why do patients with rheumatoid arthritis use complementary therapies? Musculoskeletal Care 2006; 4:101.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
" </div>",
" <!-- patTopicMiddle -->",
"</div>"].join("\n");
var script_f38_29_39378=[""].join("\n");
var outline_f38_29_39378=[" <div class=\"patTopicFancyTop\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <p>",
"    Contents of this article",
"   </p>",
"  </div>",
" </div>",
" <div class=\"patTopicFancySpacer\">",
" </div>",
" <div class=\"patTopicOutline\">",
"  <div class=\"rcbBottom\">",
"   <div class=\"rcbLeft\">",
"    <div class=\"rcbRight\">",
"     <div class=\"rcbBottomLeft\">",
"      <div class=\"rcbBottomRight rcbBottomRightBottomOnly\">",
"       <div id=\"outline\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          <a href=\"#H1\">",
"           COMPLEMENTARY THERAPY OVERVIEW",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H2\">",
"           CONVENTIONAL TREATMENT OF RA",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H4\">",
"           COMPLEMENTARY THERAPIES",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H13\">",
"           WHERE TO GET MORE INFORMATION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#references\">",
"           REFERENCES",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"  </div>",
" </div>"].join("\n");
var title_f38_29_39379="Ketotifen (systemic): Drug information";
var content_f38_29_39379=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Ketotifen (systemic): Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F13243974\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      APO-Ketotifen&reg;;",
"     </li>",
"     <li>",
"      Novo-Ketotifen;",
"     </li>",
"     <li>",
"      Nu-Ketotifen&reg;;",
"     </li>",
"     <li>",
"      PMS-Ketotifen;",
"     </li>",
"     <li>",
"      Zaditen&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F13243977\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Histamine H;",
"      <sub>",
"       1",
"      </sub>",
"      Antagonist",
"     </li>",
"     <li>",
"      Histamine H;",
"      <sub>",
"       1",
"      </sub>",
"      Antagonist, Second Generation",
"     </li>",
"     <li>",
"      Mast Cell Stabilizer;",
"     </li>",
"     <li>",
"      Piperidine Derivative",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F13244130\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Atopic asthma (prophylactic treatment):",
"     </b>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Children 6 months to 3 years: Initial: 0.05 mg/kg once daily or in 2 divided doses for 5 days; Maintenance: 0.05 mg/kg twice daily (maximum dose: 1 mg twice daily)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Children &gt;3 years: Initial: 1 mg once daily or in 2 divided doses for 5 days; Maintenance: 1 mg twice daily",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F13244422\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no dosage adjustments provided in manufacturer's labeling.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F13244423\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no dosage adjustments provided in manufacturer's labeling.",
"    </p>",
"   </div>",
"   <div class=\"block foccan drugH1Div\" id=\"F13244134\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: Canada",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Syrup, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Zaditen&reg;: 1 mg/5 mL (250 mL) [contains ethanol, benzoate, strawberry flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Zaditen&reg;: 1 mg",
"    </p>",
"   </div>",
"   <div class=\"block prod-avail drugH1Div\" id=\"F13244133\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Product Availability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Not available in the U.S.",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F13244131\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Administer without regards to meals.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F13243979\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adjunctive therapy in the chronic treatment of pediatric patients &ge;6 months of age with mild, atopic asthma",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F13243973\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Ketotifen may be confused with ketoprofen",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Zaditen&reg; may be confused with Zaditor&reg;",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F13244092\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Central nervous system: Sedation (8%; less than placebo), headache (1%), sleep disturbance (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Dermatologic: Rash (4%), urticaria (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Gastrointestinal: Weight gain (5%), abdominal pain (1%), appetite increased (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Respiratory: Respiratory infection (4%), epistaxis (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Miscellaneous: Flu (3%), puffy eyelid (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &lt;1% (Limited to important or life-threatening): Cystitis, dizziness, erythema multiforme, excitation, hepatitis, insomnia, irritability, nervousness, Stevens-Johnson syndrome, thrombocytopenia, transaminases increased, xerostomia",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F13243982\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to ketotifen or any component of the formulation; use of ketotifen syrup in patients sensitive to benzoate compounds",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F13243983\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Sedation (oral use): May cause drowsiness early in therapy; initiate therapy at one-half the recommended daily dose and gradually increase over 5 days to maintenance dose; patients must be cautioned about performing tasks which require mental alertness. (eg, operating machinery or driving).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Thrombocytopenia: Rare cases of thrombocytopenia have been reported in patients concurrently using oral ketotifen and oral antidiabetic agents.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Epilepsy: Use with caution in epileptic patients; may lower seizure threshold.  Seizures have been reported rarely during therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Antiasthmatic agents: Therapy with agents used for prophylaxis or relief of asthma related symptoms (eg, corticosteroids, beta",
"     <sub>",
"      2",
"     </sub>",
"     -agonists, xanthine derivatives), should be not be interrupted nor should dosing be immediately reduced with the initiation of ketotifen therapy. Reduce dosing of antiasthmatic agents gradually especially in patients taking corticosteroids or ACTH therapy. Steroid-dependent patients with adrenocortical insufficiency can take up to one year to recover a normal stress related pituitary-adrenal response.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Diabetics: Due to the carbohydrate content of the syrup preparation, diabetic patients may need to use tablet.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Benzoate allergy: Syrup products may contain benzoate compounds.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Appropriate use:  Indicated for prophylactic treatment; not effective for the prevention or treatment of acute asthma attacks.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Delayed clinical response: Therapeutic effects may not be clinically evident until several weeks after the initiation of therapy; maximum effectiveness usually requires duration of therapy &ge;10 weeks. Therapy should be maintained for at least 2-3 months to determine effectiveness. If therapy requires discontinuation, gradually reduce over 2-4 weeks.",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F13243980\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse fetal effects were found in some but not all animal studies. Safety in human pregnancy has not been established.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F13243981\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F13244117\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May be taken without regard to meals. Syrup contains carbohydrate 4 g/5 mL.",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F13733208\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Amitone (HK, SG);",
"     </li>",
"     <li>",
"      Asmaten (MY);",
"     </li>",
"     <li>",
"      Asthafen (IN);",
"     </li>",
"     <li>",
"      Asthan (TW);",
"     </li>",
"     <li>",
"      Asumalife (MY);",
"     </li>",
"     <li>",
"      Blasket (CO);",
"     </li>",
"     <li>",
"      Denerel (MY);",
"     </li>",
"     <li>",
"      Dhatifen (HK, SG);",
"     </li>",
"     <li>",
"      Edifen (KP);",
"     </li>",
"     <li>",
"      Eucycline (GR);",
"     </li>",
"     <li>",
"      Ketane (UY);",
"     </li>",
"     <li>",
"      Ketasma (IN);",
"     </li>",
"     <li>",
"      Keto (TH);",
"     </li>",
"     <li>",
"      Ketocev (AR);",
"     </li>",
"     <li>",
"      Ketof (DE);",
"     </li>",
"     <li>",
"      Ketohexal (ZA);",
"     </li>",
"     <li>",
"      Ketosma (TW);",
"     </li>",
"     <li>",
"      Ketotisin (CN);",
"     </li>",
"     <li>",
"      Ketovent (IN);",
"     </li>",
"     <li>",
"      Nazalen (KP);",
"     </li>",
"     <li>",
"      Orpidix (GR);",
"     </li>",
"     <li>",
"      Rui Na Ti (CL);",
"     </li>",
"     <li>",
"      Santiten (TW);",
"     </li>",
"     <li>",
"      Scanditen (ID);",
"     </li>",
"     <li>",
"      Soother (TW);",
"     </li>",
"     <li>",
"      Sykofen (TH);",
"     </li>",
"     <li>",
"      Tosma (ID);",
"     </li>",
"     <li>",
"      Zadec (PH);",
"     </li>",
"     <li>",
"      Zaditen (AT, BE, CH, FR, GB, GR, HK, HN, ID, IE, IT, NL, NO, PH, PL, PT, PY, SG, TR, TW, VE);",
"     </li>",
"     <li>",
"      Zerosma (IN);",
"     </li>",
"     <li>",
"      Zytofen (TH)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F13244115\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Exhibits noncompetitive H",
"     <sub>",
"      1",
"     </sub>",
"     -receptor antagonist and mast cell stabilizer properties. Efficacy in asthma likely results from a combination of anti-inflammatory and antihistaminergic actions including interference with chemokine-induced migration of eosinophils into inflamed airways, inhibition of airway hyper-reactivity due to platelet activating factor (PAF), antagonism of leukotriene-induced bronchoconstriction.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F13244118\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Absorption: Rapid, &ge;60%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Protein binding: 75%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metabolism: Hepatic via N-glucuronidation to inactive metabolite ketotifen-N-glucoronide; N-demethylation to active metabolite nor-ketotifen; and keto-reduction to hydroxyl derivative",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Clearance: Increased in children &gt;3 years; decreased in children &le;3 years",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bioavailability: ~50%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Half-life elimination: ~9-9.5 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Time to peak, plasma: 2-4 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Excretion: Urine (&gt;60% as metabolites, 1% as unchanged drug)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Hung CH, Li CY, Lai YS, et al, &ldquo;Discrepant Clinical Responses and Blood Chemokine Profiles Between Two Non-Steroidal Anti-Inflammatory Medications for Children With Mild Persistent Asthma,&rdquo;",
"      <i>",
"       Pediatr Allergy Immunol",
"      </i>",
"      , 2005, 16(4):306-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/29/39379/abstract-text/15943593/pubmed\" id=\"15943593\" target=\"_blank\">",
"        15943593",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kabra SK, Pandey RM, Singh R, et al, &ldquo;Ketotifen for Asthma in Children Aged 5 to 15 Years: A Randomized Placebo-Controlled Trial,&rdquo;",
"      <i>",
"       Ann Allergy Asthma Immunol",
"      </i>",
"      , 2000, 85(1):46-52.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/29/39379/abstract-text/10923604/pubmed\" id=\"10923604\" target=\"_blank\">",
"        10923604",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 16765 Version 15.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-202.43.93.2-04D01F2D42-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_29_39379=[""].join("\n");
var outline_f38_29_39379=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13243974\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13243977\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13244130\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13244422\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13244423\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13244134\">",
"      Dosage Forms: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13244133\">",
"      Product Availability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13244131\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13243979\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13243973\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13244092\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13243982\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13243983\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13243980\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13243981\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13244117\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13733208\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13244115\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13244118\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/16765\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/16765|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?43/26/44453?source=related_link\">",
"      Ketotifen (ophthalmic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?3/1/3092?source=related_link\">",
"      Ketotifen (ophthalmic): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?24/53/25428?source=related_link\">",
"      Ketotifen (ophthalmic): Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f38_29_39380="Chronic tinea pedis PI";
var content_f38_29_39380=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F55602%7EPI%2F63389&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F55602%7EPI%2F63389&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Athlete's foot (tinea pedis)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 342px; height: 296px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Ringworm infections of the foot, also called athlete's foot, can cause the skin on the bottom of the foot to turn red and form scales.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of John T Crissey, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Acute tinea pedis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 378px; height: 268px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This photo shows tinea pedis (athlete's foot) on the toe.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of John T Crissey, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_29_39380=[""].join("\n");
var outline_f38_29_39380=null;
var title_f38_29_39381="Brompheniramine: Drug information";
var content_f38_29_39381=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Brompheniramine: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?39/15/40180?source=see_link\">",
"    see \"Brompheniramine: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F3286540\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Bromax [DSC];",
"     </li>",
"     <li>",
"      J-Tan PD [OTC];",
"     </li>",
"     <li>",
"      LoHist-12 [DSC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F3286542\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Alkylamine Derivative;",
"     </li>",
"     <li>",
"      Histamine H;",
"      <sub>",
"       1",
"      </sub>",
"      Antagonist",
"     </li>",
"     <li>",
"      Histamine H",
"      <sub>",
"       1",
"      </sub>",
"      Antagonist, First Generation",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F3293861\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     <b>",
"      Allergic rhinitis, allergic symptoms, vasomotor rhinitis:",
"     </b>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bromax: One tablet twice daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     LoHist-12: 1-2 tablets every 12 hours (maximum: 4 tablets/day)",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F3293500\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     <b>",
"      Allergic rhinitis, allergic symptoms, vasomotor rhinitis:",
"     </b>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Children 2 to &lt;6 years (J-Tan PD): 1 mg (1 mL) every 4-6 hours (maximum: 6 mg [6 mL]/24 hours)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Children 6-12 years:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     J-Tan PD: 2 mg (2 mL) every 4-6 hours (maximum: 12 mg [12 mL]/24 hours)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     LoHist-12: One tablet every 12 hours (maximum: 2 tablets/day)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Children &gt;12 years (Bromax, LoHist-12): Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F239223\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Liquid, oral, as maleate [drops]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     J-Tan PD: 1 mg/mL (30 mL) [dye free, ethanol free, sugar free; contains propylene glycol; strawberry-banana flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, extended release, oral, as maleate:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Bromax: 11 mg [DSC] [dye free]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     LoHist-12: 6 mg [DSC] [scored; dye free]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F3286541\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F239226\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Extended release tablets are to be swallowed whole; do not crush or chew.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F239225\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Symptomatic relief of perennial and seasonal allergic rhinitis, vasomotor rhinitis, and other respiratory allergies",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F13930966\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      BEERS Criteria medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       This drug may be potentially inappropriate for use in geriatric patients (Quality of evidence - moderate; Strength of recommendation - strong).",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F3286548\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Frequency not defined.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Angina, blood pressure increased, chest tightness, circulatory collapse, extrasystoles, hypotension, palpitation, tachycardia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Anxiety, chills, confusion, coordination impaired, dizziness, drowsiness, euphoria, excitation, fatigue, headache, hysteria, insomnia, irritability, nervousness, neuritis, restlessness, sedation, seizure, stimulation, tension, vertigo",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Photosensitivity, rash, urticaria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Early menses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Abdominal cramps, anorexia, constipation, diarrhea, dry throat, epigastric distress, heartburn, nausea, vomiting, xerostomia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Genitourinary: Dysuria, polyuria, urinary retention",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Agranulocytosis, hemolytic anemia, hypoplastic anemia, thrombocytopenia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Paresthesia, tremor, weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Blurred vision, diplopia, mydriasis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Otic: Labyrinthitis (acute), tinnitus",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Dry nose, nasal congestion, thickening of bronchial secretions, wheezing",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Anaphylactic shock, diaphoresis",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F239229\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to brompheniramine or any component of the formulation; use with or within 14 days of MAO inhibitor therapy; narrow-angle glaucoma; urinary retention; peptic ulcer disease; during acute asthmatic attacks; breast-feeding; newborn or premature infants",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F239211\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; CNS depression: May cause CNS depression, which may impair physical or mental abilities; patients must be cautioned about performing tasks which require mental alertness (eg, operating machinery or driving).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Asthma: Use with caution in patients with a history of asthma.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiovascular disease: Use with caution in patients with cardiovascular disease (including hypertension and ischemic heart disease).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Increased intraocular pressure: Use with caution in patients with increased intraocular pressure.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Prostatic hyperplasia/urinary obstruction: Use with caution in patients with prostatic hyperplasia and/or GU obstruction.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Thyroid dysfunction: Use with caution in patients with thyroid dysfunction.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Sedatives: Effects may be potentiated when used with other sedative drugs or ethanol.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Avoid use of this potent anticholinergic agent due to increased risk of confusion, dry mouth, constipation, and other anticholinergic effects; clearance decreases in patients of advanced age (Beers Criteria).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pediatrics: Antihistamines may cause excitation in young children.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Tartrazine: Some products may contain tartrazine.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13298888\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F239215\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Acetylcholinesterase Inhibitors (Central): Anticholinergics may diminish the therapeutic effect of Acetylcholinesterase Inhibitors (Central). Acetylcholinesterase Inhibitors (Central) may diminish the therapeutic effect of Anticholinergics. If the anticholinergic action is a side effect of the agent, the result may be beneficial.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aclidinium: May enhance the anticholinergic effect of Anticholinergics.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alcohol (Ethyl): CNS Depressants may enhance the CNS depressant effect of Alcohol (Ethyl).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amphetamines: May diminish the sedative effect of Antihistamines.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anticholinergics: May enhance the adverse/toxic effect of other Anticholinergics.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Azelastine (Nasal): CNS Depressants may enhance the CNS depressant effect of Azelastine (Nasal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Benzylpenicilloyl Polylysine: Antihistamines may diminish the diagnostic effect of Benzylpenicilloyl Polylysine.  Management: Suspend systemic H1 antagonists for benzylpenicilloyl-polylysine skin testing and delay testing until systemic antihistaminic effects have dissipated. A histamine skin test may be used to assess persistent antihistaminic effects.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Betahistine: Antihistamines may diminish the therapeutic effect of Betahistine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Buprenorphine: CNS Depressants may enhance the CNS depressant effect of Buprenorphine.  Management: Consider reduced doses of CNS depressants used in combination with buprenorphine.  Consider avoiding other CNS depressants in patients thought to be at high risk of buprenorphine overuse or self-injection.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CNS Depressants: May enhance the adverse/toxic effect of other CNS Depressants.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Droperidol: May enhance the CNS depressant effect of CNS Depressants. Management: Consider dose reductions of droperidol or of other CNS agents (e.g., opioids, barbiturates) with concomitant use.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hyaluronidase: Antihistamines may diminish the therapeutic effect of Hyaluronidase.  Management: Patients receiving antihistamines (particularly at larger doses) may not experience the desired clinical response to standard doses of hyaluronidase.  Larger doses of hyaluronidase may be required.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ipratropium (Oral Inhalation): May enhance the anticholinergic effect of Anticholinergics.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methotrimeprazine: CNS Depressants may enhance the CNS depressant effect of Methotrimeprazine. Methotrimeprazine may enhance the CNS depressant effect of CNS Depressants.  Management: Reduce adult dose of CNS depressant agents by 50% with initiation of concomitant methotrimeprazine therapy. Further CNS depressant dosage adjustments should be initiated only after clinically effective methotrimeprazine dose is established.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metyrosine: CNS Depressants may enhance the sedative effect of Metyrosine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mirtazapine: CNS Depressants may enhance the CNS depressant effect of Mirtazapine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Perampanel: May enhance the CNS depressant effect of CNS Depressants. Management: Patients taking perampanel with any other drug that has CNS depressant activities should avoid complex and high-risk activities, particularly those such as driving that require alertness and coordination, until they have experience using the combination.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pramipexole: CNS Depressants may enhance the sedative effect of Pramipexole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pramlintide: May enhance the anticholinergic effect of Anticholinergics. These effects are specific to the GI tract.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ROPINIRole: CNS Depressants may enhance the sedative effect of ROPINIRole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rotigotine: CNS Depressants may enhance the sedative effect of Rotigotine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: CNS Depressants may enhance the adverse/toxic effect of Selective Serotonin Reuptake Inhibitors. Specifically, the risk of psychomotor impairment may be enhanced.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Oxybate: May enhance the CNS depressant effect of CNS Depressants. Management: Consider alternatives to combined use. When combined use is needed, consider minimizing doses of one or more drugs. Use of sodium oxybate with alcohol or sedative hypnotics is contraindicated.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tiotropium: Anticholinergics may enhance the anticholinergic effect of Tiotropium.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem dose to 1.75 mg for men who are also receiving other CNS depressants.  No such dose change is recommended for women.  Avoid use with other CNS depressants at bedtime; avoid use with alcohol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F3286553\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Ethanol: May increase CNS depression; monitor for increased effects with coadministration. Caution patients about effect.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F239218\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F3286543\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Maternal antihistamine use has generally not resulted in increased risk of birth defects; however, information specific to brompheniramine is limited. Brompheniramine may cause severe reactions (convulsions) in newborns and premature infants; the manufacturer recommends avoiding use in the third trimester. Antihistamines are recommended for the treatment of rhinitis, urticaria, and pruritus with rash in pregnant women (although second generation antihistamines may be preferred). Antihistamines are not recommended for treatment of pruritus associated with intrahepatic cholestasis in pregnancy.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F3286544\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/contraindicated",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F3286545\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Some antihistamines are excreted in breast milk; however, excretion of brompheniramine is not known. Premature infants and newborns have a higher risk of intolerance to antihistamines. Use while breast-feeding is contraindicated by the manufacturer. Antihistamines may decrease maternal serum prolactin concentrations when administered prior to the establishment of nursing.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F3286555\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May be taken with food, water, or milk.",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F6875303\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Bomex (MY, SG);",
"     </li>",
"     <li>",
"      Bomine (TH);",
"     </li>",
"     <li>",
"      Broramin (TW);",
"     </li>",
"     <li>",
"      Dimegan (FR);",
"     </li>",
"     <li>",
"      Dimetane (GR, TW)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F239209\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Competes with histamine for H",
"     <sub>",
"      1",
"     </sub>",
"     -receptor sites on effector cells",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F239228\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : Children: ~20 L/kg (Simons, 1999); Adults: ~12 L/kg (Simons, 1982)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 39% to 49% (Mart&iacute;nez-G&oacute;mez, 2007)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatic (Simons, 2004)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life, elimination: Children: ~12 hours (Simons, 1999); Adults: ~25 hours (Simons, 1982)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak, serum: Children: 3-3.5 hours (Simons, 1999); Adults: 2-4 hours (Simons, 1982)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (Bruce, 1968)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      American Geriatrics Society 2012 Beers Criteria Update Expert Panel, \"American Geriatrics Society Updated Beers Criteria for Potentially Inappropriate Medication Use in Older Adults,\"",
"      <i>",
"       J Am Geriatr Soc",
"      </i>",
"      , 2012, 60(4):616-31.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/29/39381/abstract-text/22376048/pubmed\" id=\"22376048\" target=\"_blank\">",
"        22376048",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bruce RB, Turnbull LB, Newman JH, et al, \"Metabolism of Brompheniramine,\"",
"      <i>",
"       J Med Chem",
"      </i>",
"      , 1968, 11(5):1031-4.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/29/39381/abstract-text/4386938/pubmed\" id=\"4386938\" target=\"_blank\">",
"        4386938",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Mart&iacute;nez-G&oacute;mez MA, Villanueva-Cama&ntilde;as RM, Sagrado S, et al, \"Evaluation of Enantioselective Binding of Antihistamines to Human Serum Albumin by ACE,\"",
"      <i>",
"       Electrophoresis",
"      </i>",
"      , 2007, 28(15):2635-43.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/29/39381/abstract-text/17605150/pubmed\" id=\"17605150\" target=\"_blank\">",
"        17605150",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Olsen KM, Gulliksen M, and Christophersen AS, &ldquo;Metabolites of Chlorpromazine and Brompheniramine May Cause False-Positive Urine Amphetamine Results with Monoclonal EMIT D.A.U. Immunoassay,&rdquo;",
"      <i>",
"       Clin Chem",
"      </i>",
"      , 1992, 38(4):611-2.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/29/39381/abstract-text/1568344/pubmed\" id=\"1568344\" target=\"_blank\">",
"        1568344",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Simons FE, \"Advances in H",
"      <sub>",
"       1",
"      </sub>",
"      -Antihistamines,\"",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2004, 351(21):2203-17.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/29/39381/abstract-text/15548781/pubmed\" id=\"15548781\" target=\"_blank\">",
"        15548781",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Simons FE, Frith EM, and Simons KJ, \"The Pharmacokinetics and Antihistaminic Effects of Brompheniramine,\"",
"      <i>",
"       J Allergy Clin Immunol",
"      </i>",
"      , 1982, 70(6):458-64.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/29/39381/abstract-text/6128358/pubmed\" id=\"6128358\" target=\"_blank\">",
"        6128358",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Simons FE, Roberts JR, Gu X, et al, \"The Clinical Pharmacology of Brompheniramine in Children,\"",
"      <i>",
"       J Allergy Clin Immunol",
"      </i>",
"      , 1999, 103(2 Pt 1):223-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?38/29/39381/abstract-text/9949311/pubmed\" id=\"9949311\" target=\"_blank\">",
"        9949311",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8916 Version 43.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-183.1.191.153-E85F879F22-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_29_39381=[""].join("\n");
var outline_f38_29_39381=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3286540\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3286542\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3293861\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3293500\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F239223\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3286541\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F239226\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F239225\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13930966\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3286548\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F239229\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F239211\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13298888\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F239215\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3286553\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F239218\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3286543\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3286544\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3286545\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3286555\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6875303\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F239209\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F239228\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8916\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8916|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?39/15/40180?source=related_link\">",
"      Brompheniramine: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f38_29_39382="Neonatal HSV scalp vesicles";
var content_f38_29_39382=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F56041&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F56041&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Neonatal herpes simplex virus scalp vesicles",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 400px; height: 304px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Scalp lesions of neonate with skin, eye, and mouth neonatal herpes simplex virus (HSV)&nbsp;infection associated with fetal scalp monitor. Gram-stained smear and bacterial cultures were negative, and the lesions did not respond to topical and systemic antibiotics. Viral cultures grew HSV type 2, and the lesions responded to intravenous acyclovir.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Jane Troendle-Atkins, MD, and Gail J Demmler-Harrison, MD, Texas Children's Hospital.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_29_39382=[""].join("\n");
var outline_f38_29_39382=null;
var title_f38_29_39383="Stroke in patients with atrial fibrillation";
var content_f38_29_39383=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Stroke in patients with atrial fibrillation",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/29/39383/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/29/39383/contributors\">",
"     Warren J Manning, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/29/39383/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/29/39383/contributors\">",
"     Peter J Zimetbaum, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/29/39383/contributors\">",
"     Scott E Kasner, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/29/39383/contributors\">",
"     Deputy Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/29/39383/contributors\">",
"     Gordon M Saperia, MD, FACC",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/29/39383/contributors\">",
"     John F Dashe, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?38/29/39383/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 22, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;An ischemic stroke may occur in patients with atrial fibrillation (AF) either as the initial presenting manifestation of AF or despite appropriate antithrombotic prophylaxis. In such patients, a cardiac embolus most commonly originating from the left atrium (LA) is a common cause of ischemic stroke. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/17/40216?source=see_link&amp;anchor=H5#H5\">",
"     \"Clinical diagnosis of stroke subtypes\", section on 'Brain ischemia'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Issues specific to stroke in patients with AF will be reviewed here. The risk of atheroembolism (including stroke), the role of antithrombotic prophylaxis (primary prevention) in patients with AF and the general evaluation and management of the patient with stroke are presented elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/23/27001?source=see_link\">",
"     \"Risk of embolization in atrial fibrillation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/32/42506?source=see_link\">",
"     \"Antithrombotic therapy to prevent embolization in atrial fibrillation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/47/28410?source=see_link\">",
"     \"Overview of the evaluation of stroke\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/8/41098?source=see_link\">",
"     \"Reperfusion therapy for acute ischemic stroke\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/60/31688?source=see_link\">",
"     \"Antithrombotic treatment of acute ischemic stroke and transient ischemic attack\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     STROKE CHARACTERISTICS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Strokes due to the embolization of clot from the left atrium or left atrial appendage in patients with AF present with the characteristics of ischemic stroke. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/17/40216?source=see_link&amp;anchor=H7#H7\">",
"     \"Clinical diagnosis of stroke subtypes\", section on 'Distinguishing stroke subtypes'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    AF is associated with more severe ischemic strokes and \"longer\" transient ischemic attacks (TIAs) than emboli from carotid disease, presumably due to embolization of larger particles with AF [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/29/39383/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. This relationship was illustrated in a report comparing ischemic brain events in patients with AF and those with carotid disease in two major trials: the ratio of hemispheric events to retinal events was 25:1 with AF compared to 2:1 with carotid disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/29/39383/abstract/1\">",
"     1",
"    </a>",
"    ]. As a result, patients with AF who suffer an ischemic stroke appear to have a worse outcome (more disability, greater mortality) than those who have an ischemic stroke in the absence of AF, even after adjustment for the advanced age of patients with AF-related stroke [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/29/39383/abstract/3-5\">",
"     3-5",
"    </a>",
"    ]. The \"longer\" TIAs typical in AF patients are more often associated with abnormal MRI diffusion imaging and would be classified as strokes by the recent, revised American Heart Association definition [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/29/39383/abstract/6\">",
"     6",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/21/18773?source=see_link\">",
"     \"Definition of transient ischemic attack\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition to causing symptomatic stroke with major deficits, AF is also associated with silent cerebral infarctions and TIAs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/29/39383/abstract/7-9\">",
"     7-9",
"    </a>",
"    ]. The frequency of silent cerebral infarction was evaluated in a report of 516 patients with nonrheumatic AF in the Veterans Administration SPINAF trial; CT scanning was performed initially and, in the absence of neurologic symptoms, at the end of follow-up [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/29/39383/abstract/7\">",
"     7",
"    </a>",
"    ]. One or more silent cerebral infarctions were seen at presentation in 15 percent; the estimated rate of new silent cerebral infarcts was about 1.3 percent per year at up to three years follow-up with a similar \"silent\" event rate for placebo and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    Anticoagulated AF patients who experience ischemic stroke typically have smaller infarcts with a lower mortality rate compared with AF patients with strokes who are not anticoagulated [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/29/39383/abstract/10\">",
"     10",
"    </a>",
"    ]. This is likely explained by a higher fraction of nonembolic strokes among anticoagulated AF patients and small size of embolic strokes: anticoagulation greatly reduced the likelihood of large stroke due to left atrial emboli, so that the remaining strokes from cerebral small artery disease or other mechanisms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/29/39383/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with AF who have suffered a stroke are likely to have had a cardioembolic event. On the other hand, AF is common in older adults, who often are at risk for other types of stroke. Thus, the presence of AF in a stroke patient does not always mean that there is a causal relationship [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/29/39383/abstract/11\">",
"     11",
"    </a>",
"    ]. As a result, all patients with a stroke, even in the setting of AF, need consideration of other causes of stroke, especially if they would result in different treatment.",
"   </p>",
"   <p>",
"    This evaluation does not usually differ from the evaluation of other stroke patients. In an occasional patient with relative contraindications to anticoagulation, transesophageal echocardiography (TEE) may be helpful to define the likelihood for embolism. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/47/28410?source=see_link\">",
"     \"Overview of the evaluation of stroke\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/29/33242?source=see_link\">",
"     \"Initial assessment and management of acute stroke\"",
"    </a>",
"    .).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Differential diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;For those AF patients with stroke in whom an embolus seems likely, other sources than the LA or left atrial appendage (LAA) need to be considered. Embolism refers to particles of debris originating elsewhere that block arterial access to a particular brain region. Embolic strokes may arise from a source in the heart, aorta, or large vessels (",
"    <a class=\"graphic graphic_table graphicRef55099 \" href=\"mobipreview.htm?20/39/21117\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Thromboembolism of aortic atheroma is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/35/10809?source=see_link\">",
"     \"Embolism from aortic plaque: Thromboembolism\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Echocardiography",
"    </span>",
"    &nbsp;&mdash;&nbsp;Echocardiographic evaluation is recommended for stroke patients, primarily to investigate the conditions associated with AF. Because chronic anticoagulation with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    is recommended in all eligible patients, echocardiography often will not have a significant impact on antithrombotic management decisions. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/50/2856?source=see_link\">",
"     \"Role of echocardiography in atrial fibrillation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/54/28522?source=see_link\">",
"     \"Epidemiology of and risk factors for atrial fibrillation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/32/42506?source=see_link\">",
"     \"Antithrombotic therapy to prevent embolization in atrial fibrillation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Residual LAA thrombus (after embolic stroke) is rarely seen on transthoracic echocardiography (TTE) but is detected by TEE in approximately 45 percent of patients presenting with an acute embolic event in the setting of new onset AF [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/29/39383/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]. Even when not seen on TEE, an intracardiac thrombus is presumed to have been present in all patients with AF who have had a recent thromboembolic event. This hypothesis is based in part upon the observations that microscopic thrombus can be identified in most patients with chronic sustained AF at autopsy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/29/39383/abstract/14\">",
"     14",
"    </a>",
"    ] and that patients with a recent thromboembolism and newly recognized AF are significantly more likely to have spontaneous echo contrast than similar patients without a thromboembolic event (87 versus 48 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/29/39383/abstract/13\">",
"     13",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/32/42506?source=see_link&amp;anchor=H5#H5\">",
"     \"Antithrombotic therapy to prevent embolization in atrial fibrillation\", section on 'Antithrombotic prevention'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Thus, diagnostic evaluation by TEE to search for a residual intraatrial thrombus is not essential since the absence of a thrombus will not alter the long-term clinical (anticoagulation) management. However, TEE may be reasonable if cardioversion is desired to confirm absence of residual thrombus. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/50/2856?source=see_link\">",
"     \"Role of echocardiography in atrial fibrillation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H400131632\">",
"    <span class=\"h2\">",
"     Cardiac monitoring",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cardiac monitoring is recommended for at least the first 24 hours after the onset of ischemic stroke to look for AF or atrial flutter [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/29/39383/abstract/15\">",
"     15",
"    </a>",
"    ]. The utility of this approach is illustrated by the findings of a systematic review of five prospective studies that included a total of 588 hospitalized patients with ischemic stroke who had Holter monitoring for 21 to 72 hours [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/29/39383/abstract/16\">",
"     16",
"    </a>",
"    ]. Monitoring detected new AF or atrial flutter in 4.6 percent of these patients (95% CI 0-12.7 percent).",
"   </p>",
"   <p>",
"    Holter monitoring or continuous telemetry may be most useful in patients with a history of palpitations, paroxysmal AF, evidence of spontaneous echo contrast on TEE, and cryptogenic TIA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/29/39383/abstract/17\">",
"     17",
"    </a>",
"    ]. Although the electrocardiogram and Holter monitoring can identify patients who have AF, the demonstration of normal sinus rhythm does not exclude intermittent atrial fibrillation. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/32/36361?source=see_link\">",
"     \"Ambulatory monitoring in the assessment of cardiac arrhythmias\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     FIBRINOLYTIC THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fibrinolytic (thrombolytic) therapy administered within 3 to 4.5 hours of the onset of symptoms in patients with acute ischemic stroke significantly reduces long-term disability with no increase in long-term mortality, despite an increase in intracerebral hemorrhage and death within the first seven to 10 days [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/29/39383/abstract/18-20\">",
"     18-20",
"    </a>",
"    ]. In the NINDS trial, the rate of symptomatic intracerebral hemorrhage was 6.4 percent within 36 hours [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/29/39383/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The general approach to fibrinolytic therapy in ischemic stroke is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/8/41098?source=see_link\">",
"     \"Reperfusion therapy for acute ischemic stroke\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Specific data on the effectiveness of fibrinolytic therapy in ischemic stroke are limited for patients with AF, although such patients account for 20 to 30 percent of those participating in clinical trials [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/29/39383/abstract/18,20\">",
"     18,20",
"    </a>",
"    ]. The NINDS trial, the largest and best study of fibrinolytic therapy in acute ischemic stroke, included 115 patients with AF (18 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/29/39383/abstract/18\">",
"     18",
"    </a>",
"    ]. No subgroup analysis of these patients has been reported, although there was no evidence of a treatment interaction between a history of AF and benefit from",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/41/11929?source=see_link\">",
"     alteplase",
"    </a>",
"    . The large size and worse prognosis of AF-associated acute ischemic stroke accentuates both the risks and the benefits of fibrinolysis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/29/39383/abstract/20\">",
"     20",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/8/41098?source=see_link\">",
"     \"Reperfusion therapy for acute ischemic stroke\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The presence of a current intracranial hemorrhage is an",
"    <strong>",
"     absolute contraindication",
"    </strong>",
"    to immediate use of fibrinolysis. Patients with a",
"    <strong>",
"     previous",
"    </strong>",
"    intracranial hemorrhage may be candidates for anticoagulation depending upon their risk of recurrent ischemic stroke. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/57/8089?source=see_link\">",
"     \"Anticoagulant and antiplatelet therapy in patients with an acute or prior intracerebral hemorrhage\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/3/10298?source=see_link&amp;anchor=H19#H19\">",
"     \"Management of warfarin-associated intracerebral hemorrhage\", section on 'Resumption of anticoagulation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     ACUTE ANTITHROMBOTIC THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients with AF who suffer an ischemic stroke, acute antithrombotic therapy may be warranted both to reduce disability and the risk of early recurrent stroke, which is 3 to 5 percent in the first two weeks [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/29/39383/abstract/21,22\">",
"     21,22",
"    </a>",
"    ]. These benefits must be balanced against the risk of intracranial bleeding with antithrombotic therapy. The management of acute antithrombotic therapy in patients with stroke is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/60/31688?source=see_link\">",
"     \"Antithrombotic treatment of acute ischemic stroke and transient ischemic attack\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     LONG-TERM THERAPY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Warfarin",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     Warfarin",
"    </a>",
"    is the most studied antithrombotic therapy for prevention of recurrent stroke in patients with AF and an ischemic stroke and its efficacy is well demonstrated.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     Aspirin",
"    </a>",
"    alone offers inadequate protection, with a stroke risk that averaged 10 percent per year in a pooled analysis of individual participants in six randomized trials [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/29/39383/abstract/23\">",
"     23",
"    </a>",
"    ]. Treatment with adjusted-dose warfarin reduced this risk to 4 percent per year.",
"   </p>",
"   <p>",
"    In an analysis from the European Atrial Fibrillation trial (EAFT) and SPAF III of 834 patients with prior nondisabling ischemic stroke at study entry, the long-term risk of recurrent stroke was lower in patients with a prior TIA than in those with a completed ischemic stroke [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/29/39383/abstract/24\">",
"     24",
"    </a>",
"    ]. However, the reduction in recurrent stroke risk with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    therapy was comparable in both groups: 3 versus 7 percent per year with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    in patients with a TIA and 4 versus 11 percent per year in those with a completed ischemic stroke.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H789229204\">",
"    <span class=\"h3\">",
"     Timing after acute stroke",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     Warfarin",
"    </a>",
"    anticoagulation is recommended in eligible patients. For medically stable patients with a small or moderate-sized infarct, warfarin can be initiated soon (after 24 hours) after admission with minimal risk of transformation to hemorrhagic stroke. We prefer to wait for 48 hours to start newer oral anticoagulants in these patients as they have a more rapid anticoagulant effect.",
"   </p>",
"   <p>",
"    Withholding anticoagulation for two weeks is generally recommended for those with large infarctions, symptomatic hemorrhagic transformation, or poorly controlled hypertension. Patients who are not treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    earlier are likely to benefit from",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    until therapeutic anticoagulation is achieved [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/29/39383/abstract/25\">",
"     25",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/60/31688?source=see_link\">",
"     \"Antithrombotic treatment of acute ischemic stroke and transient ischemic attack\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H789229211\">",
"    <span class=\"h3\">",
"     Patients with hypertension",
"    </span>",
"    &nbsp;&mdash;&nbsp;The optimal therapy is not known for AF patients with hypertension who experience a small subcortical \"lacunar\" infarct deemed as likely to be due to cerebral small artery disease as opposed to a cardiac embolus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/29/39383/abstract/26\">",
"     26",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     Warfarin",
"    </a>",
"    anticoagulation is recommended, given the large benefit of warfarin consistently documented in randomized trials and the inability to define stroke mechanism with certainty.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H789229218\">",
"    <span class=\"h3\">",
"     Stroke in patients taking warfarin",
"    </span>",
"    &nbsp;&mdash;&nbsp;In AF patients who suffer ischemic stroke during",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    anticoagulation, the intensity of anticoagulation is most often subtherapeutic, and continuing warfarin (after two weeks of temporary interruption with large infarcts) with renewed efforts to keep the INR in the 2.0 to 3.0 therapeutic range is recommended. When ischemic stroke occurs with a therapeutic INR (2.0 to 3.0), it is often \"lacunar\" related to cerebral small artery disease, rather than cardioembolic etiology. Nevertheless, we favor increasing the target INR to 2.5 to 3.5, rather than routine addition of antiplatelet therapy. The addition of antiplatelet therapy is known to increase major hemorrhage (and particularly brain hemorrhage) and the benefit is less well defined.",
"   </p>",
"   <p>",
"    The management of patients with AF who develop a",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    -associated intracranial hemorrhage is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/3/10298?source=see_link\">",
"     \"Management of warfarin-associated intracerebral hemorrhage\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Patients who cannot receive warfarin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dual antiplatelet therapy may be a reasonable alternative to therapy with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    alone in high-risk patients with AF who CANNOT be treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    anticoagulation because of lack of access to adequate INR monitoring, widely fluctuating and difficult-to-control INR, inability to take",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/39/8825?source=see_link\">",
"     dabigatran",
"    </a>",
"    (see",
"    <a class=\"local\" href=\"#H15\">",
"     'Dabigatran'",
"    </a>",
"    below), or because of strong patient preference following careful consideration of the advantages of oral anticoagulation. This issue is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/32/42506?source=see_link&amp;anchor=H16#H16\">",
"     \"Antithrombotic therapy to prevent embolization in atrial fibrillation\", section on 'Alternatives to anticoagulant monotherapy'",
"    </a>",
"    .),",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Dabigatran",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/39/8825?source=see_link\">",
"     Dabigatran",
"    </a>",
"    was compared with adjusted-dose",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    in a trial involving over 18,000 AF patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/29/39383/abstract/27\">",
"     27",
"    </a>",
"    ]. Dabigatran compared favorably to warfarin, including in the subset of participants with prior stroke. Other oral thrombin inhibitors and oral factor Xa inhibitors are currently being studied for efficacy in preventing thromboembolism. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/32/42506?source=see_link&amp;anchor=H524842274#H524842274\">",
"     \"Antithrombotic therapy to prevent embolization in atrial fibrillation\", section on 'Direct thrombin and factor Xa inhibitors'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H555483693\">",
"    <span class=\"h2\">",
"     Rivaroxaban",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/16/5384?source=see_link\">",
"     Rivaroxaban",
"    </a>",
"    was compared with adjusted-dose",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    in a randomized trial of over 14,000 patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/29/39383/abstract/28\">",
"     28",
"    </a>",
"    ]. Data for the subset with prior stroke or TIA have not been published, but nearly 55 percent of the patients had a history of stroke, TIA, or systemic embolism and the mean CHADS2 score was 3.5. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/32/42506?source=see_link&amp;anchor=H358919860#H358919860\">",
"     \"Antithrombotic therapy to prevent embolization in atrial fibrillation\", section on 'Rivaroxaban'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Control of hypertension",
"    </span>",
"    &nbsp;&mdash;&nbsp;Control of hypertension is an important component of the management of patients with AF who have had a stroke. Antihypertensive therapy, preferably including an angiotensin converting enzyme (ACE) inhibitor, reduces the risk of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    -associated intracranial hemorrhage and may reduce the rate of recurrent stroke. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/3/10298?source=see_link\">",
"     \"Management of warfarin-associated intracerebral hemorrhage\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The latter benefit was suggested in a secondary analysis from the PROGRESS trial, which demonstrated the benefit of blood pressure lowering (using",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/24/34183?source=see_link\">",
"     perindopril-indapamide",
"    </a>",
"    ) among both hypertensive and nonhypertensive patients who had a previous stroke or TIA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/29/39383/abstract/29\">",
"     29",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/57/17305?source=see_link&amp;anchor=H3#H3\">",
"     \"Antihypertensive therapy to prevent recurrent stroke or transient ischemic attack\", section on 'Trials of long-term antihypertensive therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Among the subset of 476 patients with AF, perindopril-based therapy produced a mean",
"    <span class=\"nowrap\">",
"     7.3/3.4",
"    </span>",
"    mmHg reduction in blood pressure compared to placebo and a 34 percent reduction in the incidence of recurrent stroke (13.6 versus 18.9 percent), a difference that was not statistically significant because of the small number of recurrent events [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/29/39383/abstract/30\">",
"     30",
"    </a>",
"    ]. However, there was a significant 38 percent reduction in all major vascular events (one major vascular event prevented in every 11 patients treated for five years), providing a strong rationale for blood pressure lowering.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Patients with carotid artery stenosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;About 10 percent of AF patients with ischemic stroke or TIA have a cervical carotid stenosis of &gt;50 percent diameter stenosis, slightly more than half of which are ipsilateral to the neurological symptoms. Based on estimates of attributable risk, ipsilateral stenosis of &gt;70 percent stenosis is equally likely to be the cause of cerebral ischemia as is cardiogenic embolism. Consequently, carotid endarterectomy or stenting seems reasonable for AF patients with high-grade ipsilateral stenosis, followed by chronic anticoagulation and antiplatelet therapy, although this approach is empiric, without good supporting evidence. The management of symptomatic coronary artery disease is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/1/21530?source=see_link\">",
"     \"Management of symptomatic carotid atherosclerotic disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     RISK OF RECURRENT EMBOLISM",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients who have had a prior embolic event already have the most potent high-risk factor for subsequent stroke, as defined by the CHADS2 score (",
"    <a class=\"graphic graphic_table graphicRef61615 \" href=\"mobipreview.htm?39/45/40668\">",
"     table 2",
"    </a>",
"    ). The risk of recurrent stroke in the first few weeks after the initial event is 3 to 5 percent based upon large numbers of patients observed in the control arms of randomized trials [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/29/39383/abstract/21,22\">",
"     21,22",
"    </a>",
"    ]. In addition, a risk of up to 12 percent per year has been reported in untreated patients in the first two to three years after a stroke [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/29/39383/abstract/31,32\">",
"     31,32",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/23/27001?source=see_link\">",
"     \"Risk of embolization in atrial fibrillation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Due to the high risk of recurrent embolism, lifelong anticoagulation is strongly recommended for secondary prevention.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Ischemic stroke may be the presenting manifestation of atrial fibrillation (AF) in some patients, while in others it may occur despite appropriate antithrombotic prophylaxis.",
"     </li>",
"     <li>",
"      AF is associated with more severe ischemic strokes and \"longer\" transient ischemic attacks (TIAs) than emboli from carotid disease, presumably due to embolization of larger particles in AF. AF is associated with particularly severe ischemic strokes, mostly caused by relatively large emboli from the left atrial appendage. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Stroke characteristics'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Evaluation of patients with AF and acute stroke is similar to other patients with stroke. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A computed tomogram or magnetic resonance image of the head should be obtained before commencing fibrinolytic or antithrombotic therapy to confirm the absence of intracranial hemorrhage and to assess the size of any cerebral infarction. The size of the infarction impacts the timing of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      initiation.",
"     </li>",
"     <li>",
"      Fibrinolytic therapy (usually with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?11/41/11929?source=see_link\">",
"       alteplase",
"      </a>",
"      ) administered within 4.5, and preferably 3, hours of the onset of symptoms in patients with acute ischemic stroke significantly reduces long-term disability with no increase in long-term mortality. Patients with a",
"      <strong>",
"       previous",
"      </strong>",
"      intracranial hemorrhage may be candidates for anticoagulation depending upon their risk of recurrent ischemic stroke. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Fibrinolytic therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Anticoagulation is the most effective long-term antithrombotic therapy for prevention of recurrent stroke. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Long-term therapy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/29/39383/abstract/1\">",
"      Anderson DC, Kappelle LJ, Eliasziw M, et al. Occurrence of hemispheric and retinal ischemia in atrial fibrillation compared with carotid stenosis. Stroke 2002; 33:1963.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/29/39383/abstract/2\">",
"      Harrison MJ, Marshall J. Atrial fibrillation, TIAs and completed strokes. Stroke 1984; 15:441.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/29/39383/abstract/3\">",
"      Lin HJ, Wolf PA, Kelly-Hayes M, et al. Stroke severity in atrial fibrillation. The Framingham Study. Stroke 1996; 27:1760.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/29/39383/abstract/4\">",
"      J&oslash;rgensen HS, Nakayama H, Reith J, et al. Acute stroke with atrial fibrillation. The Copenhagen Stroke Study. Stroke 1996; 27:1765.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/29/39383/abstract/5\">",
"      Lamassa M, Di Carlo A, Pracucci G, et al. Characteristics, outcome, and care of stroke associated with atrial fibrillation in Europe: data from a multicenter multinational hospital-based registry (The European Community Stroke Project). Stroke 2001; 32:392.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/29/39383/abstract/6\">",
"      Easton JD, Saver JL, Albers GW, et al. Definition and evaluation of transient ischemic attack: a scientific statement for healthcare professionals from the American Heart Association/American Stroke Association Stroke Council; Council on Cardiovascular Surgery and Anesthesia; Council on Cardiovascular Radiology and Intervention; Council on Cardiovascular Nursing; and the Interdisciplinary Council on Peripheral Vascular Disease. The American Academy of Neurology affirms the value of this statement as an educational tool for neurologists. Stroke 2009; 40:2276.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/29/39383/abstract/7\">",
"      Ezekowitz MD, James KE, Nazarian SM, et al. Silent cerebral infarction in patients with nonrheumatic atrial fibrillation. The Veterans Affairs Stroke Prevention in Nonrheumatic Atrial Fibrillation Investigators. Circulation 1995; 92:2178.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/29/39383/abstract/8\">",
"      Kempster PA, Gerraty RP, Gates PC. Asymptomatic cerebral infarction in patients with chronic atrial fibrillation. Stroke 1988; 19:955.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/29/39383/abstract/9\">",
"      Cullinane M, Wainwright R, Brown A, et al. Asymptomatic embolization in subjects with atrial fibrillation not taking anticoagulants: a prospective study. Stroke 1998; 29:1810.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/29/39383/abstract/10\">",
"      Hylek EM, Go AS, Chang Y, et al. Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation. N Engl J Med 2003; 349:1019.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/29/39383/abstract/11\">",
"      Hart RG, Pearce LA, Miller VT, et al. Cardioembolic vs. noncardioembolic strokes in atrial fibrillation: frequency and effect of antithrombotic agents in the stroke prevention in atrial fibrillation studies. Cerebrovasc Dis 2000; 10:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/29/39383/abstract/12\">",
"      Transesophageal echocardiographic correlates of thromboembolism in high-risk patients with nonvalvular atrial fibrillation. The Stroke Prevention in Atrial Fibrillation Investigators Committee on Echocardiography. Ann Intern Med 1998; 128:639.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/29/39383/abstract/13\">",
"      Manning WJ, Silverman DI, Waksmonski CA, et al. Prevalence of residual left atrial thrombi among patients with acute thromboembolism and newly recognized atrial fibrillation. Arch Intern Med 1995; 155:2193.",
"     </a>",
"    </li>",
"    <li>",
"     Fisher, CM. Embolism in atrial fibrillation. In: Atrial Fibrillation, Kulbertus, HE, Olsson, SB, Schlepper, M (Eds), Alindgren &amp; Soner AB, Moindal, Sweden 1981. p.192.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/29/39383/abstract/15\">",
"      Jauch EC, Saver JL, Adams HP Jr, et al. Guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the american heart association/american stroke association. Stroke 2013; 44:870.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/29/39383/abstract/16\">",
"      Liao J, Khalid Z, Scallan C, et al. Noninvasive cardiac monitoring for detecting paroxysmal atrial fibrillation or flutter after acute ischemic stroke: a systematic review. Stroke 2007; 38:2935.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/29/39383/abstract/17\">",
"      Flemming KD, Brown RD Jr, Petty GW, et al. Evaluation and management of transient ischemic attack and minor cerebral infarction. Mayo Clin Proc 2004; 79:1071.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/29/39383/abstract/18\">",
"      Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. N Engl J Med 1995; 333:1581.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/29/39383/abstract/19\">",
"      Del Zoppo GJ, Saver JL, Jauch EC, et al. Expansion of the time window for treatment of acute ischemic stroke with intravenous tissue plasminogen activator: a science advisory from the American Heart Association/American Stroke Association. Stroke 2009; 40:2945.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/29/39383/abstract/20\">",
"      Hart RG, Palacio S, Pearce LA. Atrial fibrillation, stroke, and acute antithrombotic therapy: analysis of randomized clinical trials. Stroke 2002; 33:2722.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/29/39383/abstract/21\">",
"      The International Stroke Trial (IST): a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19435 patients with acute ischaemic stroke. International Stroke Trial Collaborative Group. Lancet 1997; 349:1569.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/29/39383/abstract/22\">",
"      Saxena R, Lewis S, Berge E, et al. Risk of early death and recurrent stroke and effect of heparin in 3169 patients with acute ischemic stroke and atrial fibrillation in the International Stroke Trial. Stroke 2001; 32:2333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/29/39383/abstract/23\">",
"      van Walraven C, Hart RG, Singer DE, et al. Oral anticoagulants vs aspirin in nonvalvular atrial fibrillation: an individual patient meta-analysis. JAMA 2002; 288:2441.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/29/39383/abstract/24\">",
"      Hart RG, Pearce LA, Koudstaal PJ. Transient ischemic attacks in patients with atrial fibrillation: implications for secondary prevention: the European Atrial Fibrillation Trial and Stroke Prevention in Atrial Fibrillation III trial. Stroke 2004; 35:948.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/29/39383/abstract/25\">",
"      Chen ZM, Sandercock P, Pan HC, et al. Indications for early aspirin use in acute ischemic stroke : A combined analysis of 40 000 randomized patients from the chinese acute stroke trial and the international stroke trial. On behalf of the CAST and IST collaborative groups. Stroke 2000; 31:1240.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/29/39383/abstract/26\">",
"      Evans A, Perez I, Yu G, Kalra L. Should stroke subtype influence anticoagulation decisions to prevent recurrence in stroke patients with atrial fibrillation? Stroke 2001; 32:2828.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/29/39383/abstract/27\">",
"      Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361:1139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/29/39383/abstract/28\">",
"      Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011; 365:883.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/29/39383/abstract/29\">",
"      PROGRESS Collaborative Group. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet 2001; 358:1033.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/29/39383/abstract/30\">",
"      Arima H, Hart RG, Colman S, et al. Perindopril-based blood pressure-lowering reduces major vascular events in patients with atrial fibrillation and prior stroke or transient ischemic attack. Stroke 2005; 36:2164.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/29/39383/abstract/31\">",
"      Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. EAFT (European Atrial Fibrillation Trial) Study Group. Lancet 1993; 342:1255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/29/39383/abstract/32\">",
"      Sandercock P, Bamford J, Dennis M, et al. Atrial fibrillation and stroke: prevalence in different types of stroke and influence on early and long term prognosis (Oxfordshire community stroke project). BMJ 1992; 305:1460.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1059 Version 17.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-213.131.41.98-E13A3EE944-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_29_39383=[""].join("\n");
var outline_f38_29_39383=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H19\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      STROKE CHARACTERISTICS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Differential diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Echocardiography",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H400131632\">",
"      Cardiac monitoring",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      FIBRINOLYTIC THERAPY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      ACUTE ANTITHROMBOTIC THERAPY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      LONG-TERM THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Warfarin",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H789229204\">",
"      - Timing after acute stroke",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H789229211\">",
"      - Patients with hypertension",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H789229218\">",
"      - Stroke in patients taking warfarin",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Patients who cannot receive warfarin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Dabigatran",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H555483693\">",
"      Rivaroxaban",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Control of hypertension",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Patients with carotid artery stenosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      RISK OF RECURRENT EMBOLISM",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/1059\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/1059|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?20/39/21117\" title=\"table 1\">",
"      Ischemic stroke classification",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?39/45/40668\" title=\"table 2\">",
"      CHADS2 score and thromboembolic risk with and without warfarin",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/32/36361?source=related_link\">",
"      Ambulatory monitoring in the assessment of cardiac arrhythmias",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/57/8089?source=related_link\">",
"      Anticoagulant and antiplatelet therapy in patients with an acute or prior intracerebral hemorrhage",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/57/17305?source=related_link\">",
"      Antihypertensive therapy to prevent recurrent stroke or transient ischemic attack",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/32/42506?source=related_link\">",
"      Antithrombotic therapy to prevent embolization in atrial fibrillation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/60/31688?source=related_link\">",
"      Antithrombotic treatment of acute ischemic stroke and transient ischemic attack",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/17/40216?source=related_link\">",
"      Clinical diagnosis of stroke subtypes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/21/18773?source=related_link\">",
"      Definition of transient ischemic attack",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/35/10809?source=related_link\">",
"      Embolism from aortic plaque: Thromboembolism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/54/28522?source=related_link\">",
"      Epidemiology of and risk factors for atrial fibrillation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/29/33242?source=related_link\">",
"      Initial assessment and management of acute stroke",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/1/21530?source=related_link\">",
"      Management of symptomatic carotid atherosclerotic disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/3/10298?source=related_link\">",
"      Management of warfarin-associated intracerebral hemorrhage",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/47/28410?source=related_link\">",
"      Overview of the evaluation of stroke",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/8/41098?source=related_link\">",
"      Reperfusion therapy for acute ischemic stroke",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/23/27001?source=related_link\">",
"      Risk of embolization in atrial fibrillation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/50/2856?source=related_link\">",
"      Role of echocardiography in atrial fibrillation",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f38_29_39384="Retained products of conception";
var content_f38_29_39384=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Retained products of conception",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/29/39384/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/29/39384/contributors\">",
"     Daniela A Carusi, MD, MSc",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/29/39384/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/29/39384/contributors\">",
"     Robert L Barbieri, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/29/39384/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/29/39384/contributors\">",
"     Sandy J Falk, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?38/29/39384/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 22, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The term retained products of conception (RPOC) refers to placental",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    fetal tissue that remains in the uterus after a spontaneous pregnancy loss (miscarriage), planned pregnancy termination, or",
"    <span class=\"nowrap\">",
"     preterm/term",
"    </span>",
"    delivery. The presence of RPOC after a spontaneous pregnancy loss distinguishes an incomplete from a complete miscarriage.",
"   </p>",
"   <p>",
"    This topic will review the evaluation and management of women who present with bleeding",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    signs of infection after uterine evacuation in the first half of pregnancy. Management of RPOC after",
"    <span class=\"nowrap\">",
"     preterm/term",
"    </span>",
"    delivery and the initial management of an incomplete miscarriage are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/38/42600?source=see_link\">",
"     \"Overview of postpartum hemorrhage\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/11/39097?source=see_link\">",
"     \"Postpartum endometritis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/49/2841?source=see_link\">",
"     \"Spontaneous abortion: Management\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     INCIDENCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The reported incidence of RPOC varies widely and depends on several factors, including initial treatment (higher with nonsurgical versus surgical management), criteria for diagnosis",
"    <span class=\"nowrap\">",
"     (signs/symptoms",
"    </span>",
"    versus",
"    <span class=\"nowrap\">",
"     laboratory/pathology/imaging",
"    </span>",
"    results), and duration of follow-up (RPOC eventually resorb or are passed) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/29/39384/abstract/1-17\">",
"     1-17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The characteristic clinical manifestations of RPOC include one or more of the following: uterine bleeding, pelvic pain, fever,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    uterine tenderness. These clinical findings are nonspecific; moreover, it is normal to have some postabortal bleeding and discomfort.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Uterine bleeding",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women routinely have some uterine bleeding after a miscarriage or pregnancy termination, so it can be difficult to distinguish normal from abnormal bleeding. A reasonable approach is to assume that bleeding is probably abnormal if it is heavy (ie, has the potential to result in anemia [passage of large clots or flow that is significantly greater than menses, or not diminishing over time]) or prolonged (ie, lasting longer than three weeks).",
"   </p>",
"   <p>",
"    Prospective studies of women with miscarriage report an average of 8 to 11 bleeding days after identification of the miscarriage; however, the bleeding often lasted two weeks or more [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/29/39384/abstract/1,3\">",
"     1,3",
"    </a>",
"    ]. Following medical treatment of miscarriage, the average number of bleeding days was 9 to 12, but many women bled for more than 14 days [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/29/39384/abstract/1,18\">",
"     1,18",
"    </a>",
"    ]. The duration of vaginal bleeding was significantly shorter after surgical evacuation of the uterus. These studies generally included an intervention if symptoms continued beyond 7 to 21 days; few allowed the bleeding to continue for more than three to six weeks.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Fever and/or pain",
"    </span>",
"    &nbsp;&mdash;&nbsp;Necrotic RPOC are prone to infection by cervicovaginal flora. Clinical manifestations include fever, abnormal uterine bleeding, crampy lower abdominal pain, and uterine tenderness.",
"   </p>",
"   <p>",
"    Fever is never normal following evacuation of the uterus, but cramping for a few hours or days is common. Most women will obtain adequate pain relief with a short course of analgesics, such as nonsteroidal anti-inflammatory drugs. Women with poorly controlled pain or pain that does not resolve over a few days or is increasing may have RPOC. If the woman has been instrumented, the possibility of uterine perforation with visceral injury should be excluded. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/19/4408?source=see_link\">",
"     \"Uterine perforation during gynecologic procedures\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Clostridial toxic shock syndrome has been reported following first trimester miscarriage and medical abortion, and almost all of the cases were fatal. These patients generally present with abdominal pain, chills, tachycardia, and profound leukocytosis, but they are often afebrile [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/29/39384/abstract/19,20\">",
"     19,20",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/62/12264?source=see_link\">",
"     \"Clostridial myonecrosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/38/33386?source=see_link\">",
"     \"Mifepristone for the medical termination of pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Amenorrhea",
"    </span>",
"    &nbsp;&mdash;&nbsp;Menses typically resume by six weeks post miscarriage or pregnancy termination. If the patient fails to menstruate by this time, viable trophoblastic tissue may be present.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Bleeding",
"    </span>",
"    &nbsp;&mdash;&nbsp;The differential diagnosis of uterine bleeding after uterine evacuation includes:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Retained products of conception (including placenta accreta)",
"     </li>",
"     <li>",
"      Hematometra (see Overview of pregnancy termination-I\", section on Hematometra)",
"     </li>",
"     <li>",
"      Uterine",
"      <span class=\"nowrap\">",
"       atony/subinvolution",
"      </span>",
"     </li>",
"     <li>",
"      Ectopic pregnancy (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?1/9/1178?source=see_link\">",
"       \"Clinical manifestations, diagnosis, and management of ectopic pregnancy\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Trauma (cervical or vaginal laceration, uterine arteriovascular malformation, uterine perforation)",
"     </li>",
"     <li>",
"      Gestational trophoblastic disease",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fever and pain after uterine evacuation may be related to:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Endometritis (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?38/11/39097?source=see_link\">",
"       \"Postpartum endometritis\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Infected retained products of conception",
"     </li>",
"     <li>",
"      Pelvic inflammatory disease (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?1/0/1032?source=see_link\">",
"       \"Clinical features and diagnosis of pelvic inflammatory disease\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Other abdominopelvic infections, possibly related to uterine perforation if the uterus has been instrumented",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     DIAGNOSTIC EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Routine evaluation for RPOC after all cases of miscarriage or pregnancy termination is likely to result in false positive diagnoses and unnecessary interventions since RPOC do not always lead to morbidity. On the other hand, evaluation is indicated in women whose symptoms fall outside the normal range, such as those with bleeding that is heavy or prolonged, and those with fever, uterine tenderness, or significant abdominopelvic pain. Combined clinical, laboratory, and sonographic evaluation of these patients can help direct management [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/29/39384/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The goal of the evaluation is to determine whether RPOC are the probable source of the woman's symptoms, or whether another diagnosis is more likely (see",
"    <a class=\"local\" href=\"#H7\">",
"     'Differential diagnosis'",
"    </a>",
"    above). If RPOC are thought to be causing the symptoms, treatment with surgical evacuation or medication is warranted. In women who have undergone surgical intervention, the possibility of a procedure-related complication needs to be considered (cervical or vaginal laceration, uterine perforation, traumatic arteriovenous malformation) (see",
"    <a class=\"local\" href=\"#H22\">",
"     'Surgical intervention'",
"    </a>",
"    below).",
"   </p>",
"   <p>",
"    Since RPOC and other postabortal complications can be life-threatening, prompt assessment for severe hemorrhage or sepsis is crucial.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     History",
"    </span>",
"    &nbsp;&mdash;&nbsp;The patient should be asked details of the antecedent pregnancy, including the gestational age of the pregnancy (determined by last menstrual period, timing of fertility treatment, or prior ultrasound examination), timing of tissue passage or uterine evacuation, and whether any tissue had been examined by the patient's clinician or a pathologist. If an intrauterine pregnancy has not been confirmed by prior ultrasound or examination of tissue, then ectopic pregnancy must be excluded as part of the evaluation.",
"   </p>",
"   <p>",
"    The amount and duration of bleeding should be determined. While it is difficult to quantify vaginal bleeding, the passage of large blood clots (larger than a plum or fist), bleeding that saturates a standard sanitary pad in an hour, syncope, or orthostasis suggest excessive bleeding.",
"   </p>",
"   <p>",
"    The intensity, location, and pattern of pain should be determined. Pain that is not controlled with oral analgesia or is becoming worse over time suggests a pathologic process.",
"   </p>",
"   <p>",
"    Symptoms of uterine infection include fever, lower abdominal or pelvic pain, and possibly chills or purulent vaginal discharge. Fever that is accompanied by palpitations, dyspnea, severe abdominal pain, or mental status changes can signify sepsis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/10/24744?source=see_link\">",
"     \"Sepsis and the systemic inflammatory response syndrome: Definitions, epidemiology, and prognosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/20/5449?source=see_link\">",
"     \"Pathophysiology of sepsis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Physical examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;Generalized evaluation of the patient should assess for restlessness, inability to move without pain, mental status changes, diaphoresis, pallor, or dyspnea, any of which can signify serious illness, such as sepsis. Likewise, tachycardia, hypotension, orthostasis, tachypnea,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    hypoxemia often signify serious illness. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/62/6120?source=see_link\">",
"     \"Shock in adults: Types, presentation, and diagnostic approach\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The abdomen is evaluated for distention, rigidity, rebound or involuntary guarding, suggestive of an inflammatory intraabdominal process. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/44/17095?source=see_link\">",
"     \"Evaluation of acute pelvic pain in women\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    On speculum examination, the amount and character of uterine bleeding are assessed. Active bleeding that fills the upper vagina during the examination is excessive. Blood clot or tissue may extrude from the cervical os or lie in the vagina; it should be examined for evidence of fetal parts, membranes, or villi (to identify villi, it helps to float the tissue in saline) and then sent for pathologic analysis. If a large cotton swab can be passed into the uterine cavity, the internal cervical os is dilated, which suggests RPOC since the cervix usually closes rapidly (within a day) after a complete uterine evacuation.",
"   </p>",
"   <p>",
"    The bimanual examination should evaluate for cervical motion tenderness, significant uterine tenderness or enlargement, and adnexal masses or tenderness.",
"   </p>",
"   <p>",
"    Significant uterine tenderness, heavy vaginal bleeding, cervical dilation, uterine enlargement, or signs of systemic infection should prompt further evaluation for RPOC.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Laboratory",
"    </span>",
"    &nbsp;&mdash;&nbsp;Laboratory studies are often normal and thus of limited value. However, markedly abnormal values help guide treatment recommendations.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Complete blood count and differential &mdash; An elevated white blood cell count supports the diagnosis of uterine infection, but can be a normal finding in postpartum women secondary to the physiologic leukocytosis of pregnancy and labor. However, a rising neutrophil count associated with elevated numbers of bands is suggestive of an infectious process. A low",
"      <span class=\"nowrap\">",
"       hemoglobin/hematocrit",
"      </span>",
"      supports a diagnosis of heavy or prolonged bleeding and likely warrants consideration of surgical intervention and assessment for coagulopathy.",
"     </li>",
"     <li>",
"      General endometrial cultures are not performed routinely when infection is suspected because of the difficulty in obtaining a clean specimen through the cervix. Furthermore, they yield results too late for clinical use, while rarely changing treatment; thus, they are not cost-effective when performed as a routine procedure in women with fever.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Blood cultures are costly and the initial choice of antibiotic therapy has to be made before the results are available. However, they can be useful in guiding antimicrobial treatment if the patient fails to respond to empiric therapy or appears acutely ill with fever and chills. Interestingly, only a single organism may be identified despite polymicrobial endometrial infection.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A single qualitative or quantitative human chorionic gonadotropin (hCG) concentration is not useful, as hCG can remain positive for weeks after an uncomplicated miscarriage or pregnancy termination. Alternatively, an hCG level that is less than the assay threshold does not exclude the possibility of RPOC as the cause of the patient's symptoms since necrotic RPOCs may remain in the uterus without actively secreting hormone.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In stable afebrile patients with persistent abnormal bleeding over three or more weeks and inconclusive findings on ultrasound examination, serially monitoring hCG levels may identify a plateau or rise, which suggests residual, viable trophoblast related to ectopic pregnancy, ongoing intrauterine pregnancy, or gestational trophoblastic disease.",
"   </p>",
"   <p>",
"    Several studies have attempted to define the normal decline in hCG levels after pregnancy loss or termination. In one study, for example, the authors analyzed data from 710 patients who had a nondiagnostic transvaginal ultrasound examination on presentation (no intrauterine or extrauterine gestational sac) and whose subsequent serial hCG measurements spontaneously declined to less than 5",
"    <span class=\"nowrap\">",
"     mIU/mL",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/29/39384/abstract/22\">",
"     22",
"    </a>",
"    ]. It was assumed that these patients had undergone a complete miscarriage, although some may have had spontaneous resolution of an ectopic pregnancy (eg, tubal abortion). The rate of hCG decline depended, in part, on the initial level, with higher initial hCG levels showing a more rapid rate of decline. For 95 percent of patients, the slowest rate of decline over 48 hours was 21 to 35 percent; over seven days, the decline was 60 to 84 percent; and, on average, the hCG level became undetectable by 12 to 16 days of follow-up. Based on the curves generated in this study, when the rate of hCG decline is less than 20 percent over 48 hours or 60 percent in one week, then residual trophoblastic tissue (eg, RPOCs, ectopic pregnancy) should be suspected. These data have not been validated in prospective studies.",
"   </p>",
"   <p>",
"    HCG levels have also been studied following medical abortion. In a prospective study, 217 patients undergoing medical abortion had hCG levels drawn at the time of initial treatment and again 6 to 18 days later [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/29/39384/abstract/23\">",
"     23",
"    </a>",
"    ]. An hCG decline of 80 percent during this interval identified 98.5 percent of patients with a complete abortion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/29/39384/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Imaging studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sonography has limited value in triaging women with suspected RPOC because sonographic findings correlate poorly with clinical symptoms and histologic results. The appearance of necrotic decidua and blood clots can mimic RPOC. There is marked overlap in the sonographic uterine appearance of asymptomatic and symptomatic women; the endometrial cavity is commonly irregular and thickened and may show prominent color Doppler flow in women with an uneventful course, as well as those with histologically proven RPOC [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/29/39384/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Furthermore, there is great variability among studies in terms of diagnostic and patient management criteria, no studies have blinded managing clinicians to the ultrasound results, and ultrasound interpretation often influences the choice to perform uterine evacuation. Thus, although histologic findings can often be correlated with imaging results in symptomatic patients with abnormal ultrasound scans, there is less information about RPOC in symptomatic women with normal ultrasound scans since surgical intervention may be avoided in this group, or in asymptomatic women since typically they are not scanned. Likewise, the clinical outcome of expectant management of symptomatic women with abnormal ultrasound findings cannot be determined since these patients often undergo surgical intervention.",
"   </p>",
"   <p>",
"    Sonographic parameters that may be helpful in supporting a clinical diagnosis of RPOC include identification of an echogenic mass within the endometrium and the presence of low-resistance flow within the myometrium or just beneath the endometrium. Endometrial thickness has also been studied, but there is no good evidence that it is useful.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Echogenic mass &mdash; The combination of a hyperechoic endometrial mass or solid component within the endometrium and abnormal (heavy or prolonged) bleeding or infection is a sensitive indicator of RPOC [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/29/39384/abstract/25-28\">",
"       25-28",
"      </a>",
"      ]. On the other hand, in the absence of clinical symptoms, surgical intervention for these ultrasound findings is not indicated, as prevention of future morbidity is unproven.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Of note, ultrasound findings suggestive of an arteriovenous malformation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/29/39384/abstract/29-32\">",
"     29-32",
"    </a>",
"    ] or gestational trophoblastic disease can mimic those associated with RPOC [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/29/39384/abstract/33,34\">",
"     33,34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Low resistance Doppler flow &mdash; Pulsed Doppler can be applied during ultrasound examination to calculate a resistance index; RPOCs are suspected when there is abundant low-resistance flow within the myometrium or just beneath the endometrium [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/29/39384/abstract/28,35\">",
"       28,35",
"      </a>",
"      ]. The value of this test is unclear since the placental implantation site may appear vascular even after trophoblast has separated, and residual tissue causing subinvolution may be present even in the absence of significant blood flow to that tissue [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/29/39384/abstract/36\">",
"       36",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In a prospective study, 62 women underwent ultrasound and Doppler evaluation following miscarriage, and those with a positive Doppler study then underwent uterine evacuation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/29/39384/abstract/37\">",
"     37",
"    </a>",
"    ]. Twenty-nine percent of the women had a positive study, and 89 percent of these women had RPOC on pathologic analysis. Of 44 subjects with a negative Doppler study, 86 percent had an uneventful clinical course, 14 percent had uterine evacuation performed for heavy bleeding, and 33 percent of these women had RPOCs confirmed by pathologic analysis. As in other studies of ultrasound performance, it is not possible to know how many of the women with positive Doppler findings would have done well without surgical intervention, and how many of those expectantly managed actually had RPOCs within the uterus.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Endometrial thickness &mdash; A thickened endometrium has been used as a sign of RPOC. Endometrial thickness is determined by measuring the width of the endometrium in the anterior-posterior dimension. Relatively arbitrary cut-offs of 8 to 25 mm have been defined in the literature [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/29/39384/abstract/3\">",
"       3",
"      </a>",
"      ]. However, there is no good evidence that any cut-off is clinically useful [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/29/39384/abstract/27,38-41\">",
"       27,38-41",
"      </a>",
"      ]. Measurement of endometrial thickness following miscarriage or a pregnancy termination should not be used as a test for RPOCs or as a predictor of need for surgical intervention.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Sonohysterography",
"    </span>",
"    &nbsp;&mdash;&nbsp;An advantage of sonohysterography over conventional ultrasound examination is that it can better define focal irregularities in the uterine cavity and distinguish a free-floating echogenic mass (which is likely to pass through the cervix naturally) from a mass adherent to the uterine wall (which may require surgical intervention). However, this test is invasive and costly compared to standard ultrasound examination; there is inadequate evidence to support its use in management of suspected RPOC.",
"   </p>",
"   <p>",
"    In one small study, 43 percent of the patients with late postabortion and postpartum bleeding and an echogenic mass on conventional ultrasound had either an empty cavity or free floating mass on sonohysterogram [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/29/39384/abstract/42\">",
"     42",
"    </a>",
"    ]. These patients were managed conservatively and did well. Those with an adherent mass underwent surgical intervention, and all had RPOCs confirmed by pathology. As with the other ultrasound studies, it is not possible to know if these patients also would have done well if managed conservatively.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Hysteroscopy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Like sonohysterography, hysteroscopy better defines focal irregularities in the uterine cavity than conventional ultrasound examination and can distinguish a free-floating echogenic mass from a mass adherent to the uterine wall; unlike sonohysterography, hysteroscopy potentially allows diagnosis and therapy during a single procedure. If bleeding is not heavy, hysteroscopy can be performed in the office with a flexible hysteroscope and no anesthesia, but requires specialized equipment and expertise.",
"   </p>",
"   <p>",
"    We prefer hysteroscopy to sonohysterography in stable patients with persistent (three or more weeks) mild symptoms and nondiagnostic ultrasound examination. If RPOC are identified, the tissue can often be removed with a hysteroscopic grasper or with a manual vacuum aspirator.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following discussion applies to women in whom the suspicion of RPOC is high based upon history and physical examination, with or without support from imaging studies.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Patients who are hemodynamically unstable",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients who are hemodynamically unstable due to excessive uterine bleeding after miscarriage or pregnancy termination should be stabilized with fluid and blood products, as needed, and undergo urgent surgical intervention. &nbsp;Uterotonic drugs (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/41/662?source=see_link\">",
"     misoprostol",
"    </a>",
"    800 mcg per rectum or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/50/32549?source=see_link\">",
"     methylergonovine",
"    </a>",
"    0.2 mg orally three or four times per day) may be useful, but have not been studied in this setting.",
"   </p>",
"   <p>",
"    If an alternate source of significant bleeding is found before surgical evacuation, such as a cervical laceration, it should be repaired first. Uterine evacuation may not be necessary if repair of the laceration controls the hemorrhage.",
"   </p>",
"   <p>",
"    After uterine evacuation, if removal of clots and RPOC fail to slow the bleeding, uterine tamponade with an intrauterine balloon catheter (eg, Foley, Bakri, BT-Cath) is the next step. Uterine artery embolization may be an option for patients who do not respond to this therapy, while hysterectomy is the last resort.",
"   </p>",
"   <p>",
"    Usually there is not enough time for formal imaging studies prior to surgery. If an ultrasound examination is possible intraoperatively or at the bedside, evidence of free fluid in the abdomen, which suggests uterine perforation or ruptured ectopic pregnancy, can alter the surgical plan to laparotomy.",
"   </p>",
"   <p>",
"    Surgical intervention is discussed below (see",
"    <a class=\"local\" href=\"#H22\">",
"     'Surgical intervention'",
"    </a>",
"    below).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Patients with sepsis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with suspected sepsis due to infected RPOC should be managed by prompt evacuation of the uterus after stabilization and initiation of intravenous broad spectrum antibiotic therapy; delay in evacuation may be fatal since antibiotics may not eradicate infection in poorly perfused necrotic tissue. Sepsis can be defined as clinical diagnosis of infection with two or more of the following: temperature &gt;38.5&ordm;C or &lt;35&ordm;C; heart rate &gt;90",
"    <span class=\"nowrap\">",
"     beats/min;",
"    </span>",
"    respiratory rate &gt;20",
"    <span class=\"nowrap\">",
"     breaths/min",
"    </span>",
"    or PaCO2 &lt;32 mmHg; and WBC &gt;12,000",
"    <span class=\"nowrap\">",
"     cells/mm3,",
"    </span>",
"    &lt;4000",
"    <span class=\"nowrap\">",
"     cells/mm3,",
"    </span>",
"    or &gt;10 percent immature (band) forms.",
"   </p>",
"   <p>",
"    In patients who have been instrumented, generalized abdominal tenderness, guarding, tachycardia, high fever, and prostration suggest advanced sepsis. These patients require aggressive therapy with broad spectrum intravenous antibiotics, uterine re-evacuation, assessment for uterine perforation, and monitoring and support in an intensive care unit. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/49/2841?source=see_link&amp;anchor=H3#H3\">",
"     \"Spontaneous abortion: Management\", section on 'Septic abortion'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Severely ill patients who do not respond to adequate medical therapy and surgical evacuation may have bowel injury, pelvic abscess, or clostridial myometritis. These patients require laparotomy and may need hysterectomy.",
"   </p>",
"   <p>",
"    Surgical intervention is discussed below (see",
"    <a class=\"local\" href=\"#H22\">",
"     'Surgical intervention'",
"    </a>",
"    below).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Medically stable patients with endometritis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with uncomplicated endometritis (low grade fever, mild uterine tenderness, empty uterus on ultrasound examination) are managed with a trial of broad spectrum antibiotics, with coverage of anaerobes (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/55/17269?source=see_link\">",
"     cefotetan",
"    </a>",
"    [2 g intravenously] plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/41/2714?source=see_link\">",
"     doxycycline",
"    </a>",
"    [100 mg intravenously or orally] every 12 hours). This regimen can be completed as an outpatient oral regimen for a 14-day course. An alternative outpatient regimen is",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/17/10521?source=see_link\">",
"     ceftriaxone",
"    </a>",
"    250 mg intramuscularly in a single dose plus doxycycline 100 mg orally twice a day for 14 days with or without",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/38/20065?source=see_link\">",
"     metronidazole",
"    </a>",
"    500 mg orally twice a day for 14 days.",
"   </p>",
"   <p>",
"    The presence of a focal echogenic abnormality in the endometrium, particularly with Doppler evidence of blood flow, suggests RPOC complicating endometritis and the possible need for surgical intervention. In these cases, antibiotics alone may not reach the poorly perfused nidus of infection. The positive predictive value of positive ultrasound findings (echogenic mass, hematometra, endometrium &gt;3 cm thick, Doppler flow) is low in stable, minimally symptomatic patients, but higher in a symptomatic, infected patient. Surgical intervention is discussed below (see",
"    <a class=\"local\" href=\"#H22\">",
"     'Surgical intervention'",
"    </a>",
"    below).",
"   </p>",
"   <p>",
"    If the ultrasound is negative or borderline (possible small amount of material in the uterus), then an otherwise stable patient can be given antibiotics and monitored. An evacuation procedure can be avoided if there is an excellent response to medical therapy within 24 hours. Failure to respond adequately to antibiotics should prompt evacuation. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/11/39097?source=see_link\">",
"     \"Postpartum endometritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Medically stable patients with prolonged bleeding",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surgical intervention may be initiated to manage bothersome bleeding lasting more than three weeks, or sooner if there is strong suspicion for retained POCs and the bleeding is persistently heavy. Bleeding will eventually resolve as the RPOC are resorbed, but surgical management has the potential for immediate removal of the retained tissue, which is preferable for many patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Surgical intervention",
"    </span>",
"    &nbsp;&mdash;&nbsp;Uterine evacuation may be accomplished with sharp or suction curettage. Some patients with RPOC will present with an open cervix, and will not require further dilation. If dilation is needed, the cervix is dilated just enough to allow the curette or suction catheter to enter the uterine cavity. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/41/35480?source=see_link\">",
"     \"Dilation and curettage\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Three concerns of instrumenting the postabortal uterus are (1) infection from introduction of cervicovaginal flora; (2) uterine perforation, which may injure blood vessels or internal organs (bowel or bladder) and require arterial embolization or surgical repair; and (3) development of synechiae.",
"   </p>",
"   <p>",
"    Two trials have evaluated antibiotic use prior to surgical evacuation of an incomplete miscarriage. One trial randomized women to intravenous",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/41/2714?source=see_link\">",
"     doxycycline",
"    </a>",
"    or placebo, and found the same 6 percent rate of infection in both groups [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/29/39384/abstract/43\">",
"     43",
"    </a>",
"    ]. Notably, this study had a high loss-to-follow-up rate of 30 percent. The other prescribed oral",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/49/2840?source=see_link\">",
"     tetracycline",
"    </a>",
"    or placebo for one week following the procedure. They also found no difference in infection rate, but did note a high rate of non-compliance with the medication [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/29/39384/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are, however, high quality data that prophylactic antibiotics reduce periabortal endometritis in all subgroups of women undergoing pregnancy termination, even women at low risk of infection (ie, no history of pelvic inflammatory disease and a negative preoperative chlamydia culture). Although this evidence is indirect, we suggest antibiotic prophylaxis prior to surgical evacuation of RPOC. We use a single dose of a broad spectrum antibiotic at the time of the procedure, but give a full course of endometritis treatment for patients who are clinically infected.",
"   </p>",
"   <p>",
"    If uterine perforation occurs, abdominal exploration is warranted if electrosurgical energy or suction curettage was used at the time of perforation, if the patient is hemodynamically unstable, or if there are signs of severe uterine bleeding or vascular or visceral injury. The original procedure can be completed with use of sharp curettage under direct vision of the exterior surface of the uterus. If uterine perforation occurred during cervical dilation or with a blunt instrument, with no suction or electrosurgical energy source, the risk of vascular or visceral injury is low and close observation may be sufficient. The procedure can be completed under ultrasound guidance (with use of sharp curettage rather than use of suction or an electrosurgical device) and the woman can be observed for signs of complications. Another option is to complete the procedure under laparoscopic guidance: laparoscopy allows for direct visualization of the perforation site and retraction of surrounding structures. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/19/4408?source=see_link\">",
"     \"Uterine perforation during gynecologic procedures\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with suspected perforation should be treated with antibiotics, such as a single dose of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/17/10521?source=see_link\">",
"     ceftriaxone",
"    </a>",
"    250 mg intramuscularly or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/41/2714?source=see_link\">",
"     doxycycline",
"    </a>",
"    100 mg orally twice per day plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/38/20065?source=see_link\">",
"     metronidazole",
"    </a>",
"    500 mg orally three times per day for one week.",
"   </p>",
"   <p>",
"    Uterine synechiae, also known as Asherman's syndrome, are the result of scarring within the uterine cavity. The synechiae may range from inconsequential filmy adhesions to very thick scars that obliterate the endometrium, leading to",
"    <span class=\"nowrap\">",
"     amenorrhea/hypomenorrhea",
"    </span>",
"    and infertility [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/29/39384/abstract/45\">",
"     45",
"    </a>",
"    ]. The major risk factor for developing uterine synechiae is curettage of a pregnant or recently pregnant uterus, particularly in the setting of an infection, and the risk appears to increase with the number of surgical procedures [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/29/39384/abstract/45-48\">",
"     45-48",
"    </a>",
"    ]. As an example, a hysteroscopic study of 147 women who had had prior curettage for miscarriage reported 15 percent had synechiae after one or two curettage procedures and 32 percent had synechiae after three procedures [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/29/39384/abstract/47\">",
"     47",
"    </a>",
"    ]. The scar tissue appeared denser after the second or third curettage. The benefits of a second procedure in a stable patient should be weighed against this risk. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/31/26101?source=see_link\">",
"     \"Intrauterine adhesions\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Medical intervention",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/41/662?source=see_link\">",
"     Misoprostol",
"    </a>",
"    (a prostaglandin E1 analog) is the most commonly used drug for medical treatment of incomplete miscarriage. Its safety and efficacy have been established by multiple randomized and controlled trials. Notably, these trials have excluded patients with suspected or confirmed infection or active hemorrhage; these patients have been treated with antibiotics (if infected)",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    surgical (suction) evacuation.",
"   </p>",
"   <p>",
"    The advantages of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/41/662?source=see_link\">",
"     misoprostol",
"    </a>",
"    over other drugs (including prostaglandin E2) are its low cost, low incidence of side effects when given intravaginally, stability at room temperature, and ready availability. The risk of a major complication is rare.",
"   </p>",
"   <p>",
"    It is important to note that trials of medical management of RPOCs have generally involved patients with incomplete, inevitable, and missed abortion, rather than those with tissue left behind after a medical or surgical evacuation. It is unclear whether results from these trials can be extrapolated to the latter group, although it is reasonable to consider this option in any stable, consenting patient with RPOCs who wishes to avoid a repeat surgical procedure. Nonsurgical management may be preferable for women who wish to avoid the risks of a surgical procedure, particularly if they have had prior uterine evacuation and are concerned about uterine injury or synechiae. The medical management of incomplete abortion is discussed in detail separately (see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/49/2841?source=see_link&amp;anchor=H5#H5\">",
"     \"Spontaneous abortion: Management\", section on 'Incomplete, inevitable, and missed abortion'",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    No trials have evaluated the use of prophylactic antibiotics in uninfected patients undergoing medically induced evacuation of RPOC with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/41/662?source=see_link\">",
"     misoprostol",
"    </a>",
"    . These women should be counseled about signs and symptoms of infection, and treated promptly with antibiotics and surgical evacuation if endometritis is suspected.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Expectant management",
"    </span>",
"    &nbsp;&mdash;&nbsp;Expectant management is an option for women with RPOC who have stable vital signs and no evidence of infection. Two meta-analyses have reviewed outcomes when treating incomplete miscarriage expectantly. Although these studies are limited by heterogeneity in diagnosis and management protocols, they report success rates of 50 to 85 percent at one to two weeks of follow-up, and up to 90 percent when subjects are followed for six weeks [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/29/39384/abstract/11,49\">",
"     11,49",
"    </a>",
"    ]. Notably, these studies were also limited to patients who had undergone spontaneous miscarriage, rather than those who had prior uterine evacuation. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/49/2841?source=see_link&amp;anchor=H5#H5\">",
"     \"Spontaneous abortion: Management\", section on 'Incomplete, inevitable, and missed abortion'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    No trials have evaluated the use of prophylactic antibiotics in uninfected patients undergoing expectant management; we do not use antibiotic prophylaxis. These women should be counseled about signs and symptoms of infection, and treated promptly with antibiotics and surgical evacuation if endometritis is suspected.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The term retained products of conception (RPOC) refers to placental",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      fetal tissue that remains in the uterus after spontaneous pregnancy loss (miscarriage), planned pregnancy termination, or",
"      <span class=\"nowrap\">",
"       preterm/term",
"      </span>",
"      delivery. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      RPOC present with uterine bleeding, pelvic pain, fever,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      uterine tenderness. These clinical findings are nonspecific; moreover, some postabortal bleeding and discomfort are normal. If viable trophoblastic tissue is present, the patient may not resume normal menstrual cycles after six weeks of follow-up. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Routine evaluation for RPOC after miscarriage or pregnancy termination is likely to result in false positive diagnoses and unnecessary interventions since RPOC do not always lead to morbidity. On the other hand, evaluation is indicated in women whose symptoms fall outside the normal range, such as those with bleeding that is heavy (greater than menses) or prolonged (over three weeks), and those with fever, uterine tenderness, or abdominopelvic pain that is worsening or cannot be controlled with oral analgesics. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Diagnostic evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The goal of the evaluation is to determine whether RPOC are the probable source of the woman's symptoms or whether another diagnosis is more likely. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The presence of a focal echogenic abnormality in the endometrium, particularly with evidence of blood flow by Doppler imaging, is the best test for prediction of retained products of conception. However, the decision to intervene should be based on clinical need rather than on an isolated ultrasound finding. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Imaging studies'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients who are hemodynamically unstable from hemorrhage or septic should undergo prompt surgical evacuation. Sepsis should also be treated with broad spectrum intravenous antibiotics. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Patients who are hemodynamically unstable'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H19\">",
"       'Patients with sepsis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      If diagnostic ultrasound of medically stable patients with uterine infection does not show RPOC, we suggest treatment with antibiotics alone rather than uterine evacuation (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). These patients should be monitored closely for clinical improvement, and evacuation should be performed if there is no improvement within 24 hours. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Medically stable patients with endometritis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients who are bothered by prolonged bleeding (lasting more than three weeks), we suggest surgical evacuation rather than medical intervention or expectant management (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Bleeding will eventually resolve as the RPOC are resorbed, but surgical management has the potential for immediate removal of the retained tissue, which is preferable for many patients. (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Medically stable patients with prolonged bleeding'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/29/39384/abstract/1\">",
"      Trinder J, Brocklehurst P, Porter R, et al. Management of miscarriage: expectant, medical, or surgical? Results of randomised controlled trial (miscarriage treatment (MIST) trial). BMJ 2006; 332:1235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/29/39384/abstract/2\">",
"      Maslovitz S, Almog B, Mimouni GS, et al. Accuracy of diagnosis of retained products of conception after dilation and evacuation. J Ultrasound Med 2004; 23:749.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/29/39384/abstract/3\">",
"      Nielsen S, Hahlin M. Expectant management of first-trimester spontaneous abortion. Lancet 1995; 345:84.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/29/39384/abstract/4\">",
"      Bagratee JS, Khullar V, Regan L, et al. A randomized controlled trial comparing medical and expectant management of first trimester miscarriage. Hum Reprod 2004; 19:266.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/29/39384/abstract/5\">",
"      Herabutya Y, O-Prasertsawat P. Misoprostol in the management of missed abortion. Int J Gynaecol Obstet 1997; 56:263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/29/39384/abstract/6\">",
"      Kovavisarach E, Sathapanachai U. Intravaginal 400 microg misoprostol for pregnancy termination in cases of blighted ovum: a randomised controlled trial. Aust N Z J Obstet Gynaecol 2002; 42:161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/29/39384/abstract/7\">",
"      Lister MS, Shaffer LE, Bell JG, et al. Randomized, double-blind, placebo-controlled trial of vaginal misoprostol for management of early pregnancy failures. Am J Obstet Gynecol 2005; 193:1338.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/29/39384/abstract/8\">",
"      Wood SL, Brain PH. Medical management of missed abortion: a randomized clinical trial. Obstet Gynecol 2002; 99:563.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/29/39384/abstract/9\">",
"      Ngai SW, Chan YM, Tang OS, Ho PC. Vaginal misoprostol as medical treatment for first trimester spontaneous miscarriage. Hum Reprod 2001; 16:1493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/29/39384/abstract/10\">",
"      Luise C, Jermy K, Collons WP, Bourne TH. Expectant management of incomplete, spontaneous first-trimester miscarriage: outcome according to initial ultrasound criteria and value of follow-up visits. Ultrasound Obstet Gynecol 2002; 19:580.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/29/39384/abstract/11\">",
"      Sotiriadis A, Makrydimas G, Papatheodorou S, Ioannidis JP. Expectant, medical, or surgical management of first-trimester miscarriage: a meta-analysis. Obstet Gynecol 2005; 105:1104.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/29/39384/abstract/12\">",
"      Demetroulis C, Saridogan E, Kunde D, Naftalin AA. A prospective randomized control trial comparing medical and surgical treatment for early pregnancy failure. Hum Reprod 2001; 16:365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/29/39384/abstract/13\">",
"      Muffley PE, Stitely ML, Gherman RB. Early intrauterine pregnancy failure: a randomized trial of medical versus surgical treatment. Am J Obstet Gynecol 2002; 187:321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/29/39384/abstract/14\">",
"      Zhang J, Gilles JM, Barnhart K, et al. A comparison of medical management with misoprostol and surgical management for early pregnancy failure. N Engl J Med 2005; 353:761.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/29/39384/abstract/15\">",
"      Thonneau P, Fougeyrollas B, Ducot B, et al. Complications of abortion performed under local anesthesia. Eur J Obstet Gynecol Reprod Biol 1998; 81:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/29/39384/abstract/16\">",
"      Hakim-Elahi E, Tovell HM, Burnhill MS. Complications of first-trimester abortion: a report of 170,000 cases. Obstet Gynecol 1990; 76:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/29/39384/abstract/17\">",
"      Christin-Maitre S, Bouchard P, Spitz IM. Medical termination of pregnancy. N Engl J Med 2000; 342:946.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/29/39384/abstract/18\">",
"      Davis AR, Hendlish SK, Westhoff C, et al. Bleeding patterns after misoprostol vs surgical treatment of early pregnancy failure: results from a randomized trial. Am J Obstet Gynecol 2007; 196:31.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/29/39384/abstract/19\">",
"      Cohen AL, Bhatnagar J, Reagan S, et al. Toxic shock associated with Clostridium sordellii and Clostridium perfringens after medical and spontaneous abortion. Obstet Gynecol 2007; 110:1027.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/29/39384/abstract/20\">",
"      Fischer M, Bhatnagar J, Guarner J, et al. Fatal toxic shock syndrome associated with Clostridium sordellii after medical abortion. N Engl J Med 2005; 353:2352.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/29/39384/abstract/21\">",
"      Wolman I, Altman E, Faith G, et al. Combined clinical and ultrasonographic work-up for the diagnosis of retained products of conception. Fertil Steril 2009; 92:1162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/29/39384/abstract/22\">",
"      Barnhart K, Sammel MD, Chung K, et al. Decline of serum human chorionic gonadotropin and spontaneous complete abortion: defining the normal curve. Obstet Gynecol 2004; 104:975.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/29/39384/abstract/23\">",
"      Fiala C, Safar P, Bygdeman M, Gemzell-Danielsson K. Verifying the effectiveness of medical abortion; ultrasound versus hCG testing. Eur J Obstet Gynecol Reprod Biol 2003; 109:190.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/29/39384/abstract/24\">",
"      McEwing RL, Anderson NG, Meates JB, et al. Sonographic appearances of the endometrium after termination of pregnancy in asymptomatic versus symptomatic women. J Ultrasound Med 2009; 28:579.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/29/39384/abstract/25\">",
"      Ben-Ami I, Schneider D, Maymon R, et al. Sonographic versus clinical evaluation as predictors of residual trophoblastic tissue. Hum Reprod 2005; 20:1107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/29/39384/abstract/26\">",
"      Abbasi S, Jamal A, Eslamian L, Marsousi V. Role of clinical and ultrasound findings in the diagnosis of retained products of conception. Ultrasound Obstet Gynecol 2008; 32:704.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/29/39384/abstract/27\">",
"      Sawyer E, Ofuasia E, Ofili-Yebovi D, et al. The value of measuring endometrial thickness and volume on transvaginal ultrasound scan for the diagnosis of incomplete miscarriage. Ultrasound Obstet Gynecol 2007; 29:205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/29/39384/abstract/28\">",
"      van den Bosch T, Daemen A, Van Schoubroeck D, et al. Occurrence and outcome of residual trophoblastic tissue: a prospective study. J Ultrasound Med 2008; 27:357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/29/39384/abstract/29\">",
"      Halperin R, Schneider D, Maymon R, et al. Arteriovenous malformation after uterine curettage: a report of 3 cases. J Reprod Med 2007; 52:445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/29/39384/abstract/30\">",
"      Cura M, Martinez N, Cura A, et al. Arteriovenous malformations of the uterus. Acta Radiol 2009; 50:823.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/29/39384/abstract/31\">",
"      Rufener SL, Adusumilli S, Weadock WJ, Caoili E. Sonography of uterine abnormalities in postpartum and postabortion patients: a potential pitfall of interpretation. J Ultrasound Med 2008; 27:343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/29/39384/abstract/32\">",
"      Jain K, Fogata M. Retained products of conception mimicking a large endometrial AVM: complete resolution following spontaneous abortion. J Clin Ultrasound 2007; 35:42.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/29/39384/abstract/33\">",
"      Betel C, Atri M, Arenson AM, et al. Sonographic diagnosis of gestational trophoblastic disease and comparison with retained products of conception. J Ultrasound Med 2006; 25:985.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/29/39384/abstract/34\">",
"      Keogan MT, Hertzberg BS, Kliewer MA. Low resistance Doppler waveforms with retained products of conception: potential for diagnostic confusion with gestational trophoblastic disease. Eur J Radiol 1995; 21:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/29/39384/abstract/35\">",
"      Alc&aacute;zar JL. Transvaginal ultrasonography combined with color velocity imaging and pulsed Doppler to detect residual trophoblastic tissue. Ultrasound Obstet Gynecol 1998; 11:54.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/29/39384/abstract/36\">",
"      Durfee SM, Frates MC, Luong A, Benson CB. The sonographic and color Doppler features of retained products of conception. J Ultrasound Med 2005; 24:1181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/29/39384/abstract/37\">",
"      Alc&aacute;zar JL, Ortiz CA. Transvaginal color Doppler ultrasonography in the management of first-trimester spontaneous abortion. Eur J Obstet Gynecol Reprod Biol 2002; 102:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/29/39384/abstract/38\">",
"      Wong SF, Lam MH, Ho LC. Transvaginal sonography in the detection of retained products of conception after first-trimester spontaneous abortion. J Clin Ultrasound 2002; 30:428.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/29/39384/abstract/39\">",
"      Creinin MD, Harwood B, Guido RS, et al. Endometrial thickness after misoprostol use for early pregnancy failure. Int J Gynaecol Obstet 2004; 86:22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/29/39384/abstract/40\">",
"      Reeves MF, Lohr PA, Harwood BJ, Creinin MD. Ultrasonographic endometrial thickness after medical and surgical management of early pregnancy failure. Obstet Gynecol 2008; 111:106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/29/39384/abstract/41\">",
"      Bar-Hava I, Aschkenazi S, Orvieto R, et al. Spectrum of normal intrauterine cavity sonographic findings after first-trimester abortion. J Ultrasound Med 2001; 20:1277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/29/39384/abstract/42\">",
"      Wolman I, Jaffa AJ, Pauzner D, et al. Transvaginal sonohysterography: a new aid in the diagnosis of residual trophoblastic tissue. J Clin Ultrasound 1996; 24:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/29/39384/abstract/43\">",
"      Prieto JA, Eriksen NL, Blanco JD. A randomized trial of prophylactic doxycycline for curettage in incomplete abortion. Obstet Gynecol 1995; 85:692.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/29/39384/abstract/44\">",
"      Seeras R. Evaluation of prophylactic use of tetracycline after evacuation in abortion in Harare Central Hospital. East Afr Med J 1989; 66:607.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/29/39384/abstract/45\">",
"      Al-Inany H. Intrauterine adhesions. An update. Acta Obstet Gynecol Scand 2001; 80:986.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/29/39384/abstract/46\">",
"      Schenker JG. Etiology of and therapeutic approach to synechia uteri. Eur J Obstet Gynecol Reprod Biol 1996; 65:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/29/39384/abstract/47\">",
"      Friedler S, Margalioth EJ, Kafka I, Yaffe H. Incidence of post-abortion intra-uterine adhesions evaluated by hysteroscopy--a prospective study. Hum Reprod 1993; 8:442.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/29/39384/abstract/48\">",
"      Westendorp IC, Ankum WM, Mol BW, Vonk J. Prevalence of Asherman's syndrome after secondary removal of placental remnants or a repeat curettage for incomplete abortion. Hum Reprod 1998; 13:3347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/29/39384/abstract/49\">",
"      Nanda K, Peloggia A, Grimes D, et al. Expectant care versus surgical treatment for miscarriage. Cochrane Database Syst Rev 2006; :CD003518.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5482 Version 2.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-125.39.66.146-E8BDD971E0-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_29_39384=[""].join("\n");
var outline_f38_29_39384=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H25\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      INCIDENCE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Uterine bleeding",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Fever and/or pain",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Amenorrhea",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Bleeding",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      DIAGNOSTIC EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      History",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Physical examination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Laboratory",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Imaging studies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Sonohysterography",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Hysteroscopy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Patients who are hemodynamically unstable",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Patients with sepsis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Medically stable patients with endometritis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Medically stable patients with prolonged bleeding",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Surgical intervention",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Medical intervention",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Expectant management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/0/1032?source=related_link\">",
"      Clinical features and diagnosis of pelvic inflammatory disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/9/1178?source=related_link\">",
"      Clinical manifestations, diagnosis, and management of ectopic pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/62/12264?source=related_link\">",
"      Clostridial myonecrosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/41/35480?source=related_link\">",
"      Dilation and curettage",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/44/17095?source=related_link\">",
"      Evaluation of acute pelvic pain in women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/31/26101?source=related_link\">",
"      Intrauterine adhesions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/38/33386?source=related_link\">",
"      Mifepristone for the medical termination of pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/38/42600?source=related_link\">",
"      Overview of postpartum hemorrhage",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/20/5449?source=related_link\">",
"      Pathophysiology of sepsis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/11/39097?source=related_link\">",
"      Postpartum endometritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/10/24744?source=related_link\">",
"      Sepsis and the systemic inflammatory response syndrome: Definitions, epidemiology, and prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/62/6120?source=related_link\">",
"      Shock in adults: Types, presentation, and diagnostic approach",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/49/2841?source=related_link\">",
"      Spontaneous abortion: Management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/19/4408?source=related_link\">",
"      Uterine perforation during gynecologic procedures",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f38_29_39385="Huntington disease: Management";
var content_f38_29_39385=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Huntington disease: Management",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/29/39385/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/29/39385/contributors\">",
"     Oksana Suchowersky, MD, FRCPC, FCCMG",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/29/39385/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/29/39385/contributors\">",
"     Howard I Hurtig, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/29/39385/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/29/39385/contributors\">",
"     John F Dashe, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?38/29/39385/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 14, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Huntington disease (HD) is an inherited progressive neurodegenerative disorder characterized by choreiform movements, psychiatric problems, and dementia. It is caused by a trinucleotide (CAG) expansion in the Huntington gene on chromosome 4p and inherited in an autosomal-dominant pattern. The pathophysiology of HD is not fully understood, although it is thought to be related to toxicity of the mutant huntingtin protein. As there is no known cure, treatment is symptomatic and remains supportive. Genetic mouse models are expanding our understanding of the disease and may lead to disease modifying therapy in the future.",
"   </p>",
"   <p>",
"    This topic will review the management of HD. Other aspects of HD are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/25/8599?source=see_link\">",
"     \"Huntington disease: Genetics and pathogenesis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/8/29832?source=see_link\">",
"     \"Huntington disease: Clinical features and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     SUPPORTIVE CARE",
"    </span>",
"    &nbsp;&mdash;&nbsp;No cure or disease-modifying treatment is currently available for HD. Therapy is focused on symptom management and supportive care in order to optimize quality of life. Despite these difficult circumstances, practitioners must be vigilant in caring for patients with HD and their families. The best care is provided by an interdisciplinary team that addresses the broad physical and psychological needs of patients and families, and manages new issues as they arise through long-term follow-up.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Use of physiotherapy, occupational therapy, and home care may allow for prolongation of community living, although there is a dearth of supporting literature.",
"     </li>",
"     <li>",
"      Speech therapy and dietary services are beneficial in managing dysphagia and weight loss.",
"     </li>",
"     <li>",
"      A high calorie diet is frequently needed due to the high metabolic requirements in patients with HD.",
"     </li>",
"     <li>",
"      Gait and balance issues should be assessed by a physiotherapist, and a walker",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      wheelchair used as indicated to prevent falls. Hip protectors are recommended to decrease the risk of hip fractures, since falls are common in the late stages.",
"     </li>",
"     <li>",
"      Dysphagia and aspiration pneumonia are common causes of death in patients with end-stage HD [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/29/39385/abstract/1\">",
"       1",
"      </a>",
"      ]. The potential use of a gastric tube feeding and other end-of-life issues (eg, home care versus outside care, resuscitation, other aggressive medical interventions, guardianship, and advanced medical directives) should be discussed with the patient and family before motor symptoms and cognitive decline become severe, and before the patient loses the ability to communicate [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/29/39385/abstract/1\">",
"       1",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Social services can be of assistance with legal issues such as guardianship.",
"     </li>",
"     <li>",
"      Driving restriction should be addressed when cognitive impairment begins to impact decision making.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Resources",
"    </span>",
"    &nbsp;&mdash;&nbsp;Reputable organizations, such as the Huntington's Disease Society of America (",
"    <a class=\"external\" href=\"file://www.hdsa.org/\">",
"     www.hdsa.org",
"    </a>",
"    ) and the Huntington Society of Canada (",
"    <a class=\"external\" href=\"file://www.hsc-ca.org/\">",
"     www.hsc-ca.org",
"    </a>",
"    ), are important community resources for patients and families in need. The 1999 publication \"A physician's guide to the management of Huntington's disease\" is a comprehensive source of management information for practitioners regarding the various motor, cognitive, and psychiatric problems associated with HD. It is available for downloading at",
"    <a class=\"external\" href=\"file://www.hdsa.org/images/content/1/1/11289.pdf\">",
"     www.hdsa.org/images/content/1/1/11289.pdf",
"    </a>",
"    , and at",
"    <a class=\"external\" href=\"file://www.huntingtonsociety.ca/english/uploads/Physicians_Guide_2008.pdf\">",
"     www.huntingtonsociety.ca/english/uploads/Physicians_Guide_2008.pdf",
"    </a>",
"    (both accessed on February 1, 2009).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     CHOREA",
"    </span>",
"    &nbsp;&mdash;&nbsp;The impact of chorea in patients with HD should be carefully assessed to determine whether any specific treatment is necessary, since it may not be a debilitating or bothersome symptom [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/29/39385/abstract/1\">",
"     1",
"    </a>",
"    ]. Chorea may be aggravated by various states including stress, anxiety, and depression. Thus, underlying mood and anxiety disorders should be identified and treated. Providing a calm, predictable environment can also be beneficial.",
"   </p>",
"   <p>",
"    When chorea is prominent and interfering with function, it can be treated with various measures, including typical and atypical neuroleptics, and dopamine-depleting agents such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/31/32246?source=see_link\">",
"     tetrabenazine",
"    </a>",
"    . However, pharmacologic treatment of chorea may worsen other aspects of HD, including parkinsonism, cognition, and mood [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/29/39385/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition, the movement disorder of HD typically changes over time as the disease progresses. In many patients, the chorea reaches a peak followed by a decline [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/29/39385/abstract/1\">",
"     1",
"    </a>",
"    ], while bradykinesia and rigidity gradually become more prominent. Thus, treatment directed at chorea should be periodically reconsidered.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Nonpharmacologic interventions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chorea may vary with changes in mood, posture, and position [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/29/39385/abstract/1\">",
"     1",
"    </a>",
"    ]. In some patients, the chorea may be so severe that it results in injury to the limbs. Such patients may benefit from the use of assistive devices, such as padded reclining chairs and bed padding.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Tetrabenazine",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/31/32246?source=see_link\">",
"     Tetrabenazine",
"    </a>",
"    can be useful for controlling chorea in patients with HD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/29/39385/abstract/2,3\">",
"     2,3",
"    </a>",
"    ], particularly those with milder forms of chorea. Its mechanism of action involves blocking the transport of dopamine into vesicles in the presynaptic terminal. This depletes dopamine from the vesicles and reduces dopamine transmission.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a double-blind controlled trial, ambulatory patients with HD were randomly assigned to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/31/32246?source=see_link\">",
"       tetrabenazine",
"      </a>",
"      at a maximum dose of 100 mg daily (n = 54) or placebo (n = 30) for 12 weeks [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/29/39385/abstract/4\">",
"       4",
"      </a>",
"      ]. The following observations were noted:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/31/32246?source=see_link\">",
"       Tetrabenazine",
"      </a>",
"      treatment resulted in a significant reduction in chorea severity, measured as a change in the chorea score of the Unified Huntington Disease Rating Scale (UHDRS), compared with placebo (5 versus 1.5 units, adjusted mean effect size -3.5, 95% CI -5.2 to -1.9). For tetrabenazine treatment, this represented a clinically meaningful 24 percent reduction in chorea from baseline severity.",
"     </li>",
"     <li>",
"      Among secondary outcomes, there was a statistically significant benefit on ratings of clinical global improvement with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/31/32246?source=see_link\">",
"       tetrabenazine",
"      </a>",
"      treatment, but a statistically significant worsening on the UHDRS Functional Checklist.",
"     </li>",
"     <li>",
"      While",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/31/32246?source=see_link\">",
"       tetrabenazine",
"      </a>",
"      was generally well tolerated, there were significant serious adverse events with its use, including one suicide. Poor tolerance led to dose reduction in 44 percent of patients assigned to tetrabenazine. Side effects include sedation, akathisia, parkinsonism, and depressed mood.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Another randomized trial of 30 patients on",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/31/32246?source=see_link\">",
"       tetrabenazine",
"      </a>",
"      treatment for HD found that tetrabenazine withdrawal led to a statistically significant increase in the UHDRS chorea score [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/29/39385/abstract/5\">",
"       5",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Based upon data from these two trials [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/29/39385/abstract/4,5\">",
"     4,5",
"    </a>",
"    ], 2012 guidelines from the American Academy of Neurology concluded that",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/31/32246?source=see_link\">",
"     tetrabenazine",
"    </a>",
"    is likely effective in decreasing HD chorea to a very important degree [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/29/39385/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An earlier prospective open-label study of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/31/32246?source=see_link\">",
"     tetrabenazine",
"    </a>",
"    used blinded assessment of videotapes to rate 18 patients with HD on the motor subset of the Abnormal Involuntary Movement Scale [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/29/39385/abstract/6\">",
"     6",
"    </a>",
"    ]. Compared with baseline, there was improvement of chorea on tetrabenazine in 15 patients and worsening in two. Adverse events include sedation, akathisia, parkinsonism, depressed mood insomnia, and depression.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H113941732\">",
"    <span class=\"h3\">",
"     Tetrabenazine dosing",
"    </span>",
"    &nbsp;&mdash;&nbsp;The usual starting dose of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/31/32246?source=see_link\">",
"     tetrabenazine",
"    </a>",
"    is 12.5 mg daily. The dose can be increased to 12.5 mg twice daily after one week, and then by 12.5 mg increments at weekly intervals until chorea improves or side effects become problematic. Tetrabenazine is usually given three times a day with meals. Since chorea disappears with sleep, a bedtime dose is not required.",
"   </p>",
"   <p>",
"    Because",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/31/32246?source=see_link\">",
"     tetrabenazine",
"    </a>",
"    is metabolized by cytochrome P450 (CYP2D6), the manufacturer recommends genotyping to determine CYP2D6 expression for patients requiring doses &gt;50",
"    <span class=\"nowrap\">",
"     mg/day.",
"    </span>",
"    For poor metabolizers, the maximum recommended dose is 50 mg daily (25 mg per dose). For extensive or intermediate metabolizers, the maximum dose is 100 mg a day. In addition, care needs to be taken when tetrabenazine is used with medications that are strong CYP2D6 inhibitors, such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?14/50/15146?source=see_link\">",
"     paroxetine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?14/49/15130?source=see_link\">",
"     fluoxetine",
"    </a>",
"    . In these cases, the dose of tetrabenazine should be decreased by 50 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/29/39385/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/31/32246?source=see_link\">",
"     Tetrabenazine",
"    </a>",
"    is an expensive medication; at a dose of 50 mg daily, the estimated yearly cost in the United States is approximately $40,000 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/29/39385/abstract/8\">",
"     8",
"    </a>",
"    ]. The manufacturer offers a patient assistance program for those with financial need.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Neuroleptics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neuroleptics act by blocking dopamine transmission, and have the potential benefit of treating both chorea and certain psychiatric symptoms such as agitation and psychosis. (See",
"    <a class=\"local\" href=\"#H15\">",
"     'Psychosis and agitation'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Few studies are available comparing different agents in HD. Thus, the choice among neuroleptics is largely empiric and based on clinical experience. In cases of severe chorea, treatment with the more potent typical neuroleptic agents such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/50/32553?source=see_link\">",
"     haloperidol",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/38/30312?source=see_link\">",
"     chlorpromazine",
"    </a>",
"    may be helpful. In patients with moderate chorea, the use of typical neuroleptics has been largely replaced by the use of newer atypical neuroleptics, such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/33/11802?source=see_link\">",
"     risperidone",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?36/36/37449?source=see_link\">",
"     olanzapine",
"    </a>",
"    , which may have fewer side effects [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/29/39385/abstract/9\">",
"     9",
"    </a>",
"    ]. Nevertheless, caution should be used if parkinsonian features are present prior to starting these agents, as all neuroleptics can worsen these symptoms.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Atypical",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following atypical neuroleptics have been used to treat chorea in patients with HD:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?36/36/37449?source=see_link\">",
"       Olanzapine",
"      </a>",
"      was considered possibly useful for treating chorea in a systematic review published in 2006 [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/29/39385/abstract/10\">",
"       10",
"      </a>",
"      ]. In one 14 day open-label study, nine patients were treated with olanzapine starting at 5 mg daily, and the dose was increased every third day until an adverse event or a satisfactory response occurred, up to a maximum of 30 mg daily [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/29/39385/abstract/11\">",
"       11",
"      </a>",
"      ]. All patients experienced a response in most of the motor subscores of the United Huntington's Disease Rating Scale (UHDRS). However, based upon the author's clinical experience, olanzapine should be started at 2.5 mg daily, and is usually effective in the range of 5 to 10 mg daily. Sedation and weight gain can be seen, in addition to parkinsonism.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?11/33/11802?source=see_link\">",
"       Risperidone",
"      </a>",
"      may be beneficial for treating chorea in patients with HD, although supporting evidence is limited to case series and case reports [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/29/39385/abstract/9,12,13\">",
"       9,12,13",
"      </a>",
"      ]. Risperidone should be started at 0.5 to 1 mg once or twice a day, and the total dose may be increased up to 8 mg daily as needed and tolerated [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/29/39385/abstract/1,12,13\">",
"       1,12,13",
"      </a>",
"      ]. Side effects include sedation and parkinsonism.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/21/35161?source=see_link\">",
"       Clozapine",
"      </a>",
"      may reduce chorea in patients with HD who are not being treated with other neuroleptics. This conclusion emerged from a controlled trial involving 33 patients with HD who were randomly assigned to clozapine (maximum dose 150 mg daily) or placebo for 31 days [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/29/39385/abstract/14\">",
"       14",
"      </a>",
"      ]. However, patients who were naive to neuroleptic treatment reported aggravation of functional disability while receiving clozapine. Adverse reactions associated with clozapine treatment included drowsiness, fatigue, anticholinergic symptoms, and gait difficulties; these led to trial withdrawal in six patients and dose reduction in another eight.",
"      <br/>",
"      <br/>",
"      Clozapine has the potential to cause agranulocytosis and requires a complete blood count before initiation of treatment with subsequent weekly testing for a minimum of six months. Testing is then needed every other week for the remainder of therapy. This risk and complexity of administration has limited its use in HD.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?42/11/43193?source=see_link\">",
"       Aripiprazole",
"      </a>",
"      may have beneficial effects on chorea, as reported in a case series of three patients with HD [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/29/39385/abstract/15\">",
"       15",
"      </a>",
"      ] and a six-month cross-over trial of six patients with HD that compared aripiprazole with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/31/32246?source=see_link\">",
"       tetrabenazine",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/29/39385/abstract/16\">",
"       16",
"      </a>",
"      ]. Initiation of the drug was at 2.5 mg daily, with slow escalation up to 15 mg daily. In addition to benefit on chorea, psychiatric symptoms (and perhaps even cognition) were improved. Side effects are similar to other atypical antipsychotics, except that the risk of metabolic syndrome may be less. It may also result in less sedation than tetrabenazine. Larger controlled trials are warranted.",
"     </li>",
"     <li>",
"      High-dose",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?19/56/20361?source=see_link\">",
"       quetiapine",
"      </a>",
"      (600 mg daily) was reported to improve chorea in one case report [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/29/39385/abstract/17\">",
"       17",
"      </a>",
"      ]. However, quetiapine has no effect on chorea at the lower doses that are generally used for behavioral problems.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Typical",
"    </span>",
"    &nbsp;&mdash;&nbsp;A 2006 systematic review of clinical studies evaluating pharmacologic treatments for HD concluded that",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/50/32553?source=see_link\">",
"     haloperidol",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/10/38055?source=see_link\">",
"     fluphenazine",
"    </a>",
"    were possibly useful for treating chorea in patients with HD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/29/39385/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/50/32553?source=see_link\">",
"       Haloperidol",
"      </a>",
"      can be started at 0.5 to 1 mg daily and increased up to 8 mg daily [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/29/39385/abstract/1\">",
"       1",
"      </a>",
"      ]. Occasionally, higher doses are required.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/10/38055?source=see_link\">",
"       Fluphenazine",
"      </a>",
"      can be used at the same doses as",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/50/32553?source=see_link\">",
"       haloperidol",
"      </a>",
"      .",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Side effects of these typical neuroleptics include sedation, parkinsonism, dystonia, akathisia, and hypotension.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Amantadine",
"    </span>",
"    &nbsp;&mdash;&nbsp;The utility of the N-methyl-D-aspartate receptor antagonist",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/46/13031?source=see_link\">",
"     amantadine",
"    </a>",
"    for chorea in patients with HD is uncertain. Evidence from four small randomized, double-blind, placebo-controlled trials is conflicting [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/29/39385/abstract/18-21\">",
"     18-21",
"    </a>",
"    ]. Amantadine can be considered for individuals with HD and debilitating chorea who cannot tolerate the medications (ie,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/31/32246?source=see_link\">",
"     tetrabenazine",
"    </a>",
"    and neuroleptics) discussed above.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Two trials with a combined total of 32 patients evaluated oral",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?12/46/13031?source=see_link\">",
"       amantadine",
"      </a>",
"      300 mg daily and found no benefit for chorea [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/29/39385/abstract/18,19\">",
"       18,19",
"      </a>",
"      ]. In the larger of the two trials (n = 24), using a cross-over design, blinded video analysis showed no significant difference between amantadine treatment and placebo for effect on chorea [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/29/39385/abstract/18\">",
"       18",
"      </a>",
"      ]. However, subjective improvement in chorea was reported by more subjects during the amantadine treatment phase compared with the placebo phase (19 versus 6), a statistically significant difference.",
"     </li>",
"     <li>",
"      One positive trial enrolled 24 patients and tested oral",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?12/46/13031?source=see_link\">",
"       amantadine",
"      </a>",
"      400",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/29/39385/abstract/20\">",
"       20",
"      </a>",
"      ]. Chorea scores were significantly lower with amantadine treatment than with placebo; the median reduction in extremity chorea at rest was 36 percent. Benefit correlated with plasma amantadine concentrations, a finding that may explain the negative results of other studies, which used lower doses. The adverse events profile remained benign at the higher dose, with dose-limiting symptoms of hallucinations and confusion.",
"     </li>",
"     <li>",
"      A second positive trial enrolled nine patients with HD and tested intravenous",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?12/46/13031?source=see_link\">",
"       amantadine",
"      </a>",
"      (200 mg) versus placebo using a double-blind crossover design; all patients were then treated with open-label oral amantadine 300 mg daily for one year. Amantadine was associated with a reduction in choreic dyskinesia in both the",
"      <span class=\"nowrap\">",
"       intravenous/blind",
"      </span>",
"      and",
"      <span class=\"nowrap\">",
"       oral/open-label",
"      </span>",
"      phases of the study [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/29/39385/abstract/21\">",
"       21",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Based upon evidence from two of these trials [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/29/39385/abstract/18,20\">",
"     18,20",
"    </a>",
"    ], guidelines from the American Academy of Neurology issued in 2012 concluded that",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/46/13031?source=see_link\">",
"     amantadine",
"    </a>",
"    is likely effective in decreasing HD chorea, though the degree of benefit is unknown [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/29/39385/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/46/13031?source=see_link\">",
"     Amantadine",
"    </a>",
"    can worsen cognitive function in patients with HD, particularly at high doses (eg, &ge;300 mg daily). Therefore, it should be dosed cautiously. Leg swelling and livedo reticularis are not uncommon side effects.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5662853\">",
"    <span class=\"h2\">",
"     Riluzole",
"    </span>",
"    &nbsp;&mdash;&nbsp;The largest randomized controlled trial evaluating",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?21/31/22004?source=see_link\">",
"     riluzole",
"    </a>",
"    for the treatment of chorea in HD enrolled 537 patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/29/39385/abstract/22\">",
"     22",
"    </a>",
"    ]. Approximately 30 percent of the patients dropped out of the trial by study end. At three years, analysis of the per protocol population (n = 379) found no significant difference in UHDRS chorea score between riluzole (50 mg twice daily) and placebo. An earlier eight-week trial of 63 subjects with HD found a significant reduction in the UHDRS chorea score for riluzole 200 mg daily but not 100 mg daily compared with placebo (-2.2, -0.2, +0.7 respectively) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/29/39385/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Given the weak and conflicting evidence [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/29/39385/abstract/22,23\">",
"     22,23",
"    </a>",
"    ], we do not recommend",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?21/31/22004?source=see_link\">",
"     riluzole",
"    </a>",
"    for the treatment of chorea in patients with HD.",
"   </p>",
"   <p>",
"    Based upon evidence from these same trials [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/29/39385/abstract/22,23\">",
"     22,23",
"    </a>",
"    ], 2012 guidelines from the American Academy of Neurology reached a somewhat different interpretation, concluding that the effect of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?21/31/22004?source=see_link\">",
"     riluzole",
"    </a>",
"    likely differs by dose and treatment duration: riluzole 200 mg daily likely moderately decreases HD chorea at eight weeks, riluzole 100 mg daily likely has no benefit at eight weeks (though a modest benefit cannot be excluded), and riluzole 100 mg daily likely fails to improve chorea at three years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/29/39385/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Of note, when studied for the treatment of amyotrophic lateral sclerosis,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?21/31/22004?source=see_link\">",
"     riluzole",
"    </a>",
"    200 mg daily compared with 100 mg daily was associated with an increased rate of adverse events, mainly asthenia, dizziness, gastrointestinal disorders, and hepatotoxicity, but no increased benefit [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/29/39385/abstract/24\">",
"     24",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/44/23240?source=see_link&amp;anchor=H2#H2\">",
"     \"Disease modifying treatment of amyotrophic lateral sclerosis\", section on 'Riluzole'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Other medications",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is limited evidence regarding other agents for chorea in HD.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Two small placebo-controlled trials have evaluated cannabinoids. In a cross-over trial of 15 patients with HD, cannabidiol was",
"      <strong>",
"       not",
"      </strong>",
"      effective for improving clinical outcomes, including chorea [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/29/39385/abstract/25\">",
"       25",
"      </a>",
"      ]. Another cross-over trial of 22 patients with five-week treatment blocks found that the synthetic cannabinoid",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?5/63/6133?source=see_link\">",
"       nabilone",
"      </a>",
"      (1 or 2 mg daily) significantly decreased UHDRS chorea scores by 1.7 compared with placebo [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/29/39385/abstract/26\">",
"       26",
"      </a>",
"      ]. The 2012 guidelines from the American Academy of Neurology concluded that nabilone possibly modestly improves HD chorea. However, nabilone is a psychoactive controlled substance with a potential for drug abuse and dependency. Further trials are needed to determine long term benefits and potential side effects.",
"     </li>",
"     <li>",
"      Anticonvulsants, such as",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?42/52/43847?source=see_link\">",
"       levetiracetam",
"      </a>",
"      , reduced chorea in a small open-label study [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/29/39385/abstract/27\">",
"       27",
"      </a>",
"      ]. Other anticonvulsants, such as",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?5/27/5561?source=see_link\">",
"       topiramate",
"      </a>",
"      , have been reported to improve chorea (but not specifically in HD) in case reports [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/29/39385/abstract/28\">",
"       28",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Benzodiazepines may be added intermittently when there is a transient worsening of chorea in stressful situations.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Choosing interventions for chorea",
"    </span>",
"    &nbsp;&mdash;&nbsp;As already mentioned, chorea may not be a debilitating or bothersome symptom in some patients with HD. A major concern is that pharmacologic treatment of chorea may worsen other aspects of HD, including parkinsonism, cognition, and mood.",
"   </p>",
"   <p>",
"    For patients with HD who have chorea that interferes with function, nonpharmacologic methods may be helpful. These include a non-stressful environment with padded reclining chairs and bed padding. In addition, underlying mood and anxiety disorders that aggravate chorea should be identified and treated if possible. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Nonpharmacologic interventions'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    We suggest initial drug therapy with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/31/32246?source=see_link\">",
"     tetrabenazine",
"    </a>",
"    for patients with HD who have moderately severe chorea that is refractory to nonpharmacologic treatments. The patient and family should be warned about the potential side effect of depression, which may be severe and rapid in onset. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Tetrabenazine'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/31/32246?source=see_link\">",
"     Tetrabenazine",
"    </a>",
"    is generally used to treat chorea ahead of neuroleptics, but it is not effective as monotherapy in severe chorea. However, the combination of tetrabenazine and a neuroleptic may occasionally be beneficial if chorea is very severe and unresponsive to monotherapy with neuroleptics",
"   </p>",
"   <p>",
"    We suggest treatment with atypical neuroleptics for patients with HD who have chorea that does not respond to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/31/32246?source=see_link\">",
"     tetrabenazine",
"    </a>",
"    . Atypical neuroleptics can be used as initial therapy for patients with both chorea and agitation or psychosis. Choices include",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?36/36/37449?source=see_link\">",
"     olanzapine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/33/11802?source=see_link\">",
"     risperidone",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/11/43193?source=see_link\">",
"     aripiprazole",
"    </a>",
"    . There is limited evidence that",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/56/20361?source=see_link\">",
"     quetiapine",
"    </a>",
"    may be effective at high doses (600 mg daily). We suggest",
"    <strong>",
"     not",
"    </strong>",
"    using",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/21/35161?source=see_link\">",
"     clozapine",
"    </a>",
"    for chorea since it appears to have no additional benefit compared with other neuroleptics. In addition, its use is associated with a risk of life-threatening agranulocytosis. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Neuroleptics'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    We suggest treatment with typical neuroleptics for patients who have severe chorea that is refractory to treatment with the atypical neuroleptics. Preferred choices include",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/50/32553?source=see_link\">",
"     haloperidol",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/10/38055?source=see_link\">",
"     fluphenazine",
"    </a>",
"    . Alternatives include other typical neuroleptics such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?29/38/30312?source=see_link\">",
"     chlorpromazine",
"    </a>",
"    . The combination of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/31/32246?source=see_link\">",
"     tetrabenazine",
"    </a>",
"    plus a neuroleptic may occasionally be helpful for patients with debilitating chorea who fail treatment with neuroleptic monotherapy. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Tetrabenazine'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    For patients who do not respond to or tolerate any of the preferred agents, alternative treatment options include",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/46/13031?source=see_link\">",
"     amantadine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/52/43847?source=see_link\">",
"     levetiracetam",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/27/5561?source=see_link\">",
"     topiramate",
"    </a>",
"    . The effectiveness of these alternative agents is not established. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Amantadine'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H11\">",
"     'Other medications'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Guidelines issued in 2012 by the American Academy of Neurology (AAN) conclude that clinicians should prescribe",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/31/32246?source=see_link\">",
"     tetrabenazine",
"    </a>",
"    (up to 100 mg daily),",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/46/13031?source=see_link\">",
"     amantadine",
"    </a>",
"    (300 to 400 mg daily) or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?21/31/22004?source=see_link\">",
"     riluzole",
"    </a>",
"    (200 mg daily) for chorea requiring treatment in HD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/29/39385/abstract/3\">",
"     3",
"    </a>",
"    ]. The AAN guidelines note that clinicians should discuss possible adverse events with patients and monitor for side effects such as parkinsonism, depression, and suicidality with tetrabenazine and elevated liver enzymes with riluzole. The AAN guidelines also conclude that clinicians may prescribe",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/63/6133?source=see_link\">",
"     nabilone",
"    </a>",
"    for HD chorea, though the AAN found insufficient information to recommend its long-term use, particularly given the potential for abuse of this drug.",
"   </p>",
"   <p>",
"    Our recommendations diverge from those of the AAN in that we do",
"    <strong>",
"     not",
"    </strong>",
"    suggest treating chorea in HD with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?21/31/22004?source=see_link\">",
"     riluzole",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/63/6133?source=see_link\">",
"     nabilone",
"    </a>",
"    , and we reserve",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/46/13031?source=see_link\">",
"     amantadine",
"    </a>",
"    for patients who do not respond to or tolerate any of our preferred treatment options.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     RIGIDITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Generally, rigidity and bradykinesia in HD do not require treatment. Furthermore, they seldom respond to addition of dopaminergic therapy.",
"   </p>",
"   <p>",
"    In exceptional cases when patients with HD develop or present with a severe akinetic-rigid syndrome, treatment with levodopa or dopamine agonists (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/19/32055?source=see_link\">",
"     pramipexole",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/11/18615?source=see_link\">",
"     ropinirole",
"    </a>",
"    ) has been tried. However, the evidence of benefit is limited to case series and case reports [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/29/39385/abstract/10,29,30\">",
"     10,29,30",
"    </a>",
"    ]. In addition, these medications may worsen the cognitive and behavioral problems associated with HD.",
"   </p>",
"   <p>",
"    The treatment of rigidity in patients with HD using levodopa and dopamine agonists should be attempted only by physicians with expertise in movement disorders",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    HD.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     PSYCHIATRIC SYMPTOMS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Psychosis and agitation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with HD who have psychosis and agitation can be treated with atypical neuroleptics, but there are no rigorous clinical trials confirming benefit.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Evidence from case reports [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/29/39385/abstract/17,31\">",
"       17,31",
"      </a>",
"      ] and a small case series [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/29/39385/abstract/32\">",
"       32",
"      </a>",
"      ] published in 2006 suggests that",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?19/56/20361?source=see_link\">",
"       quetiapine",
"      </a>",
"      may be particularly useful for treating psychosis in HD, since it will not cause worsening of bradykinesia. In the case series, five institutionalized patients with HD were treated with quetiapine, 150 to 600 mg daily, and showed improvement of psychiatric and behavioral symptoms (eg, delusions, agitation, irritability, and insomnia) without deterioration of motor symptoms [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/29/39385/abstract/32\">",
"       32",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A 2006 systematic review searched the literature through August 2005 and therefore did not include the study cited above suggesting benefit with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?19/56/20361?source=see_link\">",
"       quetiapine",
"      </a>",
"      . The reviewers concluded that",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?11/33/11802?source=see_link\">",
"       risperidone",
"      </a>",
"      was possibly useful for treatment of psychosis in patients with HD, and that",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?36/36/37449?source=see_link\">",
"       olanzapine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/50/32553?source=see_link\">",
"       haloperidol",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?29/19/30006?source=see_link\">",
"       buspirone",
"      </a>",
"      were possibly useful for treatment of behavioral problems (defined to include irritability, aggression, and lack of control) seen with HD [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/29/39385/abstract/10\">",
"       10",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Evidence supporting",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?11/33/11802?source=see_link\">",
"       risperidone",
"      </a>",
"      for treating psychosis in patients with HD is limited to a few case reports [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/29/39385/abstract/12,33,34\">",
"       12,33,34",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?36/36/37449?source=see_link\">",
"       Olanzapine",
"      </a>",
"      was evaluated in an open-label study of 11 patients who were treated with a median dose of 10 mg daily [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/29/39385/abstract/35\">",
"       35",
"      </a>",
"      ]. Two patients stopped treatment early due to poor tolerability and lack of effectiveness. In the remaining nine patients, who were treated for a mean of 10 months, a statistically significant improvement was observed in the behavioral subset score of the United Huntington's Disease Rating Scale (UHDRS).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Limited data suggest that",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/11/43193?source=see_link\">",
"     aripiprazole",
"    </a>",
"    is also helpful in treatment of psychosis and agitation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/29/39385/abstract/15,16\">",
"     15,16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As with chorea, providing a calm, predictable, and structured environment may be helpful for ameliorating psychiatric and behavioral symptoms in patients with HD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/29/39385/abstract/1\">",
"     1",
"    </a>",
"    ]. For patients who have psychosis",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    disruptive behavioral symptoms, we suggest starting treatment with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/56/20361?source=see_link\">",
"     quetiapine",
"    </a>",
"    12.5 mg daily given at bedtime, and gradually titrating up by 25 mg every one to two weeks as tolerated until symptoms improve. The maximum suggested dose is 600 mg daily, given in two or three divided doses.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?36/36/37449?source=see_link\">",
"     Olanzapine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/50/32553?source=see_link\">",
"     haloperidol",
"    </a>",
"    are alternative choices that may be preferred for patients who also have debilitating chorea. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Neuroleptics'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Depression",
"    </span>",
"    &nbsp;&mdash;&nbsp;Depression is a common symptom of HD and should be asked about at every visit, along with a screen for suicidal thoughts or behavior. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/13/11481?source=see_link\">",
"     \"Clinical manifestations and diagnosis of depression\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Depression can be effectively managed with tricyclic antidepressants or selective serotonin reuptake inhibitors. The treatment of depression is reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/8/40074?source=see_link\">",
"     \"Initial treatment of depression in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/61/27609?source=see_link\">",
"     \"Treatment of resistant depression in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     DEMENTIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no known effective therapy for dementia associated with HD. Small studies and case reports in patients with HD have failed to show clear improvement for motor and cognitive impairment with the cholinesterase inhibitors",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/30/10726?source=see_link\">",
"     donepezil",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/29/39385/abstract/36\">",
"     36",
"    </a>",
"    ],",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/26/6567?source=see_link\">",
"     rivastigmine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/29/39385/abstract/37,38\">",
"     37,38",
"    </a>",
"    ], and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/27/6582?source=see_link\">",
"     galantamine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/29/39385/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Treatment of behavioral problems in HD is reviewed above. (See",
"    <a class=\"local\" href=\"#H15\">",
"     'Psychosis and agitation'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     INVESTIGATIONAL THERAPIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Disease-modifying treatment for HD is not yet available [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/29/39385/abstract/40\">",
"     40",
"    </a>",
"    ], but a number of pharmacologic, surgical and genetic approaches that might delay disease onset or slow progression are being tested [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/29/39385/abstract/41,42\">",
"     41,42",
"    </a>",
"    ]. These include efforts to change metabolic-oxidative stress, minimize excitotoxicity, modify metabolic pathways, alter degradation of huntingtin, infuse neurotrophic factors, and transplant tissue or genes into the striatum. Much of this research is currently being done in animal models and awaits verification in human trials.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Clinical trials",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following interventions have been tested in clinical trials:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Pridopidine, a dopamine stabilizer, was evaluated in a randomized trial of 437 adults with HD [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/29/39385/abstract/43\">",
"       43",
"      </a>",
"      ]. At 26 weeks, there was no significant benefit with pridopidine (45 or 90 mg daily) compared with placebo for primary or secondary outcomes. However, there was significant improvement with pridopidine 90 mg in a prespecified tertiary outcome, the Unified Huntington Disease Rating Scale Total Motor Score. This result suggests that further study of pridopidine for treating motor symptoms of HD is warranted.",
"     </li>",
"     <li>",
"      Creatine supplementation (5 g daily) was not associated with significant improvement in motor, neuromuscular, or cognitive function in a one-year, nonrandomized, placebo-controlled study of 41 patients [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/29/39385/abstract/44\">",
"       44",
"      </a>",
"      ]. This result was in keeping with two other preliminary studies that found no improvement in clinical measures with creatine treatment [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/29/39385/abstract/45-47\">",
"       45-47",
"      </a>",
"      ]. A later randomized clinical trial (not designed to evaluate efficacy) enrolled 64 patients and showed that creatine 8 g daily was well tolerated for 16 weeks [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/29/39385/abstract/48\">",
"       48",
"      </a>",
"      ]. A large multicenter trial to further test the safety and effectiveness of creatine for HD is underway [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/29/39385/abstract/49\">",
"       49",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Coenzyme Q10, a mitochondrial stabilizer, and remacemide, a glutamate antagonist, were compared with placebo in a randomized clinical trial that enrolled 347 patients with early HD [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/29/39385/abstract/50\">",
"       50",
"      </a>",
"      ]. At 30 months, neither treatment, alone or in combination, significantly altered the decline in functional capacity, the primary outcome measure. Nonsignificant beneficial trends were seen in the coenzyme Q10 treatment group. A larger ongoing multicenter trial is testing coenzyme Q10 versus placebo [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/29/39385/abstract/51\">",
"       51",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Highly unsaturated fatty acid (HUFA) administration may enhance huntingtin clearance. A randomized clinical trial of 17 patients with HD found that treatment with HUFA for an average duration of 19 months was associated with statistically significant improvement in dyskinesia compared with placebo, and nonsignificant improvement in the Unified Huntington Disease Rating Scale [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/29/39385/abstract/52\">",
"       52",
"      </a>",
"      ]. Confirmation of these preliminary findings is needed.",
"     </li>",
"     <li>",
"      Interventions for HD that have failed to show significant benefit in clinical trials include ethyl eicosapentaenoate (a fatty acid derivative and a component of HUFA) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/29/39385/abstract/53,54\">",
"       53,54",
"      </a>",
"      ], and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?3/10/3240?source=see_link\">",
"       minocycline",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/29/39385/abstract/55\">",
"       55",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Animal models",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several developments using animal models of HD deserve special mention.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The development of transgenic mouse models has advanced the effort to stop and even reverse HD pathology and symptoms by inhibiting huntingtin expression or by altering its clearance [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/29/39385/abstract/56,57\">",
"       56,57",
"      </a>",
"      ]. One mouse model was engineered to have suppressible huntingtin expression of a truncated HD gene with an expanded repeat sequence. Investigators first allowed the mice to develop HD-like pathology and phenotype, and then suppressed the expression of huntingtin. The result was reversal of symptoms and pathology. It appears these changes can be quite rapid [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/29/39385/abstract/57\">",
"       57",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?8/25/8599?source=see_link\">",
"       \"Huntington disease: Genetics and pathogenesis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Gene silencing through RNA interference [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/29/39385/abstract/58\">",
"       58",
"      </a>",
"      ] and antisense oligonucleotide [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/29/39385/abstract/59,60\">",
"       59,60",
"      </a>",
"      ] techniques can reduce mutant human huntingtin expression in HD mice and improve motor",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      neuropathologic disease manifestations.",
"     </li>",
"     <li>",
"      A novel approach to increase clearance of huntingtin in animal models of HD is through vaccination with the huntingtin protein. A preliminary study used insulin resistance to measure the degree of metabolic disruption [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/29/39385/abstract/61\">",
"       61",
"      </a>",
"      ]. While there are many important questions about the validity of this model, it emphasizes the diversity of research that genetic animal models of HD allow.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Surgical treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Experimental surgery in HD has encompassed a number of possible interventions in symptom management.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The utility of deep brain stimulation in HD is unknown. Data are limited to case studies, which suggest some benefit in chorea [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/29/39385/abstract/62\">",
"       62",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Bilateral pallidotomy for dystonia in a patient with juvenile onset HD resulted in minimal benefit and worsening of spasticity [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/29/39385/abstract/63\">",
"       63",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    There are many technical hurdles to surgical interventions, including the state of the underlying parenchyma, accurate localization in atrophied structures, and persistent multi-focal neuron loss outside the site of intervention. Currently, it is felt that surgical strategies should not be used to treat HD outside of clinical trials.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Fetal transplantation",
"    </span>",
"    &nbsp;&mdash;&nbsp;At present, the utility of fetal tissue transplantation for the treatment of HD is uncertain [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/29/39385/abstract/64-66\">",
"     64-66",
"    </a>",
"    ]. Implantation of fetal tissue into the striatum of patients is both technically and logistically difficult. Significant adverse events such as intracerebral hemorrhage, subdural hematoma, and complications of immunosuppression can reduce any potential benefit. Most researchers have questioned the utility of modifying such a small portion of striatum function in the context of a diffuse neurodegenerative process. This intervention is not recommended at this time.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Neurotrophic factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Increasing the presence of neurotrophic factors (eg, brain-derived neurotrophic factor [BDNF], ciliary neurotrophic factor [CNTF], glial cell line-derived neurotrophic factor [GDNF]) in the striatum is a possible approach to prolong the survival of native neurons in patients with HD. A number of studies have shown benefit in animal models, but clinical evidence is limited [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/29/39385/abstract/67-69\">",
"     67-69",
"    </a>",
"    ]. A preliminary human study used encapsulated CNTF-releasing cells in the ventricle of patients over two years with no clear benefit [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/29/39385/abstract/70\">",
"     70",
"    </a>",
"    ]. The technical difficulties were significant and remain an obstacle to this technology.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?26/56/27521?source=see_link\">",
"       \"Patient information: Huntington disease (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Huntington disease (HD) is a condition of relentless progression of motor, cognitive, and psychiatric symptoms, resulting in challenges in management. Treatment is limited to symptom management and optimizing quality of life. The best care is provided by an interdisciplinary team that addresses the broad physical and psychological needs of patients and families, and manages new issues as they arise through long-term follow-up. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Supportive care'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      End-of-life issues should be discussed with the patient and family before cognitive and motor impairment become severe, and before the patient loses the ability to communicate. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Supportive care'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The impact of chorea in patients with HD should be carefully assessed to determine whether any specific treatment is necessary, since it may not be a debilitating or bothersome symptom, particularly in early stages. Pharmacologic treatment of chorea may worsen other aspects of HD, including parkinsonism, cognition, and mood. When chorea does become severe, padded reclining chairs and bed padding are recommended to reduce the risk of injury. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Chorea'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H12\">",
"       'Choosing interventions for chorea'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with HD who have moderately severe chorea that does not respond to nonpharmacologic intervention, we suggest initial treatment with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/31/32246?source=see_link\">",
"       tetrabenazine",
"      </a>",
"      (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Tetrabenazine'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with HD who have chorea that does not respond to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/31/32246?source=see_link\">",
"       tetrabenazine",
"      </a>",
"      , we suggest treatment with atypical neuroleptics (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). In addition, atypical neuroleptics can be used as initial therapy for patients with both chorea and agitation or psychosis. Choices include",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?36/36/37449?source=see_link\">",
"       olanzapine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?11/33/11802?source=see_link\">",
"       risperidone",
"      </a>",
"      , or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?42/11/43193?source=see_link\">",
"       aripiprazole",
"      </a>",
"      .",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/21/35161?source=see_link\">",
"       Clozapine",
"      </a>",
"      appears to provide no additional benefit compared with other neuroleptics, and its use is associated with a risk of life-threatening agranulocytosis. Therefore, we suggest",
"      <strong>",
"       not",
"      </strong>",
"      using clozapine for chorea (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ).",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?19/56/20361?source=see_link\">",
"       Quetiapine",
"      </a>",
"      is usually not helpful in managing chorea, except in very high doses. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Neuroleptics'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients who have severe chorea that is refractory to treatment with the atypical neuroleptics, we suggest treatment with typical neuroleptics (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Choices include",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/50/32553?source=see_link\">",
"       haloperidol",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/10/38055?source=see_link\">",
"       fluphenazine",
"      </a>",
"      among others. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Neuroleptics'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with debilitating chorea who fail treatment with neuroleptic monotherapy, the combination of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/31/32246?source=see_link\">",
"       tetrabenazine",
"      </a>",
"      and a neuroleptic may occasionally be helpful. For those who do not respond to any of the preferred agents, alternative treatment options include",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?12/46/13031?source=see_link\">",
"       amantadine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?42/52/43847?source=see_link\">",
"       levetiracetam",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?5/27/5561?source=see_link\">",
"       topiramate",
"      </a>",
"      . However, the effectiveness of these alternative agents is not established. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Amantadine'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H11\">",
"       'Other medications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Rigidity and bradykinesia in HD generally do not require treatment. Furthermore, they seldom respond to addition of dopaminergic therapy. In exceptional cases when children or adults with HD develop or present with a severe akinetic-rigid syndrome, treatment with levodopa or dopamine agonists has been tried, but there is little evidence to support this approach. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Rigidity'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with HD who have psychosis",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      disruptive behavioral symptoms but lack debilitating chorea, we suggest initial treatment with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?19/56/20361?source=see_link\">",
"       quetiapine",
"      </a>",
"      (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ).",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?36/36/37449?source=see_link\">",
"       Olanzapine",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?11/33/11802?source=see_link\">",
"       risperidone",
"      </a>",
"      are alternative choices that may be preferred for patients who also have severe chorea. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Psychiatric symptoms'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Depression is a common symptom of HD and is usually managed with tricyclic antidepressants or selective serotonin reuptake inhibitors. Treatment of depression is discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?39/8/40074?source=see_link\">",
"       \"Initial treatment of depression in adults\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?26/61/27609?source=see_link\">",
"       \"Treatment of resistant depression in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      There is no known effective therapy for dementia associated with HD. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Dementia'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Researchers continue to explore new therapeutic options for HD but have yet to make a significant impact on delaying onset or slowing disease progression. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Investigational therapies'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Rosenblatt A, Ranen NG, Nance MA, Paulsen JS. A physician's guide to the management of Huntington's disease, 2nd Ed, Huntington&rsquo;s Disease Society of America, New York 1999. www.hdsa.org/images/content/1/1/11289.pdf (Accessed on January 24, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/29/39385/abstract/2\">",
"      Mestre T, Ferreira J, Coelho MM, et al. Therapeutic interventions for symptomatic treatment in Huntington's disease. Cochrane Database Syst Rev 2009; :CD006456.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/29/39385/abstract/3\">",
"      Armstrong MJ, Miyasaki JM, American Academy of Neurology. Evidence-based guideline: pharmacologic treatment of chorea in Huntington disease: report of the guideline development subcommittee of the American Academy of Neurology. Neurology 2012; 79:597.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/29/39385/abstract/4\">",
"      Huntington Study Group. Tetrabenazine as antichorea therapy in Huntington disease: a randomized controlled trial. Neurology 2006; 66:366.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/29/39385/abstract/5\">",
"      Frank S, Ondo W, Fahn S, et al. A study of chorea after tetrabenazine withdrawal in patients with Huntington disease. Clin Neuropharmacol 2008; 31:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/29/39385/abstract/6\">",
"      Ondo WG, Tintner R, Thomas M, Jankovic J. Tetrabenazine treatment for Huntington's disease-associated chorea. Clin Neuropharmacol 2002; 25:300.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/29/39385/abstract/7\">",
"      Guay DR. Tetrabenazine, a monoamine-depleting drug used in the treatment of hyperkinetic movement disorders. Am J Geriatr Pharmacother 2010; 8:331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/29/39385/abstract/8\">",
"      Tetrabenazine (Xenazine) for Huntington's chorea. Med Lett Drugs Ther 2009; 51:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/29/39385/abstract/9\">",
"      Dallocchio C, Buffa C, Tinelli C, Mazzarello P. Effectiveness of risperidone in Huntington chorea patients. J Clin Psychopharmacol 1999; 19:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/29/39385/abstract/10\">",
"      Bonelli RM, Wenning GK. Pharmacological management of Huntington's disease: an evidence-based review. Curr Pharm Des 2006; 12:2701.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/29/39385/abstract/11\">",
"      Bonelli RM, Mahnert FA, Niederwieser G. Olanzapine for Huntington's disease: an open label study. Clin Neuropharmacol 2002; 25:263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/29/39385/abstract/12\">",
"      Madhusoodanan S, Brenner R. Use of risperidone in psychosis associated with Huntington's disease. Am J Geriatr Psychiatry 1998; 6:347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/29/39385/abstract/13\">",
"      Meco G, Bonifati V, Alessandri A, Brusa L. Risperidone in Huntington's disease. Hum Psychopharmacol 1995; 10:353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/29/39385/abstract/14\">",
"      van Vugt JP, Siesling S, Vergeer M, et al. Clozapine versus placebo in Huntington's disease: a double blind randomised comparative study. J Neurol Neurosurg Psychiatry 1997; 63:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/29/39385/abstract/15\">",
"      Ciammola A, Sassone J, Colciago C, et al. Aripiprazole in the treatment of Huntington's disease: a case series. Neuropsychiatr Dis Treat 2009; 5:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/29/39385/abstract/16\">",
"      Brusa L, Orlacchio A, Moschella V, et al. Treatment of the symptoms of Huntington's disease: preliminary results comparing aripiprazole and tetrabenazine. Mov Disord 2009; 24:126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/29/39385/abstract/17\">",
"      Bonelli RM, Niederwieser G. Quetiapine in Huntington's disease: a first case report. J Neurol 2002; 249:1114.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/29/39385/abstract/18\">",
"      O'Suilleabhain P, Dewey RB Jr. A randomized trial of amantadine in Huntington disease. Arch Neurol 2003; 60:996.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/29/39385/abstract/19\">",
"      Heckmann JM, Legg P, Sklar D, et al. IV amantadine improves chorea in Huntington's disease: an acute randomized, controlled study. Neurology 2004; 63:597.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/29/39385/abstract/20\">",
"      Verhagen Metman L, Morris MJ, Farmer C, et al. Huntington's disease: a randomized, controlled trial using the NMDA-antagonist amantadine. Neurology 2002; 59:694.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/29/39385/abstract/21\">",
"      Lucetti C, Del Dotto P, Gambaccini G, et al. IV amantadine improves chorea in Huntington's disease: an acute randomized, controlled study. Neurology 2003; 60:1995.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/29/39385/abstract/22\">",
"      Landwehrmeyer GB, Dubois B, de Y&eacute;benes JG, et al. Riluzole in Huntington's disease: a 3-year, randomized controlled study. Ann Neurol 2007; 62:262.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/29/39385/abstract/23\">",
"      Huntington Study Group. Dosage effects of riluzole in Huntington's disease: a multicenter placebo-controlled study. Neurology 2003; 61:1551.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/29/39385/abstract/24\">",
"      Lacomblez L, Bensimon G, Leigh PN, et al. Dose-ranging study of riluzole in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis/Riluzole Study Group II. Lancet 1996; 347:1425.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/29/39385/abstract/25\">",
"      Consroe P, Laguna J, Allender J, et al. Controlled clinical trial of cannabidiol in Huntington's disease. Pharmacol Biochem Behav 1991; 40:701.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/29/39385/abstract/26\">",
"      Curtis A, Mitchell I, Patel S, et al. A pilot study using nabilone for symptomatic treatment in Huntington's disease. Mov Disord 2009; 24:2254.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/29/39385/abstract/27\">",
"      Zesiewicz TA, Sullivan KL, Hauser RA, Sanchez-Ramos J. Open-label pilot study of levetiracetam (Keppra) for the treatment of chorea in Huntington's disease. Mov Disord 2006; 21:1998.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/29/39385/abstract/28\">",
"      Gatto EM, Uribe Roca C, Raina G, et al. Vascular hemichorea/hemiballism and topiramate. Mov Disord 2004; 19:836.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/29/39385/abstract/29\">",
"      Racette BA, Perlmutter JS. Levodopa responsive parkinsonism in an adult with Huntington's disease. J Neurol Neurosurg Psychiatry 1998; 65:577.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/29/39385/abstract/30\">",
"      Bonelli RM, Niederwieser G, Diez J, et al. Pramipexole ameliorates neurologic and psychiatric symptoms in a Westphal variant of Huntington's disease. Clin Neuropharmacol 2002; 25:58.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/29/39385/abstract/31\">",
"      Seitz DP, Millson RC. Quetiapine in the management of psychosis secondary to huntington's disease: a case report. Can J Psychiatry 2004; 49:413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/29/39385/abstract/32\">",
"      Alpay M, Koroshetz WJ. Quetiapine in the treatment of behavioral disturbances in patients with Huntington's disease. Psychosomatics 2006; 47:70.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/29/39385/abstract/33\">",
"      Madhusoodanan S, Brenner R, Moise D, et al. Psychiatric and neuropsychological abnormalities in Huntington's disease: a case study. Ann Clin Psychiatry 1998; 10:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/29/39385/abstract/34\">",
"      Erdemoglu AK, Boratav C. Risperidone in chorea and psychosis of Huntington's disease. Eur J Neurol 2002; 9:182.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/29/39385/abstract/35\">",
"      Paleacu D, Anca M, Giladi N. Olanzapine in Huntington's disease. Acta Neurol Scand 2002; 105:441.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/29/39385/abstract/36\">",
"      Fernandez HH, Friedman JH, Grace J, Beason-Hazen S. Donepezil for Huntington's disease. Mov Disord 2000; 15:173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/29/39385/abstract/37\">",
"      Rot U, Kobal J, Sever A, et al. Rivastigmine in the treatment of Huntington's disease. Eur J Neurol 2002; 9:689.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/29/39385/abstract/38\">",
"      de Tommaso M, Specchio N, Sciruicchio V, et al. Effects of rivastigmine on motor and cognitive impairment in Huntington's disease. Mov Disord 2004; 19:1516.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/29/39385/abstract/39\">",
"      Petrikis P, Andreou C, Piachas A, et al. Treatment of Huntington's disease with galantamine. Int Clin Psychopharmacol 2004; 19:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/29/39385/abstract/40\">",
"      Mestre T, Ferreira J, Coelho MM, et al. Therapeutic interventions for disease progression in Huntington's disease. Cochrane Database Syst Rev 2009; :CD006455.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/29/39385/abstract/41\">",
"      Munoz-Sanjuan I, Bates GP. The importance of integrating basic and clinical research toward the development of new therapies for Huntington disease. J Clin Invest 2011; 121:476.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/29/39385/abstract/42\">",
"      Sah DW, Aronin N. Oligonucleotide therapeutic approaches for Huntington disease. J Clin Invest 2011; 121:500.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/29/39385/abstract/43\">",
"      de Yebenes JG, Landwehrmeyer B, Squitieri F, et al. Pridopidine for the treatment of motor function in patients with Huntington's disease (MermaiHD): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet Neurol 2011; 10:1049.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/29/39385/abstract/44\">",
"      Verbessem P, Lemiere J, Eijnde BO, et al. Creatine supplementation in Huntington's disease: a placebo-controlled pilot trial. Neurology 2003; 61:925.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/29/39385/abstract/45\">",
"      Bender A, Auer DP, Merl T, et al. Creatine supplementation lowers brain glutamate levels in Huntington's disease. J Neurol 2005; 252:36.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/29/39385/abstract/46\">",
"      Tabrizi SJ, Blamire AM, Manners DN, et al. Creatine therapy for Huntington's disease: clinical and MRS findings in a 1-year pilot study. Neurology 2003; 61:141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/29/39385/abstract/47\">",
"      Tabrizi SJ, Blamire AM, Manners DN, et al. High-dose creatine therapy for Huntington disease: a 2-year clinical and MRS study. Neurology 2005; 64:1655.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/29/39385/abstract/48\">",
"      Hersch SM, Gevorkian S, Marder K, et al. Creatine in Huntington disease is safe, tolerable, bioavailable in brain and reduces serum 8OH2'dG. Neurology 2006; 66:250.",
"     </a>",
"    </li>",
"    <li>",
"     Creatine safety, tolerability, and efficacy in Huntington's disease (CREST-E). file://clinicaltrials.gov/ct2/show/NCT00712426 (Accessed on January 26, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/29/39385/abstract/50\">",
"      Huntington Study Group. A randomized, placebo-controlled trial of coenzyme Q10 and remacemide in Huntington's disease. Neurology 2001; 57:397.",
"     </a>",
"    </li>",
"    <li>",
"     Coenzyme Q10 in Huntington's disease. file://clinicaltrials.gov/ct2/show/NCT00608881 (Accessed on January 26, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/29/39385/abstract/52\">",
"      Vaddadi KS, Soosai E, Chiu E, Dingjan P. A randomised, placebo-controlled, double blind study of treatment of Huntington's disease with unsaturated fatty acids. Neuroreport 2002; 13:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/29/39385/abstract/53\">",
"      Puri BK, Leavitt BR, Hayden MR, et al. Ethyl-EPA in Huntington disease: a double-blind, randomized, placebo-controlled trial. Neurology 2005; 65:286.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/29/39385/abstract/54\">",
"      Huntington Study Group TREND-HD Investigators. Randomized controlled trial of ethyl-eicosapentaenoic acid in Huntington disease: the TREND-HD study. Arch Neurol 2008; 65:1582.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/29/39385/abstract/55\">",
"      Huntington Study Group DOMINO Investigators. A futility study of minocycline in Huntington's disease. Mov Disord 2010; 25:2219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/29/39385/abstract/56\">",
"      Yamamoto A, Lucas JJ, Hen R. Reversal of neuropathology and motor dysfunction in a conditional model of Huntington's disease. Cell 2000; 101:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/29/39385/abstract/57\">",
"      Mart&iacute;n-Aparicio E, Yamamoto A, Hern&aacute;ndez F, et al. Proteasomal-dependent aggregate reversal and absence of cell death in a conditional mouse model of Huntington's disease. J Neurosci 2001; 21:8772.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/29/39385/abstract/58\">",
"      Harper SQ. Progress and challenges in RNA interference therapy for Huntington disease. Arch Neurol 2009; 66:933.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/29/39385/abstract/59\">",
"      Kordasiewicz HB, Stanek LM, Wancewicz EV, et al. Sustained therapeutic reversal of Huntington's disease by transient repression of huntingtin synthesis. Neuron 2012; 74:1031.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/29/39385/abstract/60\">",
"      Lu XH, Yang XW. \"Huntingtin holiday\": progress toward an antisense therapy for Huntington's disease. Neuron 2012; 74:964.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/29/39385/abstract/61\">",
"      Miller TW, Shirley TL, Wolfgang WJ, et al. DNA vaccination against mutant huntingtin ameliorates the HDR6/2 diabetic phenotype. Mol Ther 2003; 7:572.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/29/39385/abstract/62\">",
"      Moro E, Lang AE, Strafella AP, et al. Bilateral globus pallidus stimulation for Huntington's disease. Ann Neurol 2004; 56:290.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/29/39385/abstract/63\">",
"      Cubo E, Shannon KM, Penn RD, Kroin JS. Internal globus pallidotomy in dystonia secondary to Huntington's disease. Mov Disord 2000; 15:1248.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/29/39385/abstract/64\">",
"      Hauser RA, Furtado S, Cimino CR, et al. Bilateral human fetal striatal transplantation in Huntington's disease. Neurology 2002; 58:687.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/29/39385/abstract/65\">",
"      Bachoud-L&eacute;vi AC, Hantraye P, Peschanski M. Fetal neural grafts for Huntington's disease: a prospective view. Mov Disord 2002; 17:439.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/29/39385/abstract/66\">",
"      Bachoud-L&eacute;vi AC, Gaura V, Brugi&egrave;res P, et al. Effect of fetal neural transplants in patients with Huntington's disease 6 years after surgery: a long-term follow-up study. Lancet Neurol 2006; 5:303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/29/39385/abstract/67\">",
"      Alberch J, P&eacute;rez-Navarro E, Canals JM. Neurotrophic factors in Huntington's disease. Prog Brain Res 2004; 146:195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/29/39385/abstract/68\">",
"      Emerich DF, Thanos CG. Intracompartmental delivery of CNTF as therapy for Huntington's disease and retinitis pigmentosa. Curr Gene Ther 2006; 6:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/29/39385/abstract/69\">",
"      Zuccato C, Cattaneo E. Role of brain-derived neurotrophic factor in Huntington's disease. Prog Neurobiol 2007; 81:294.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/29/39385/abstract/70\">",
"      Bloch J, Bachoud-L&eacute;vi AC, D&eacute;glon N, et al. Neuroprotective gene therapy for Huntington's disease, using polymer-encapsulated cells engineered to secrete human ciliary neurotrophic factor: results of a phase I study. Hum Gene Ther 2004; 15:968.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4902 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-125.39.66.147-E57427EB1A-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_29_39385=[""].join("\n");
var outline_f38_29_39385=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H24\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      SUPPORTIVE CARE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Resources",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      CHOREA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Nonpharmacologic interventions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Tetrabenazine",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H113941732\">",
"      - Tetrabenazine dosing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Neuroleptics",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Atypical",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Typical",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Amantadine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5662853\">",
"      Riluzole",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Other medications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Choosing interventions for chorea",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      RIGIDITY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      PSYCHIATRIC SYMPTOMS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Psychosis and agitation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Depression",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      DEMENTIA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      INVESTIGATIONAL THERAPIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Clinical trials",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Animal models",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Surgical treatment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Fetal transplantation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Neurotrophic factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/13/11481?source=related_link\">",
"      Clinical manifestations and diagnosis of depression",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/44/23240?source=related_link\">",
"      Disease modifying treatment of amyotrophic lateral sclerosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/8/29832?source=related_link\">",
"      Huntington disease: Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/25/8599?source=related_link\">",
"      Huntington disease: Genetics and pathogenesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/8/40074?source=related_link\">",
"      Initial treatment of depression in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?26/56/27521?source=related_link\">",
"      Patient information: Huntington disease (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/61/27609?source=related_link\">",
"      Treatment of resistant depression in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f38_29_39386="Breast reconstruction in women with breast cancer";
var content_f38_29_39386=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Breast reconstruction in women with breast cancer",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/29/39386/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/29/39386/contributors\">",
"     Maurice Nahabedian, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/29/39386/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/29/39386/contributors\">",
"     Anees B Chagpar, MD, MSc, MA, MPH, FACS, FRCS(C)",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/29/39386/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/29/39386/contributors\">",
"     Rosemary B Duda, MD, MPH, FACS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?38/29/39386/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 16, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Primary surgical treatment options for early stage invasive, intraductal (ductal carcinoma in situ, DCIS), and some locally advanced breast cancers include breast conserving surgery or mastectomy. The type of breast surgery impacts the need for breast reconstruction. A woman undergoing lumpectomy or quadrantectomy usually does not require reconstruction unless she is left with a significant deformity after breast conservation therapy.",
"   </p>",
"   <p>",
"    The growing population of breast cancer survivors serves as a motive for clinicians and researchers to address the multifaceted needs of those living with and beyond a cancer diagnosis. Common sequelae that disrupt the psychosocial aspects of life for adult breast cancer survivors who have undergone mastectomy include poor body image [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/29/39386/abstract/1-4\">",
"     1-4",
"    </a>",
"    ], severe depression, feelings of diminished self-worth, and disturbances in social and occupational functioning [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/29/39386/abstract/3-6\">",
"     3-6",
"    </a>",
"    ]. Over the past 30 years, several studies have documented the psychological, social, emotional, and functional benefits of breast reconstruction, including improved psychological health, self-esteem [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/29/39386/abstract/7-9\">",
"     7-9",
"    </a>",
"    ], sexuality, body image [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/29/39386/abstract/5,6,10-12\">",
"     5,6,10-12",
"    </a>",
"    ], and reduced concern for cancer recurrence [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/29/39386/abstract/13-15\">",
"     13-15",
"    </a>",
"    ]. The literature provides support for offering postmastectomy reconstruction, as this is an important determinant of long-term health and wellbeing for breast cancer patients.",
"   </p>",
"   <p>",
"    This topic review will discuss the different methods of breast reconstruction and the factors that influence the timing of reconstructive surgery. Primary surgical treatment of breast cancer and surgical options for women with an inherited predisposition to breast cancer are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/42/31402?source=see_link\">",
"     \"Breast conserving therapy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/18/12586?source=see_link\">",
"     \"Mastectomy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/0/17418?source=see_link&amp;anchor=H3#H3\">",
"     \"Management of hereditary breast and ovarian cancer syndrome and patients with BRCA mutations\", section on 'Mastectomy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     UTILIZATION AND PATTERNS OF CARE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Outcomes research on quality of life (QOL) improvements and psychosocial benefits associated with breast reconstruction served as the driving force for the 1998 Women's Health and Cancer Rights Act, which mandated health care payer coverage for breast and nipple reconstruction, contralateral procedures to achieve symmetry, and treatment for the sequelae of mastectomy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/29/39386/abstract/16\">",
"     16",
"    </a>",
"    ]. This was followed in 2001 by additional legislation imposing penalties on noncompliant insurers. Whether passage of these laws has contributed to changes in clinical practice is unclear.",
"   </p>",
"   <p>",
"    Although the rate of breast reconstruction has increased, the number of women who undergo reconstruction after mastectomy remains low [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/29/39386/abstract/17,18\">",
"     17,18",
"    </a>",
"    ]. Data collected from the American Society of Plastic Surgeons showed that the number of breast reconstructions performed annually increased from 29,609 in 1992 to 78,832 in 2000, a 166 percent increase [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/29/39386/abstract/17\">",
"     17",
"    </a>",
"    ]. However, a review of US women undergoing mastectomy for breast cancer from 1998 to 2002 who were identified using the Surveillance, Epidemiology and End Results (SEER) database reported that only 17 percent had breast reconstruction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/29/39386/abstract/18\">",
"     18",
"    </a>",
"    ]. Geographic variation was prominent; adjusted regional rates ranged from 4.5 percent in Alaska to 34.7 percent in Atlanta, Georgia. Markedly higher rates were reported in a study of 2174 women from the National Comprehensive Cancer Network (NCCN), 42 percent had breast reconstruction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/29/39386/abstract/19\">",
"     19",
"    </a>",
"    ]. Rates were significantly higher for women covered by managed care payers (compared with Medicare or Medicaid recipients), those with more than a high school education, and for women employed outside of the home. Race and ethnicity did not influence rates of reconstruction, although other reports suggest otherwise [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/29/39386/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The low rates of breast reconstruction are in part due to a low referral rate to plastic surgeons. A survey of attending general surgeons from a population-based sample of 1844 women diagnosed with breast cancer in 2002 showed that only 24 percent of surgeons referred more than 75 percent of their mastectomy patients to plastic surgeons prior to surgery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/29/39386/abstract/21\">",
"     21",
"    </a>",
"    ]. A survey of patients diagnosed with breast cancer reported that the desire to avoid additional surgery was the most common reason given for not pursuing reconstruction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/29/39386/abstract/22\">",
"     22",
"    </a>",
"    ]. Inadequate education about reconstructive options also plays a role. In a study of 84 women treated with mastectomy, participants were able to answer only 38 percent of questions about reconstruction options correctly [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/29/39386/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Thus, despite legislation, breast reconstruction remains an underutilized option, at least in the United States. The underlying reasons seem to be multifactorial and related to socioeconomic factors, including access to care, insurance coverage, education, and",
"    <span class=\"nowrap\">",
"     race/ethnicity,",
"    </span>",
"    as well as geographic location, age, and personal choice [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/29/39386/abstract/22,24-26\">",
"     22,24-26",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     INITIAL RECONSTRUCTIVE EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Optimal management of women who have undergone mastectomy for breast cancer requires a collaborative effort between oncologic and reconstructive surgeons, radiologists, pathologists, and radiation as well as medical oncologists. This multimodality approach allows providers to coordinate cancer and reconstructive procedures with the need for radiation therapy (RT) and chemotherapy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/49/10009?source=see_link\">",
"     \"Clinical features, diagnosis, and staging of newly diagnosed breast cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A productive, caring relationship is crucial to patient satisfaction with the reconstructive process [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/29/39386/abstract/27\">",
"     27",
"    </a>",
"    ] and must be established early. The patient with newly diagnosed breast cancer may have feelings of grief and anger as well as unrealistic expectations that may be directed at her health care team. If possible, the patient's family should be included in the consultation. Educational literature, including preoperative and postoperative photographs, is helpful for the patient at the initial consultation to facilitate her decision-making process. The opportunity to speak with other women who have undergone breast reconstruction may also be worthwhile.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     History and physical examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;A thorough history and physical examination should focus on the following factors: disease status and oncologic history, future treatment plans, past surgical",
"    <span class=\"nowrap\">",
"     history/comorbid",
"    </span>",
"    health problems, volume and shape of the contralateral breast, body habitus and patient preference. A past history of RT or current disease extent for which RT is mandated may impact the patient's reconstructive options. (See",
"    <a class=\"local\" href=\"#H2464163\">",
"     'Radiation therapy and reconstruction'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Comorbidities such as obesity, insulin-dependent diabetes mellitus, chronic obstructive pulmonary disease, smoking, and connective tissue disease may also influence reconstructive options [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/29/39386/abstract/28\">",
"     28",
"    </a>",
"    ]. Likewise, past surgical histories that include open cholecystectomy, abdominoplasty, or coronary artery bypass grafting (with use of internal mammary vessels) may limit reconstructive choices because of their potential adverse effects on the blood supply to autogenous tissues at donor sites.",
"   </p>",
"   <p>",
"    Smokers are at a significantly greater risk of developing surgical complications, particularly from autogenous (natural) tissue reconstructions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/29/39386/abstract/29-31\">",
"     29-31",
"    </a>",
"    ]. In one series, compared to nonsmokers, smokers who underwent a transverse rectus abdominis musculocutaneous (TRAM) flap reconstruction had significantly higher rates of mastectomy skin flap necrosis (19 versus 9 percent), donor site complications (26 versus 14 percent), and TRAM flap necrosis (4.4 versus 0.8 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/29/39386/abstract/29\">",
"     29",
"    </a>",
"    ]. There were no significant differences in complication rates between nonsmokers and former smokers. For this reason, many surgeons consider active smoking to represent a contraindication to TRAM flap reconstruction. (See",
"    <a class=\"local\" href=\"#H21\">",
"     'Pedicled TRAM flap'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Breast reconstruction in overweight and obese patients also presents a difficult challenge for plastic surgeons. Previous studies have reported higher complication rates and disappointing aesthetic results in this population compared with normal weight women [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/29/39386/abstract/3,28,32-38\">",
"     3,28,32-38",
"    </a>",
"    ]. In a multicenter prospective analysis comparing complication rates of expander-implant and TRAM reconstructions, higher body mass index (BMI) was associated with a greater likelihood of postoperative complications [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/29/39386/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although patient satisfaction with postmastectomy reconstruction remains high in obese patients, these patients should be counseled preoperatively regarding their higher complication rates [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/29/39386/abstract/37,38\">",
"     37,38",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Physical examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;The breasts are evaluated for volume, ptosis, asymmetry, and scars, and the axilla examined for palpably abnormal lymph nodes. If RT has been administered previously, the quality of the breast and chest wall soft tissues must be assessed. The abdomen, back, and buttocks are evaluated as possible donor sites, taking note of scars, overall fat content, and abdominal wall strength.",
"   </p>",
"   <p>",
"    Potential asymmetry between the native contralateral breast and the newly reconstructed breast must be addressed. The contralateral breast may require a reconstructive procedure, such as mastopexy, reduction, or even augmentation, in order to obtain symmetry. The patient's personal distribution of excess skin and fat are also considered, because they dictate whether a given reconstructive choice can provide enough tissue volume to recreate a breast. Finally, patient's wishes regarding scar location, tissue sacrifice, postoperative recovery, and aesthetic outcome are also important in guiding the reconstructive surgeon.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Immediate versus delayed reconstruction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Breast reconstruction can be carried out at the time of the mastectomy (immediate) or during a subsequent operation (delayed). An in-depth discussion regarding appropriate timing for reconstruction is essential both to optimize outcomes and minimize the potential for postoperative complications. Immediate reconstruction can be offered to most patients. However, patients should be informed that if the skin flaps have compromised perfusion following mastectomy, delayed reconstruction will be necessary. Delayed reconstruction is more appropriate for patients who will need postmastectomy radiation for locally advanced breast cancer or inflammatory breast cancer. (See",
"    <a class=\"local\" href=\"#H2464163\">",
"     'Radiation therapy and reconstruction'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H173461702\">",
"    <span class=\"h3\">",
"     Immediate reconstruction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Opinion within the surgical community of immediate breast reconstruction has evolved over time. Initially, delayed procedures were favored because it was assumed that the time between mastectomy and reconstruction provided women with the opportunity to \"psychologically adjust\" to the loss of a breast, therefore allowing for a greater appreciation for their reconstruction. This assumption was found to be faulty when several studies revealed that women undergoing immediate reconstruction experienced significant psychosocial benefits. It is our belief that immediate reconstruction provides at least some \"buffer\" from the psychological and body image disturbances associated with a breast cancer diagnosis and mastectomy.",
"   </p>",
"   <p>",
"    The advantages of immediate reconstruction include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The surgical process is streamlined, since removal of the breast cancer and reconstruction are done in one operative setting. As a result, the overall cost of the reconstructive process is decreased [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/29/39386/abstract/39\">",
"       39",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Accumulating data support the view that immediate breast reconstruction provides substantial psychosocial benefits over delayed reconstruction and preserves normal perceptions of body image in women undergoing mastectomy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/29/39386/abstract/5,40-46\">",
"       5,40-46",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Normal breast landmarks (such as the inframammary fold) are preserved with immediate reconstruction. Particularly with skin-sparing mastectomies and autogenous tissue reconstructions, the remaining breast skin can be incorporated into the new breast, yielding a more natural-appearing shape in many cases [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/29/39386/abstract/47-49\">",
"       47-49",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?12/18/12586?source=see_link&amp;anchor=H7005314#H7005314\">",
"       \"Mastectomy\", section on 'Skin-sparing mastectomy'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The disadvantages of immediate reconstruction include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Immediate reconstruction prolongs operative time. Also, necrosis of the mastectomy skin flaps can adversely affect the aesthetic result of the reconstruction. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?12/18/12586?source=see_link&amp;anchor=H1378593387#H1378593387\">",
"       \"Mastectomy\", section on 'Skin flap necrosis'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      One multicenter prospective cohort study found that at two years, women with immediate reconstruction had a higher rate of complications, particularly among those who had TRAM flaps [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/29/39386/abstract/36\">",
"       36",
"      </a>",
"      ], although others have not observed this result [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/29/39386/abstract/50\">",
"       50",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Large tumor size, direct skin involvement, or documented lymph node involvement in four or more lymph nodes will necessitate postoperative RT, which can adversely affect the reconstruction [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/29/39386/abstract/51\">",
"       51",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H2464163\">",
"       'Radiation therapy and reconstruction'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Relative contraindications to immediate reconstruction:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Advanced disease (stage III or higher) (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?23/45/24278?source=see_link\">",
"       \"Tumor node metastasis (TNM) staging classification for breast cancer\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Need for postoperative RT (see",
"      <a class=\"local\" href=\"#H2464163\">",
"       'Radiation therapy and reconstruction'",
"      </a>",
"      below)",
"     </li>",
"     <li>",
"      Medical comorbidities such as active smoking, obesity, or cardiopulmonary disease",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H173461709\">",
"    <span class=\"h3\">",
"     Delayed reconstruction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Delayed reconstruction is indicated when there is impaired perfusion of skin flaps after mastectomy or when postmastectomy radiation will be needed.",
"   </p>",
"   <p>",
"    The advantages of delayed reconstruction include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Assurance of clear margins prior to definitive reconstruction",
"     </li>",
"     <li>",
"      Minimize the effect of poorly perfused mastectomy skin flaps on the quality of the reconstruction",
"     </li>",
"     <li>",
"      Allows completion of all adjuvant treatment",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The disadvantages of delayed reconstruction include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Need for subsequent surgery",
"     </li>",
"     <li>",
"      Limited reconstructive options following radiation therapy (see",
"      <a class=\"local\" href=\"#H2464163\">",
"       'Radiation therapy and reconstruction'",
"      </a>",
"      below)",
"     </li>",
"     <li>",
"      Lesser aesthetic quality compared to immediate reconstruction",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     RECONSTRUCTIVE OPTIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women who choose reconstruction face a complex decision-making process with regard to both the type and timing of reconstruction. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Immediate versus delayed reconstruction'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    There are two general types of reconstructive options:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Prosthetic devices (eg, saline implants, silicone implants, tissue expanders)",
"     </li>",
"     <li>",
"      Autologous tissue reconstructions with tissue flaps that are transferred from adjoining or distant donor sites to the anterior chest wall",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The following sections will review the process, advantages, and disadvantages for these various types of reconstructions, salient aspects of patient selection for each procedure, and procedure-associated complications.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     PROSTHETIC DEVICES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5976686\">",
"    <span class=\"h2\">",
"     Implants",
"    </span>",
"    &nbsp;&mdash;&nbsp;Modern breast reconstruction began in 1964 with the introduction of the prosthetic device, the silicone breast implant. Since that time, implants have evolved, although the basic component, the silicone polymer shell, remains essentially unchanged. The implant shell can be filled with silicone, saline, or a combination of the two.",
"   </p>",
"   <p>",
"    Implant reconstruction originally entailed placement of a silicone-filled prosthesis beneath the remaining mastectomy skin flaps and (in some cases) the pectoralis major muscle. This approach is sometimes termed primary implant reconstruction. Without providing additional soft tissue coverage to replace the skin removed by the mastectomy, the resulting breast shape was often distorted and lacked adequate projection.",
"   </p>",
"   <p>",
"    With the advent of tissue expansion, primary implant reconstruction is now infrequently used and usually reserved for cases in which the reconstructed breast has a small volume and is minimally ptotic (",
"    <a class=\"graphic graphic_picture graphicRef80679 \" href=\"mobipreview.htm?27/7/27763\">",
"     picture 1",
"    </a>",
"    ). In most cases, placement of a reconstructive implant is preceded by tissue expansion (\"secondary\" or two-stage",
"    <span class=\"nowrap\">",
"     implant/expander",
"    </span>",
"    reconstruction), in order to grow additional soft tissue covering (mainly skin) for the new breast (",
"    <a class=\"graphic graphic_figure graphicRef77306 \" href=\"mobipreview.htm?29/57/30608\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Advantages and disadvantages",
"    </span>",
"    &nbsp;&mdash;&nbsp;The advantages of implant reconstruction are surgical simplicity, the use of cosmetically similar adjacent tissue for coverage of the implant, the lack of donor site morbidity, reduced operative time, and more rapid postoperative recovery as compared to purely autologous reconstructions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/29/39386/abstract/52,53\">",
"     52,53",
"    </a>",
"    ]. For older patients, those with significant medical comorbidity, and women with minimal abdominal tissue,",
"    <span class=\"nowrap\">",
"     expander/implant",
"    </span>",
"    techniques may be the preferred option. The best candidates have minimal ptosis (breast sag), a moderate breast volume (500 g or less), and adequate soft tissue for coverage (see",
"    <a class=\"local\" href=\"#H16\">",
"     'Patient selection'",
"    </a>",
"    below).",
"   </p>",
"   <p>",
"    The main disadvantages are that tissue expansion requires frequent clinic visits for expansion (usually every one to two weeks for one to two months) and a second surgery to place the reconstructive implant. Additionally, the prevailing literature favors autogenous tissue reconstruction over implant reconstruction due to the aesthetic superiority and higher patient satisfaction associated with natural tissue techniques [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/29/39386/abstract/48,54-59\">",
"     48,54-59",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H41\">",
"     'Outcomes associated with breast reconstruction'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Patient selection",
"    </span>",
"    &nbsp;&mdash;&nbsp;As with any type of reconstruction, patients need to be carefully selected and counseled prior to undertaking reconstruction with",
"    <span class=\"nowrap\">",
"     expander/implant",
"    </span>",
"    techniques. Women with smaller, minimally ptotic breasts are good candidates, while those with large, ptotic breasts need more expansion and are more difficult to match with this technique. Such women may require a contralateral breast procedure in order to achieve acceptable symmetry. As noted above, for women who require postmastectomy chest wall RT, tissue expansion is a difficult, complication-prone endeavor. In these cases, autogenous tissue (flap) reconstruction is generally preferred. (See",
"    <a class=\"local\" href=\"#H2464163\">",
"     'Radiation therapy and reconstruction'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5611043\">",
"    <span class=\"h3\">",
"     One stage implant reconstruction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women with small, non-ptotic breasts (Brassiere size &ldquo;A&rdquo; cup or small &ldquo;B&rdquo; cup) can occasionally be reconstructed in a single stage. This type of reconstruction is usually performed as an immediate procedure, provided the mastectomy flaps are nontraumatized and well perfused. Single-stage reconstruction may also be possible in patients who have been previously augmented, because the skin and soft tissues are pre-expanded, and the contralateral augmented breast is usually well matched with an implant (",
"    <a class=\"graphic graphic_picture graphicRef80679 \" href=\"mobipreview.htm?27/7/27763\">",
"     picture 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Single-stage implant reconstruction has been uncommon because most women require additional skin for implant coverage and the two-stage implant reconstruction usually yields aesthetically superior results. However, advancements with skin sparing and nipple-areolar sparing mastectomy allow consideration of the one stage implant option, although revisional procedures are sometimes necessary.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5611050\">",
"    <span class=\"h3\">",
"     Two stage implant reconstruction",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common technique used for",
"    <span class=\"nowrap\">",
"     expander/implant",
"    </span>",
"    placement consists of initially positioning the expander in a pocket deep to the pectoralis major muscle and overlying breast skin. For immediate tissue expander reconstructions, the serratus anterior muscle may be used to provide additional muscle coverage for the expander. Overall the pocket size should match the size of the expander. It is critical to not alter or undermine the inframammary fold, as this is a critical landmark for aesthetic appearance of the breast. If there is concern that the mastectomy flaps have compromised vascular supply, expander placement should be delayed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5611057\">",
"    <span class=\"h3\">",
"     Acellular dermal matrices and implant reconstruction",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of acellular dermal matrices (ADM) from allografts (human cadaveric) or xenografts (non-human) sources has expanded the indications for prosthetic reconstruction following mastectomy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/29/39386/abstract/60-62\">",
"     60-62",
"    </a>",
"    ]. The ADM is supplied as a sheet of decellularized material consisting primarily of collagen and elastin. ADM is purported to serve as biologic scaffolding for fibroblast and angioblast ingrowth and are replaced by host connective tissue at varying rates. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/33/11799?source=see_link\">",
"     \"Reconstructive materials used in surgery: Classification and host response\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The principle benefit of ADM in breast reconstruction is to compartmentalize the implant or expander, preserve the aesthetic landmarks such as the inframammary and lateral mammary folds, and improve aesthetic outcomes. ADM can be used for both one and two stage prosthetic reconstruction.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5611116\">",
"    <span class=\"h2\">",
"     Tissue expanders",
"    </span>",
"    &nbsp;&mdash;&nbsp;A tissue expander is a silicone shell that is incrementally filled with saline through either an integrated or remote port. Modern expanders are shaped anatomically to preferentially expand in the lower pole of the breast. One to three weeks after the expander is placed, in-office expansion begins. For expanders with integrated ports, a magnetic finder (compass) is used to locate the proper injection site under the skin. A needle is then inserted into the skin through the port and sterile saline is infused into the expander. This procedure is repeated every one to two weeks, until the desired volume of expansion is achieved. Tissue expansion should not be attempted during radiotherapy. (See",
"    <a class=\"local\" href=\"#H2464163\">",
"     'Radiation therapy and reconstruction'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Several months after the last expansion (to allow for maximal skin growth), the patient is returned to the operating room for the second stage of the reconstruction. The expander is removed, and the reconstructive implant is placed. The implant (a silicone shell) may be filled with silicone or saline. In addition, necessary revisions are performed at this time, and a nipple may be reconstructed. (See",
"    <a class=\"local\" href=\"#H19\">",
"     'Silicone and breast reconstruction'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H40\">",
"     'Reconstruction of the nipple/areolar complex'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Common complications of reconstructive implants and expanders are infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/29/39386/abstract/63\">",
"     63",
"    </a>",
"    ], capsular contracture (in which a scar forms around the implant and contracts, resulting in pain and loss of breast contour), and deflation. Capsular contracture rates may be lessened by the use of implants with a textured shell rather than a smooth shell, by placement of the implant in a submuscular rather than subcutaneous location, and by avoiding use of this technique in women who need RT [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/29/39386/abstract/64,65\">",
"     64,65",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H2464163\">",
"     'Radiation therapy and reconstruction'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    In a series of 171 consecutive two-stage",
"    <span class=\"nowrap\">",
"     expander/implant",
"    </span>",
"    reconstructions, the rate of infection requiring expander removal was 1.2 percent, while 1.8 percent of the tissue expanders were complicated by spontaneous deflation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/29/39386/abstract/66\">",
"     66",
"    </a>",
"    ]. Capsular contractures developed in only 3 percent, but four of the five cases occurred in previously irradiated patients. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/43/42678?source=see_link\">",
"     \"Breast implant infections\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The cosmetic outcome of implants also appears to deteriorate with time. In one series, 86 percent of patients reporting acceptable appearance two years postoperatively, compared to only 54 percent at five years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/29/39386/abstract/67\">",
"     67",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H44\">",
"     'Patient satisfaction'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Silicone and breast reconstruction",
"    </span>",
"    &nbsp;&mdash;&nbsp;In some patients, silicone gel implants allow for more natural contour and texture in the reconstructed breast than do saline-filled implants. Adverse publicity about a possible link between silicone implants and autoimmune diseases (despite the lack of substantive evidence) led to a moratorium on their use in 1992. Epidemiologic studies and a meta-analysis failed to support a causative relationship [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/29/39386/abstract/68-73\">",
"     68-73",
"    </a>",
"    ], leading the American College of Rheumatology to conclude in 1995 that silicone implants expose patients to",
"    <strong>",
"     no",
"    </strong>",
"    demonstrable additional risk for connective tissue or rheumatologic disease.",
"   </p>",
"   <p>",
"    After extensive review of the data and a report from the Institute of Medicine, the United States Food and Drug Administration (FDA) also concluded that there was no convincing evidence linking silicone implants with connective tissue disease. Restrictions on their use were lifted in 2006 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/29/39386/abstract/74\">",
"     74",
"    </a>",
"    ]. The FDA recommends that all women with silicone implants undergo regular MRI screening throughout their lifetimes to assess for leakage (silent rupture), starting three years after the first implant surgery and every two years thereafter [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/29/39386/abstract/75\">",
"     75",
"    </a>",
"    ]. However, there is little evidence to support a recommendation for regular MRI screening, which is expensive and may lead to anxiety and false positive results, resulting in unnecessary surgery. Therefore, most experts agree that breast MRI should be used as a confirmatory diagnostic test and not be used to screen asymptomatic women for implant rupture [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/29/39386/abstract/76,77\">",
"     76,77",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/29/23002?source=see_link&amp;anchor=H633682#H633682\">",
"     \"MRI of the breast and emerging technologies\", section on 'Assessment of breast implants'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H46564970\">",
"    <span class=\"h3\">",
"     Association of breast implants with lymphoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are a few reports of a very rare type of cancer called anaplastic large cell lymphoma (ALCL) arising in the breast, in the scar capsule adjacent to a silicone or saline-filled breast implant. As an example, a population-based Dutch case-control study reported an 18-fold higher rate of ALCL arising in the breast among women with silicone breast implants when compared with women who did not have implants [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/29/39386/abstract/78\">",
"     78",
"    </a>",
"    ]. However, among the entire Dutch population (8 million women), there were only 11 cases reported over a 17-year period. Based upon their estimate of 100,000 to 300,000 women in the Netherlands with a cosmetic breast prosthesis, the predicted incidence of ALCL would be one to three cases per million women with prostheses per year. Thus, the overall risk of a breast lymphoma among women who have breast implants is extremely low and a causal relationship is far from proven. The usual clinical presentation is of a periprosthetic mass or fluid collection. Whether there is any link between the reports of autoimmune disease or chronic immune stimulation and the discovery of ALCL in some of these patients is unclear. Lymphomas of the breast are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/19/36150?source=see_link\">",
"     \"Breast lymphoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A United States Food Drug Administration (FDA) review reported a total of 60 cases of ALCL out of an estimated 5 to 10 million women worldwide with breast implants. The FDA requested breast implant manufacturers to include this information in their product labeling materials for patients and health care professionals. In addition, the FDA is requesting that health care professionals report any confirmed cases of ALCL in women with breast implants using the FDA's MedWatch Safety Information and Adverse Event Reporting Program. Information about the reporting process is available at",
"    <a class=\"external\" href=\"file://www.fda.gov/MedWatch/report.htm\">",
"     www.fda.gov/MedWatch/report.htm",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/29/39386/abstract/79\">",
"     79",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     AUTOGENOUS TISSUE RECONSTRUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The development of musculocutaneous flaps and microsurgical tissue transplantation paved the way for modern autogenous tissue breast reconstruction. Musculocutaneous flaps consist of a segment of vascularized muscle with the overlying skin and fat which are perfused by perforating vessels from the underlying muscle. These flaps may be transposed into position with their vascular origin intact (\"pedicled\" flaps).",
"   </p>",
"   <p>",
"    Alternatively, the flap and its vascular supply can be completely harvested and transferred to the mastectomy site, requiring anastomosis of the flap's artery and vein to local vessels at the recipient site, usually the internal mammary or thoracodorsal vessels (\"free\" or microsurgical flaps). Although these microvascular free flaps have traditionally included a segment of underlying muscle, a newer version, called a perforator free flap, harvests only the vascular supply (artery and vein) and the overlying skin and fat.",
"   </p>",
"   <p>",
"    When reconstruction of the breast mound is accomplished using the patient's own tissues, the result is typically more natural in both appearance and feel than with",
"    <span class=\"nowrap\">",
"     expander/implant",
"    </span>",
"    reconstruction. Autogenous tissue reconstruction also tends to provide a better match for a large, ptotic contralateral breast if alteration of the opposite breast is not desired. Furthermore, autogenous reconstruction may be the only available reconstructive option for patients who have large soft tissue deficits or chest wall skin that is unsuitable for tissue expansion due to scar tissue or radiation-induced changes. The disadvantages of autologous reconstruction include longer surgical procedures and prolonged recovery time as compared to prosthetic reconstruction. The risk of total flap failure is usually less than 3 percent with experienced surgeons. As an example, in one series of 614 microsurgical flaps for breast reconstruction there were 12 cases of flap loss (1.9 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/29/39386/abstract/80\">",
"     80",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Pedicled TRAM flap",
"    </span>",
"    &nbsp;&mdash;&nbsp;One of the most commonly used autogenous tissue reconstructions is the TRAM (transverse rectus abdominus myocutaneous) flap. The flap is comprised of an ellipse of lower abdominal skin, subcutaneous fat, and muscle. The skin and subcutaneous fat of the lower abdomen receive their blood supply from the underlying muscle via perforating vessels from the superior and inferior epigastric arteries, which arborize through the rectus abdominus muscle. The pedicled TRAM flap is based on the superior epigastric artery and vein, and is rotated into the breast pocket with the superior portion of the muscle still attached to the costal margin (",
"    <a class=\"graphic graphic_figure graphicRef54291 \" href=\"mobipreview.htm?21/25/21909\">",
"     figure 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    TRAM flaps use a transversely oriented skin island from the lower abdomen [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/29/39386/abstract/81\">",
"     81",
"    </a>",
"    ]. This design incorporates an abdominoplasty (\"tummy tuck\") as part of the donor site closure. Using a single rectus muscle, up to 75 percent of the infraumbilical skin and fat can be harvested for the pedicled TRAM flap (",
"    <a class=\"graphic graphic_picture graphicRef71810 \" href=\"mobipreview.htm?10/21/10580\">",
"     picture 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Some women have a greater tissue volume requirement than can be provided by a single rectus muscle. In these cases, both rectus muscles may be raised with the TRAM flap (a bipedicled TRAM). By using both rectus muscles to feed the flap, a larger portion of the abdominal skin and fat can be carried, and the likelihood of fat necrosis or flap loss is reduced [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/29/39386/abstract/82\">",
"     82",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other methods are commonly used to augment the sometimes tenuous arterial blood supply or venous drainage of a pedicled TRAM flap. With a preliminary delay procedure, the inferior epigastric vessels are ligated at least one week prior to the reconstruction. The superior epigastric vessels dilate in response to the relative hypoperfusion of the tissue in their vascular territory, an effect that appears to permanently augment the vascular supply [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/29/39386/abstract/83\">",
"     83",
"    </a>",
"    ]. This procedure can be used for both unipedicled and bipedicled flaps, and is most often used in patients who are at higher risk for fat necrosis and flap loss.",
"   </p>",
"   <p>",
"    A second technique, called \"supercharging\" the flap, involves anastomosing the deep inferior artery and vein microsurgically into the thoracodorsal or internal mammary vessels to augment the vascular supply of the pedicled TRAM flap.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Advantages and disadvantages",
"      </strong>",
"      &ndash; Like other autogenous tissue reconstructions, pedicled TRAM flaps produce a natural appearance and texture in the new breast. The aesthetic results tend to age well, seldom requiring revision in later life to maintain symmetry with the contralateral breast. Unlike",
"      <span class=\"nowrap\">",
"       expander/implant",
"      </span>",
"      techniques, pedicled TRAM reconstructions are essentially one-staged procedures: patients do not require multiple operations or weekly tissue expansions.",
"      <br/>",
"      <br/>",
"      Disadvantages of this type of reconstruction include long operative times (four to six hours), relatively long hospitalizations (three to five days), and long postoperative recovery. It may take women two to four months to return to their preoperative physical functioning. Other outcomes associated with TRAM flap reconstruction, including patient satisfaction and postreconstruction physical functioning, are discussed below. (See",
"      <a class=\"local\" href=\"#H41\">",
"       'Outcomes associated with breast reconstruction'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      <strong>",
"       Patient selection",
"      </strong>",
"      &ndash; Although TRAM reconstruction is a safe, reliable procedure, patient selection is critical in order to avoid flap loss and donor site morbidity. The ideal candidate for a pedicled TRAM flap is a nonsmoking, nondiabetic patient of normal weight with adequate soft tissue in the lower abdomen to match the volume of the contralateral breast.",
"      <br/>",
"      <br/>",
"      Absolute contraindications include a previous TRAM flap, abdominoplasty, or an open cholecystectomy scar that violates the blood supply of the pedicle. Active smoking, obesity, diabetes, collagen vascular disease, postmastectomy radiation therapy (RT), and the presence of certain abdominal scars all increase the risk of complications with the flap and wound healing problems at the lower abdominal donor site.",
"     </li>",
"     <li>",
"      <strong>",
"       Outcomes",
"      </strong>",
"      &ndash; Major complications from TRAM flap reconstruction are rare. These include total flap loss (1 percent or less) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/29/39386/abstract/36,84\">",
"       36,84",
"      </a>",
"      ], which necessitates surgery to both remove necrotic tissue and perform an additional procedure to reconstruct the breast. Rarely, patients can also experience bleeding, infection, deep venous thrombosis, or pulmonary embolism.",
"      <br/>",
"      <br/>",
"      Lesser complications are relatively common, including fat necrosis, acute partial flap loss, seroma, and lower abdominal laxity or hernias. Fat necrosis",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      partial flap loss occur when a fatty region of the flap within the flap does not receive enough blood supply. The resulting tissue fibrosis",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      calcification can simulate a mass in the reconstructed breast on postoperative physical examinations.",
"      <br/>",
"      <br/>",
"      Acute partial flap loss, usually manifest by small areas of skin loss, is usually treated nonoperatively, with dressing changes to promote secondary healing. Seromas most commonly occur in the donor site and may require percutaneous aspiration or reinsertion of a surgical drain.",
"      <br/>",
"      <br/>",
"      The incidence of long-term complications such as abdominal wall laxity, bulge, or hernia was 8 percent in one series [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/29/39386/abstract/36\">",
"       36",
"      </a>",
"      ] and 3 percent on a second [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/29/39386/abstract/84\">",
"       84",
"      </a>",
"      ]. These complications generally require surgical repair.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Free TRAM flap",
"    </span>",
"    &nbsp;&mdash;&nbsp;Unlike the pedicled TRAM flap, which leaves the rectus abdominis muscle attached to the costal margin and tunnels the lower abdominal skin and fat in to the mastectomy site, the free TRAM flap completely detaches and directly transfers the lower abdominal tissue to the mastectomy site. The deep inferior epigastric artery and vein, which provide the vascular supply for the free flap, are anastomosed to local recipient vessels, using either the internal mammary or thoracodorsal arteries and veins. Thereafter, the free TRAM flap is contoured and inset in a fashion similar to that of the pedicled TRAM. Donor site closure is the same with both types of TRAM flaps (",
"    <a class=\"graphic graphic_figure graphicRef64061 \" href=\"mobipreview.htm?40/44/41669\">",
"     figure 3",
"    </a>",
"    ). (See",
"    <a class=\"local\" href=\"#H21\">",
"     'Pedicled TRAM flap'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Advantages and disadvantages",
"      </strong>",
"      &ndash; Free TRAM flaps may provide a more robust blood flow, particularly to the perforators, making the flaps more reliable than pedicled TRAM flaps. Disadvantages of this technique include potentially longer operating times and the need for microsurgical expertise. Furthermore, a trained nursing staff is required in the early post-operative period for flap monitoring in order to detect vessel thrombosis and resulting flap compromise. The rate of total flap loss is also somewhat higher than that for pedicled TRAM flaps (2 to 5 versus less than 1 percent).",
"     </li>",
"     <li>",
"      <strong>",
"       Patient selection",
"      </strong>",
"      &ndash; Because the free TRAM flap may provide a more robust blood supply than the pedicled TRAM flap, the free TRAM may be preferred when the mastectomy defect requires large amounts of skin and soft tissue coverage, or when large unilateral or bilateral reconstructions (",
"      <a class=\"graphic graphic_picture graphicRef75822 \" href=\"mobipreview.htm?2/5/2130\">",
"       picture 3",
"      </a>",
"      ) require the use of peripheral portions of the flap. In addition, the more generous blood supply can improve flap survival in patients who have risk factors such as smoking, diabetes, or obesity. In addition, some women who are not candidates for pedicled TRAM flaps due to previous subcostal incisions and resultant interruption of the superior epigastric vessels can undergo free TRAM flap reconstruction without difficulty.",
"     </li>",
"     <li>",
"      <strong>",
"       Outcomes",
"      </strong>",
"      &ndash; Complications in the early postoperative period include infection, hematoma, seroma, donor site necrosis, and partial or total flap loss. As noted above, the rate of total flap failure is somewhat higher for free TRAM than for pedicled flaps (2 to 5 versus less than 1 percent, respectively) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/29/39386/abstract/85\">",
"       85",
"      </a>",
"      ], although the free flap is more resistant to partial loss than is the pedicled TRAM flap. As with pedicled TRAM reconstructions, long-term complications for the free TRAM flap include abdominal wall laxity or hernia.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Latissimus dorsi reconstruction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Another reliable option for autologous tissue reconstruction is the latissimus dorsi (LD) flap (",
"    <a class=\"graphic graphic_figure graphicRef67952 \" href=\"mobipreview.htm?42/6/43107\">",
"     figure 4",
"    </a>",
"    ). Usually transferred to the mastectomy site as a pedicled flap, the LD flap is tunneled through the axilla, leaving its vascular pedicle, the thoracodorsal artery and vein, intact. Because the LD is not a bulky flap, it usually is used in combination with a saline or silicone implant to provide sufficient breast volume and projection. Alternatively, some surgeons inset the LD flap over a tissue expander, relying on the subsequent expansions to create the needed breast contour. As described above, the expander is later replaced with a saline or silicone reconstructive implant (",
"    <a class=\"graphic graphic_picture graphicRef64914 \" href=\"mobipreview.htm?8/52/9026\">",
"     picture 4",
"    </a>",
"    ). &nbsp;(See",
"    <a class=\"local\" href=\"#H5976686\">",
"     'Implants'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Patient selection",
"      </strong>",
"      &ndash; LD flaps are useful in patients who are not candidates for",
"      <span class=\"nowrap\">",
"       expander/implant",
"      </span>",
"      or TRAM reconstruction [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/29/39386/abstract/86,87\">",
"       86,87",
"      </a>",
"      ]. In some individuals, the skin at the mastectomy site may be compromised from previous RT or surgical trauma, thus eliminating expander-implant reconstruction as a viable option.",
"      <br/>",
"      <br/>",
"      LD flaps also represent an acceptable alternative for patients who require autogenous tissue reconstruction but are not appropriate candidates for TRAM flaps because of obesity, active smoking, or significant medical comorbidity. LD flaps also are commonly used for reconstruction of contour defects following lumpectomy and RT in breast cancer patients. Finally, LD flaps can work well for salvage of breast reconstruction in cases of partial or total loss of other types of autogenous tissue reconstruction, provided that the thoracodorsal vessels or the LD muscle have not been sacrificed in previous operations.",
"     </li>",
"     <li>",
"      <strong>",
"       Advantages and disadvantages",
"      </strong>",
"      &ndash; The advantages of LD reconstruction include flap reliability and suitability in patients who may be marginal candidates for more complicated flap techniques.",
"      <br/>",
"      <br/>",
"      Disadvantages of the LD flap include significant donor site scarring and the frequent need for an implant",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      tissue expander placement due to insufficient flap volume. The latissimus dorsi muscle may also atrophy over time, making the underlying implant more prominent and causing contour irregularities in the reconstructed breast. In a report of 68 women undergoing reconstruction with combined LD flaps and implants followed for at least 10 years, one-half needed additional surgeries for exchange or removal of the prosthesis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/29/39386/abstract/88\">",
"       88",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Outcomes",
"      </strong>",
"      &ndash; Complications from LD flaps include hematoma, infection, fat necrosis, and partial or total flap loss. Because the blood supply to the latissimus is extremely reliable, the incidence of flap loss is relatively low, compared to other autogenous tissue options for breast reconstruction.",
"      <br/>",
"      <br/>",
"      The most common complication is seroma formation in the LD donor site; rates as high as 12 to 21 percent are reported [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/29/39386/abstract/89,90\">",
"       89,90",
"      </a>",
"      ]. Although it has not been systematically studied, the impact of LD harvest on shoulder function appears to be minimal [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/29/39386/abstract/91\">",
"       91",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h2\">",
"     Perforator flaps",
"    </span>",
"    &nbsp;&mdash;&nbsp;In an effort to conserve muscle, \"perforator\" flaps harvest only the skin and fat overlying the muscle along with the perforating vessels and dominant artery and vein supplying the flap. The free flap is then transferred as described above for free TRAM flaps. Although the underlying muscle must be split to dissect out the perforating vessels, the muscle itself is not included in the transfer. (See",
"    <a class=\"local\" href=\"#H25\">",
"     'Free TRAM flap'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H895837\">",
"    <span class=\"h3\">",
"     DIEP perforator flaps",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most commonly used perforator flap for breast reconstruction is the deep inferior epigastric perforator (DIEP) flap (",
"    <a class=\"graphic graphic_figure graphicRef66615 \" href=\"mobipreview.htm?14/44/15045\">",
"     figure 5",
"    </a>",
"    ). The DIEP uses the same lower abdominal island of skin and fat as TRAM techniques but spares the rectus abdominis muscle. Also as with TRAM flaps, the DIEP donor site is closed as a modified abdominoplasty.",
"   </p>",
"   <p>",
"    <strong>",
"     Patient selection",
"    </strong>",
"    &mdash; Similar to TRAM flaps, patient selection for DIEP flaps should be made on the basis of body weight, medical comorbidities, quantity of abdominal fat, and breast volume. Patients who are very concerned about abdominal wall morbidity or bulging after a TRAM reconstruction may also be candidates.",
"    <br/>",
"    <br/>",
"    Contraindications to DIEP reconstruction are similar to those for TRAM flaps and include prior history of abdominoplasty or abdominal liposuction, obesity, and active smoking (within one month of surgery). Relative contraindications include large transverse or oblique abdominal incisions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/29/39386/abstract/92\">",
"     92",
"    </a>",
"    ]. Pfannenstiel scars do not appear to influence complication rates [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/29/39386/abstract/93\">",
"     93",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Successful transplantation of perforator flaps requires blood vessels of suitable caliber and location. Accordingly, some surgeons employ preoperative evaluation of perforator vessels using modalities such as computerized tomographic angiography (CTA) or magnetic resonance angiography [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/29/39386/abstract/94-96\">",
"     94-96",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Advantages and disadvantages",
"      </strong>",
"      &ndash; The DIEP flap has all of the advantages of the free TRAM flap and a similar aesthetic outcome, but may be associated with a lower incidence of abdominal wall laxity, and weakness, less postoperative pain, and shorter recovery [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/29/39386/abstract/92,97-103\">",
"       92,97-103",
"      </a>",
"      ]. In appropriately selected patients, some microsurgeons prefer DIEP flaps over free TRAM reconstruction.",
"      <br/>",
"      <br/>",
"      Significant microsurgical expertise is required for the meticulous dissection and anastomosis of perforators as small as one millimeter in diameter. The complexity of the procedure contributes to long operative times.",
"     </li>",
"     <li>",
"      <strong>",
"       Outcomes",
"      </strong>",
"      &ndash; Patients should be counseled preoperatively that consideration of a DIEP flap as a reconstructive option depends upon the number, caliber, and location of the perforating vessels. If the inferior epigastric perforators are noted intraoperatively to be insufficient to support the entire flap, the procedure may need to be converted to a standard free TRAM reconstruction, in which case a portion of the rectus muscle would be harvested with the flap.",
"      <br/>",
"      <br/>",
"      Complications of the DIEP flap include fat necrosis, partial flap loss, total flap loss, and abdominal wall laxity or hernia. In a series of 758 DIEP flaps performed for breast reconstruction, 6 percent of patients were returned to the operating room for flap-related problems [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/29/39386/abstract/97\">",
"       97",
"      </a>",
"      ]. Partial flap loss occurred in 2.5 percent and total flap loss in less than 1 percent. Other problems included fat necrosis in 13 percent (risk factors were smoking and post reconstruction RT), seroma formation at the abdominal donor site in 5 percent, and abdominal hernia in 0.7 percent.",
"      <br/>",
"      <br/>",
"      Whether the incidence of partial and total flap loss is higher than with traditional TRAM procedures is unclear. Some studies show that DIEP flaps have a less robust blood supply than TRAM flaps, and therefore an increased risk of fat necrosis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/29/39386/abstract/104,105\">",
"       104,105",
"      </a>",
"      ]. One study, for example, compared 105 women who underwent bilateral pedicled TRAM flaps with 58 women who had bilateral DIEP flap reconstructions; there were significantly higher rates of partial skin loss, wound dehiscence, and fat necrosis with the DIEP flap [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/29/39386/abstract/105\">",
"       105",
"      </a>",
"      ]. There were no significant differences in the incidence of seromas or hematomas, back pain, abdominal hernias or bulges between the two groups. Other studies suggest that rates of partial flap loss and fat necrosis are no higher with perforator flaps than with pedicled TRAM procedures [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/29/39386/abstract/106\">",
"       106",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H37\">",
"    <span class=\"h3\">",
"     SEIA perforator flaps",
"    </span>",
"    &nbsp;&mdash;&nbsp;The superficial inferior epigastric artery (SIEA) perforator flap, provides the same abdominal tissue for breast reconstruction as the DIEP flap [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/29/39386/abstract/107\">",
"     107",
"    </a>",
"    ]. While not all patients have superficial inferior epigastric vessels of sufficient caliber to support transfer of the associated lower abdominal skin and fat, basing the flap on the inferior epigastric vessels can provide a reliable, less invasive free flap option for breast reconstruction in appropriately selected patients.",
"   </p>",
"   <p>",
"    Careful intraoperative evaluation of the superficial inferior epigastric vessels is mandatory with this procedure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/29/39386/abstract/92\">",
"     92",
"    </a>",
"    ]. If the vessels are undersized or otherwise not suitable, the flap can be converted into a DIEP or free TRAM for a more reliable vascular supply.",
"   </p>",
"   <p>",
"    The indications for an SIEA flap are the same as for a DIEP flap [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/29/39386/abstract/107\">",
"     107",
"    </a>",
"    ]. However, the SIEA flap is associated with even less donor site morbidity than the DIEP flap as no fascial incisions or muscle dissection are required. The SIEA flap is limited by variable anatomy, particularly with regard to the presence and size of the superficial inferior epigastric arteries. SIEA flaps are not anatomically and technically possible in most patients and the available volume of tissue is limited.",
"   </p>",
"   <p>",
"    As with the DIEP flap procedures, significant microsurgical expertise is required for the meticulous dissection and anastomosis of SIEA perforators as small as one millimeter in diameter. The complexity of the procedure contributes to long operative times. In a retrospective review of over 200 SIEA flap breast reconstructions, there were no flap losses and the rate of return to the operating room was similar to that with DIEP flap reconstructions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/29/39386/abstract/108\">",
"     108",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H38\">",
"    <span class=\"h3\">",
"     GAP perforator flaps",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients who do not have sufficient lower abdominal fat for TRAM, DIEP or SIEA flaps, but who prefer the use of autologous tissue, a more viable donor site may be the buttock area [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/29/39386/abstract/108,109\">",
"     108,109",
"    </a>",
"    ] (",
"    <a class=\"graphic graphic_figure graphicRef75614 \" href=\"mobipreview.htm?5/44/5826\">",
"     figure 6",
"    </a>",
"    ). For this free flap, perforating vessels from either the superior gluteal artery (SGAP flap) or the inferior gluteal artery (IGAP flap) can be used as the vascular supply for the transferred tissue. For the SGAP flap, upper buttock tissue is used, resulting in a donor site scar that is concealable under most swimwear. If an IGAP flap is performed, the donor site scar lies within the lower buttock crease.",
"   </p>",
"   <p>",
"    Advantages of GAP flaps include the ready availability of sufficient soft tissue for breast reconstruction in most patients. Furthermore, these flaps do not require the sacrifice of the gluteus maximus muscle and thus do not appear to have any adverse impact on postoperative functioning.",
"   </p>",
"   <p>",
"    Disadvantages of GAP flaps include the technical challenges of flap harvest and transfer, and the associated risk of sciatic nerve injury. In general, the caliber and length of the vascular pedicle associated with gluteal perforator flaps is less than its abdominal counterpart (DIEP flap). Some patients report postoperative pain due to insufficient padding of the sciatic nerve.",
"   </p>",
"   <p>",
"    In a retrospective review of 170 GAP flaps, 8 percent of patients required a return to the operating room with a 6 percent rate of vascular complications and total flap failure rate of 2 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/29/39386/abstract/108\">",
"     108",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4082052\">",
"    <span class=\"h3\">",
"     TUG flaps",
"    </span>",
"    &nbsp;&mdash;&nbsp;The transverse upper gracilis (TUG) flap is based on the proximal gracilis muscle and its vascular pedicle, the ascending branch of the medial circumflex femoral artery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/29/39386/abstract/110,111\">",
"     110,111",
"    </a>",
"    ] (",
"    <a class=\"graphic graphic_figure graphicRef54628 \" href=\"mobipreview.htm?0/49/788\">",
"     figure 7",
"    </a>",
"    ). This flap utilizes tissue from the posterior upper",
"    <span class=\"nowrap\">",
"     thigh/lower",
"    </span>",
"    buttock and provides another choice for women with insufficient lower abdominal fat for breast reconstruction. The advantage of the TUG flap is avoidance of scars on the abdomen, back, or gluteal region. The TUG flap is appropriate for small to moderate volume breast reconstruction because there is usually not a large quantity of fat in the upper thigh.",
"   </p>",
"   <p>",
"    As with the DIEP flap procedure, significant microsurgical expertise is required for the meticulous dissection and anastomosis of TUG perforators, which are as small as one mm in diameter. The complexity of the procedure contributes to long operative times.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10133119\">",
"    <span class=\"h2\">",
"     Postoperative morbidity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Free flaps have the highest 30-day morbidity rates, while complications following latissimus dorsi flaps are relatively few. A retrospective review of the National Surgical Quality Improvement Program (NSQIP) database, including 3296 patients undergoing autologous breast reconstruction, found that patients undergoing autologous free flap reconstruction (n = 609) had the highest overall rates of complications compared with patients undergoing pedicled TRAM flaps (n = 1608) or latissimus dorsi flaps (19.4 versus 13.4 versus 7.1 percent, respectively) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/29/39386/abstract/112\">",
"     112",
"    </a>",
"    ]. Patients undergoing autologous free flap reconstruction also had a higher rate of reoperation (15.6 versus 9.9 versus 5.7 percent, respectively) and a higher rate of flap failure (5.7 versus 3.4 versus 1.3 percent, respectively).",
"   </p>",
"   <p>",
"    In addition, independent predictors of complications for patients undergoing free flap transfer included:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Obesity",
"     </li>",
"     <li>",
"      Prolonged operating times",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Independent predictors of complications for patients undergoing pedicled TRAM flap procedures included:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      American Society of Anesthesia (ASA) classification score &ge;3. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?19/22/19817?source=see_link&amp;anchor=H19#H19\">",
"       \"Overview of anesthesia and anesthetic choices\", section on 'Preoperative risk assessment'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Obesity",
"     </li>",
"     <li>",
"      Diabetes mellitus",
"     </li>",
"     <li>",
"      Previous operation within 30 days",
"     </li>",
"     <li>",
"      Delayed reconstruction",
"     </li>",
"     <li>",
"      Prolonged operating time",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Independent predictors of complications for patients undergoing latissimus dorsi flap reconstruction included:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      ASA classification score &ge;3",
"     </li>",
"     <li>",
"      Delayed reconstruction procedure",
"     </li>",
"     <li>",
"      Prolonged operating time",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H39\">",
"    <span class=\"h1\">",
"     OPTIONS FOR THE CONTRALATERAL NORMAL BREAST (SYMMETRY PROCEDURES)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Once reconstruction of the affected breast has begun, the challenge of creating symmetry with the contralateral breast is undertaken. Contralateral breast surgery can be performed at the time of the initial reconstruction or during the second stage [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/29/39386/abstract/113\">",
"     113",
"    </a>",
"    ]. Mastopexy, reduction, augmentation or a combination of procedures can be used both for aesthetic improvement and improved symmetry (",
"    <a class=\"graphic graphic_picture graphicRef62910 \" href=\"mobipreview.htm?9/58/10147\">",
"     picture 5",
"    </a>",
"    ). As an example, in a woman with very large breasts who undergoes a mastectomy with reconstruction, a contralateral reduction will decrease the size discrepancy, resulting in improved patient comfort and increased symmetry.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H40\">",
"    <span class=\"h1\">",
"     RECONSTRUCTION OF THE NIPPLE/AREOLAR COMPLEX",
"    </span>",
"    &nbsp;&mdash;&nbsp;The final component of breast reconstruction is the creation of the nipple and areola. This is typically performed during the second stage of breast reconstruction, but can also be performed in an office setting. The goal of nipple and areolar reconstruction is to achieve symmetry of position of the nipple-areolar complex in the contralateral breast with comparable appearance and color.",
"   </p>",
"   <p>",
"    There are multiple techniques of local tissue rearrangement for creation of a new nipple. Some are based on skin grafts, while others utilize donor sites that are closed primarily. Nipple projection varies among the different techniques, but adequate results can be achieved with most. Symmetry of position on the breast mound is the most important goal of nipple reconstruction, as even small discrepancies are obvious. Once the projecting papilla has been created, the appearance of the entire nipple-areola complex can be enhanced by the use of tattooing (",
"    <a class=\"graphic graphic_picture graphicRef54178 \" href=\"mobipreview.htm?0/28/448\">",
"     picture 6",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2464163\">",
"    <span class=\"h1\">",
"     RADIATION THERAPY AND RECONSTRUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Following the publication of randomized trials in 1997 demonstrating superior locoregional control and survival with postmastectomy RT, this approach has become increasingly common. Contemporary guidelines advocate postmastectomy chest wall RT in the setting of four or more positive nodes, tumor size greater than 5 cm, any T4 primary, positive margins, and for gross extracapsular nodal extension. There is some controversy as to the benefit of RT among patients with one to three positive nodes and for those undergoing neoadjuvant or preoperative chemotherapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/29/39386/abstract/114\">",
"     114",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/45/24278?source=see_link\">",
"     \"Tumor node metastasis (TNM) staging classification for breast cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/3/41017?source=see_link\">",
"     \"Postmastectomy chest wall irradiation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Women who require postmastectomy RT present a unique reconstructive challenge. Depending upon treatment planning technique, immediate breast reconstruction may pose limitations on treatment planning for postmastectomy RT and can adversely affect the technical delivery of RT, with a risk of excessive dosage to the lung or inadequate dosage to the internal mammary lymph nodes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/29/39386/abstract/47,115-117\">",
"     47,115-117",
"    </a>",
"    ]. In a retrospective study of 146 women with locally advanced breast cancer requiring postmastectomy radiation, the local recurrence rate was lower when radiation therapy was given before reconstruction (15 percent) as compared to radiation after reconstruction (27 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/29/39386/abstract/118\">",
"     118",
"    </a>",
"    ]. However, this has not been seen in all studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/29/39386/abstract/119\">",
"     119",
"    </a>",
"    ], and the impact of immediate breast reconstruction on the delivery of RT remains unsettled.",
"   </p>",
"   <p>",
"    RT leads to fibrosis, which compromises the quality of the skin and underlying tissue, results in a higher incidence of complications from the reconstructive procedure and may produce a less aesthetically pleasing result [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/29/39386/abstract/120\">",
"     120",
"    </a>",
"    ]. In the case of prosthetic devices, radiation may result in fibrosis, capsular contracture, or premature implant removal. In the cases of autologous reconstruction, radiation may result in flap shrinkage and fibrosis. In a retrospective of study of 113 women who underwent postmastectomy radiotherapy and breast reconstruction, the complication rate was 32 percent for patients who had radiation first and 44 percent for patients who had breast reconstruction first [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/29/39386/abstract/121\">",
"     121",
"    </a>",
"    ]. Early complications were seen more frequently in patients having radiation first while late complications were more common in patients who had breast reconstruction first.",
"   </p>",
"   <p>",
"    The best method of integrating RT into any method of reconstruction is controversial. The impact of RT on implant and autologous flap reconstruction is discussed below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2464250\">",
"    <span class=\"h2\">",
"     Impact of RT on implants",
"    </span>",
"    &nbsp;&mdash;&nbsp;Radiation-related complication rates are highest among women undergoing",
"    <span class=\"nowrap\">",
"     expander/implant",
"    </span>",
"    reconstruction, irrespective of when RT is given in relation to surgery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/29/39386/abstract/42,47,64-66,122-125\">",
"     42,47,64-66,122-125",
"    </a>",
"    ]. The end results of the complex tissue changes induced by RT are scar formation at the",
"    <span class=\"nowrap\">",
"     implant/tissue",
"    </span>",
"    interface, capsular contracture, and impaired skin healing. Other complications associated with implant reconstruction include implant rupture or extrusion, and implant malpositioning.",
"   </p>",
"   <p>",
"    A cohort study comparing outcomes among 40 women who had reconstruction with an implant in the setting of RT with 40 others who were not irradiated showed that capsular contraction rates among the women who did and did not receive RT were 33 and 0 percent, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/29/39386/abstract/64\">",
"     64",
"    </a>",
"    ]. Nineteen of the 40 irradiated breasts ultimately needed the addition of or replacement by autogenous tissue to salvage the reconstruction. Similar findings have been reposted in other studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/29/39386/abstract/121\">",
"     121",
"    </a>",
"    ]. However, not all studies indicate poor",
"    <span class=\"nowrap\">",
"     cosmetic/aesthetic",
"    </span>",
"    outcomes in women who undergo immediate implant reconstruction followed by RT [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/29/39386/abstract/126-128\">",
"     126-128",
"    </a>",
"    ]. Furthermore, despite higher complication rates, both general satisfaction and patient aesthetic satisfaction are not significantly different in patients who undergo",
"    <span class=\"nowrap\">",
"     implant/expander",
"    </span>",
"    reconstruction following RT compared to patients who did not receive RT [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/29/39386/abstract/65\">",
"     65",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    NCCN guidelines suggest that for women undergoing implant reconstruction and who will need postmastectomy radiation, immediate reconstruction with an expander is preferred to avoid expansion of radiated tissue flaps [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/29/39386/abstract/129\">",
"     129",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2464257\">",
"    <span class=\"h2\">",
"     Impact of RT on flap reconstruction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because of the local tissue effects of RT, autogenous tissue options are preferred over implant-based techniques in previously irradiated patients.",
"   </p>",
"   <p>",
"    Although autologous tissue reconstructions may be better able to withstand RT-induced tissue damage [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/29/39386/abstract/126,130,131\">",
"     126,130,131",
"    </a>",
"    ], they are still subject to radiation-related fat necrosis, fibrosis, atrophy, and flap contracture. The incidence of late complications (fat necrosis, flap volume loss, flap contracture) is significantly higher in immediate reconstructions that have undergone RT [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/29/39386/abstract/48,116,132,133\">",
"     48,116,132,133",
"    </a>",
"    ]. In a study comparing outcomes between 32 patients who underwent immediate TRAM flap reconstruction followed by RT and 70 women who underwent RT and subsequent delayed flap reconstruction the incidence of late complications was significantly higher in the immediate compared with the delayed reconstruction group (88 versus 9 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/29/39386/abstract/116\">",
"     116",
"    </a>",
"    ]. Nine patients (28 percent) in the immediate reconstruction group required an additional flap to correct contour deformities resulting from flap shrinkage and contracture.",
"   </p>",
"   <p>",
"    Transferring nonirradiated tissue to the mastectomy site may avoid some of the radiation-associated wound healing complications. Tissues severely damaged by RT can be resected and discarded at the time of the reconstruction, and the skin \"paddle\" of the designed flap can be tailored to replace the missing breast surface skin. In general, prior RT increases the amount of tissue required for breast reconstruction, and this may limit flap selection.",
"   </p>",
"   <p>",
"    For women undergoing autologous tissue reconstruction, NCCN guidelines support delaying reconstruction until after completion of radiation therapy to avoid fibrosis and compromised cosmesis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/29/39386/abstract/129\">",
"     129",
"    </a>",
"    ]. Delayed autologous flap reconstruction provides the best cosmetic result with the fewest complications (",
"    <a class=\"graphic graphic_picture graphicRef55849 \" href=\"mobipreview.htm?35/62/36834\">",
"     picture 7",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/29/39386/abstract/114\">",
"     114",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2464271\">",
"    <span class=\"h2\">",
"     Selecting patients likely to need postmastectomy RT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The need for postmastectomy RT often cannot be determined definitively until the final pathologic evaluation is complete (typically three to five days following mastectomy). A number of approaches have been suggested to circumvent this problem and permit suitable patients who have a low likelihood of needing postmastectomy RT to undergo immediate reconstruction, if they desire it.",
"   </p>",
"   <p>",
"    Since nodal status is a key factor in deciding whether postmastectomy RT will be recommended if tumor size is &lt;5 cm, one approach is to perform a sentinel lymph node (SLN) biopsy prior to mastectomy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/29/39386/abstract/134,135\">",
"     134,135",
"    </a>",
"    ]. If the SLNs are tumor-free, then the likelihood that postmastectomy RT will be needed is low (but not zero), and immediate reconstruction can be considered. A model to predict the likelihood of requiring postmastectomy RT has been proposed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/29/39386/abstract/136\">",
"     136",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/47/36602?source=see_link\">",
"     \"Sentinel lymph node dissection for breast cancer: Indications and outcomes\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    To lessen the risk of an immediately reconstructed breast undergoing postoperative RT, other investigators have recommended the so-called \"immediate-delayed\" reconstruction approach [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/29/39386/abstract/137\">",
"     137",
"    </a>",
"    ]. The first stage consists of a skin-sparing mastectomy with subpectoral insertion of a filled tissue expander to preserve the shape and dimensions of the breast envelope. After a review of the permanent histologic sections, patients who do not need postmastectomy RT then undergo a \"delayed-immediate\" reconstruction within two weeks of mastectomy. In contrast, those who need RT undergo this therapy with the expander deflated on the chest wall to optimize treatment delivery, followed by delayed reconstruction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/29/39386/abstract/51\">",
"     51",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Early results with this approach have been promising, but RT-related tissue expander complications may still require interruption of postmastectomy RT, with the associated risk of compromising oncologic outcomes. More research on breast reconstruction in irradiated patients is needed to determine optimal management in this setting.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H41\">",
"    <span class=\"h1\">",
"     OUTCOMES ASSOCIATED WITH BREAST RECONSTRUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;For women undergoing mastectomy, breast reconstruction offers significant quality of life (QOL) benefits and is a vital option to enhance breast cancer recovery. With the variety of reconstructive techniques available, choosing the \"right\" option can sometimes be a daunting task, even for highly educated consumers. Considerations include patient preference, body habitus, and prior surgical procedures.",
"   </p>",
"   <p>",
"    Outcomes data on surgical complications, physical function, and quality of life and patient satisfaction provide both the surgeon and patient with useful information when choosing the most appropriate reconstructive technique and timing. Surgical complications associated with the individual reconstructive options are discussed above.",
"   </p>",
"   <p>",
"    The following sections emphasize data on post reconstruction outcomes that are relevant to psychosocial issues, patient satisfaction, and physical functioning, as derived from the Michigan Breast Reconstruction Outcomes Study (MBROS), a multicenter prospective cohort that included women undergoing first-time immediate or delayed breast reconstructions recruited from 12 centers and 23 plastic surgeons [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/29/39386/abstract/41\">",
"     41",
"    </a>",
"    ]. The procedures evaluated were",
"    <span class=\"nowrap\">",
"     expander/implant,",
"    </span>",
"    pedicled TRAM, and free TRAM reconstructions. Data were collected preoperatively and at one and two years postoperatively.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H42\">",
"    <span class=\"h2\">",
"     Psychosocial function and quality of life",
"    </span>",
"    &nbsp;&mdash;&nbsp;The impact of the breast cancer diagnosis affects psychologic function, regardless of the surgical procedure (ie, mastectomy, mastectomy with reconstruction, or breast conserving surgery) recommended for treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/29/39386/abstract/7\">",
"     7",
"    </a>",
"    ]. It is challenging to accurately compare the psychosocial impact of the various surgical procedures as some women who are candidates for breast conserving surgery opt for mastectomy, some who are candidates for reconstruction opt for none. In addition, some women are not candidates for either breast conservation or immediate reconstruction because of advanced stage of disease or comorbid illnesses. Another compounding variable to measuring psychosocial function is the type of reconstruction offered",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    selected. The options for a reconstructive procedure are based upon body habitus, prior abdominal procedures, and current smoking history; patient preference also plays a major role in the procedure ultimately performed. All of these variables will have an impact upon psychosocial function following a diagnosis of breast cancer.",
"   </p>",
"   <p>",
"    Within the confines of these limitations, a few studies have attempted to measure the impact of reconstruction on psychosocial function and quality of life (QOL). These include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      A prospective study of 90 women found that psychologic distress was evident regardless of reconstruction (performed or not) or timing of reconstruction (delayed or immediate) at one year after the procedure [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/29/39386/abstract/138\">",
"       138",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      QOL one year following a mastectomy and reconstruction was equivalent to age-matched control women never diagnosed with breast cancer [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/29/39386/abstract/139\">",
"       139",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The more extensive reconstructive procedures have an associated increased surgical risk and longer recovery times, but the choice of reconstruction (eg, tissue",
"      <span class=\"nowrap\">",
"       expander/implant,",
"      </span>",
"      TRAM) has a limited impact on most psychosocial measures at one and two years of observation [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/29/39386/abstract/41,140\">",
"       41,140",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A randomized trial of 75 women treated with delayed reconstruction (ie, lateral thoracodorsal flap, the latissimus dorsi flap, or the pedicled TRAM flap) found a high level of satisfaction in the majority of women regarding the cosmetic result of each procedure [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/29/39386/abstract/16\">",
"       16",
"      </a>",
"      ]. Both the latissimus dorsi and TRAM flap cohorts scored higher on QOL questionnaires compared with patients undergoing the lateral thoracodorsal flap in terms of breast symmetry and reduced problems in social situations. All three reconstructive procedures were associated with improvements in patient-defined problem areas of life, QOL, and social functioning at six months and one year after reconstruction.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Psychologic support should be offered to all women diagnosed with breast cancer, regardless of surgical procedure (breast conserving or mastectomy with or without reconstruction) offered.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H44\">",
"    <span class=\"h2\">",
"     Patient satisfaction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinicians and researchers evaluate health care not just by assessing objective outcomes (complication rates and length of hospitalization, for example) but also from the consumers' point of view in terms of patient satisfaction. As a key measure of quality of care and outcomes, patient satisfaction is being used as a basis for policy formulation, quality improvement programs, and to help direct the patient-clinician decision making process. Patient satisfaction surveys provide consumer feedback about the structure, process, and outcomes of care.",
"   </p>",
"   <p>",
"    It is well established that breast reconstruction is associated with high levels of patient satisfaction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/29/39386/abstract/58,59\">",
"     58,59",
"    </a>",
"    ]. The type of reconstructive procedure appears to affect postoperative patient satisfaction. This was illustrated in the Michigan Breast Reconstruction Outcomes Study (MBROS) project described above, which measured patient satisfaction with regard to aesthetic result (softness, symmetry) and general satisfaction with the process and outcome of care [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/29/39386/abstract/41,59\">",
"     41,59",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    At one year following surgery, women with pedicled TRAM flaps, free TRAM flaps, and",
"    <span class=\"nowrap\">",
"     expander/implants",
"    </span>",
"    had similar levels of general satisfaction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/29/39386/abstract/41\">",
"     41",
"    </a>",
"    ], but autogenous tissue reconstructions (TRAM procedures) were associated with greater aesthetic satisfaction than",
"    <span class=\"nowrap\">",
"     expander/implant",
"    </span>",
"    techniques. At year 2, these procedural differences had diminished, but patients continued to be more aesthetically satisfied with autogenous tissue compared to",
"    <span class=\"nowrap\">",
"     expander/implant",
"    </span>",
"    reconstructions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/29/39386/abstract/59\">",
"     59",
"    </a>",
"    ]. At postoperative year 2, the percentages of patients aesthetically satisfied in the",
"    <span class=\"nowrap\">",
"     expander/implant,",
"    </span>",
"    pedicled TRAM, and free TRAM groups were 43, 69, and 70 percent, respectively. With regard to general satisfaction, the percentages of patients who were satisfied with their procedure were 64, 79, and 78 percent, respectively.",
"   </p>",
"   <p>",
"    Even after controlling for possible confounding factors such as preoperative physical function and timing of surgery, patients with TRAM flaps (both free and pedicle) had higher levels of aesthetic satisfaction at year 2 as compared to",
"    <span class=\"nowrap\">",
"     expander/implant",
"    </span>",
"    patients (odds ratio [OR] 2.8, p&lt;.01). When controlling for the same confounding factors, the type of reconstruction",
"    <span class=\"nowrap\">",
"     (expander/implant,",
"    </span>",
"    pedicle TRAM and free TRAM) had no statistically significant effect on general satisfaction.",
"   </p>",
"   <p>",
"    There were no significant differences in aesthetic satisfaction between women with free and pedicle TRAM flaps, a finding which has been noted by other investigators [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/29/39386/abstract/105,141\">",
"     105,141",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H45\">",
"    <span class=\"h2\">",
"     Physical functioning",
"    </span>",
"    &nbsp;&mdash;&nbsp;The variability in the degree of muscle that is sacrificed, denervated, or injured in creating abdominal wall flaps for breast reconstruction makes the comparison of abdominal wall function after abdominal flaps challenging. Several studies have evaluated abdominal function using basic physical functioning tests such as getting out of bed and the ability to perform sit-ups, although more sensitive testing of muscle function, such as isokinetic dynamometry, which measure the maximum strength a muscle can reach, may be necessary for accurate comparison [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/29/39386/abstract/98,142,143\">",
"     98,142,143",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Physical functioning following free pedicled flap reconstructive surgery depends on whether the reconstruction was unilateral or bilateral, whether the motor innervation to the rectus abdominis muscles was sacrificed or preserved, and the degree of postoperative fibrosis occurring within the remaining muscle. In general, for most women who require unilateral reconstruction, breast reconstruction with a perforator pedicle TRAM flap will not make a significant impact on the activities of daily living. However, for women who need bilateral reconstruction, perforator or muscle sparing flaps may confer an advantage in physical function.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H46\">",
"    <span class=\"h3\">",
"     TRAM procedures",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many patients and surgeons are concerned about potential abdominal wall morbidity with TRAM procedures. Functional outcomes studies have shown mixed results, with between 6 to 23 percent of patients demonstrating deficits in trunk function following TRAM reconstruction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/29/39386/abstract/144,145\">",
"     144,145",
"    </a>",
"    ]. However, these are largely single center studies without long-term follow-up. Physical function outcomes data are especially important as more technically complex procedures, such as perforator flaps, are being increasingly performed to limit the surgical \"insult\" to the abdominal wall.",
"   </p>",
"   <p>",
"    In the Michigan Breast Reconstruction Outcomes Study (MBROS), data on trunk peak torque and range of motion were collected preoperatively and at postoperative years 1 and 2 in the",
"    <span class=\"nowrap\">",
"     expander/implant,",
"    </span>",
"    free TRAM, and pedicled TRAM groups [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/29/39386/abstract/146\">",
"     146",
"    </a>",
"    ]. At two years postoperatively, procedure type, timing and laterality (unilateral versus bilateral) did not significantly affect the range of motion for trunk flexion or extension. Peak torque for trunk flexion at year 2 was significantly lower (by 11 to 18 percent) in patients with TRAM flaps compared to those undergoing",
"    <span class=\"nowrap\">",
"     expander/implant",
"    </span>",
"    reconstructions. However, no significant difference in flexion peak torque was found between patients who had free and pedicle TRAM reconstructions.",
"   </p>",
"   <p>",
"    These data are consistent with other contemporary breast reconstruction functional outcomes studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/29/39386/abstract/147-149\">",
"     147-149",
"    </a>",
"    ]. In a review of 20 studies of abdominal wall function following breast reconstruction, bilateral reconstruction was associated with the greatest difficulty in performing some daily activities [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/29/39386/abstract/150\">",
"     150",
"    </a>",
"    ]. However, unilateral reconstruction did not affect the performance of activities of daily living.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H47\">",
"    <span class=\"h3\">",
"     Perforator flaps",
"    </span>",
"    &nbsp;&mdash;&nbsp;The available outcomes data on perforator flaps are limited to retrospective reviews. One study evaluated sit-up ability three and six months following perforator flap reconstruction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/29/39386/abstract/151\">",
"     151",
"    </a>",
"    ]. At three months, 95 percent of women were able to return to their preoperative sit-up activity; this was 100 percent by six months postoperatively. Another retrospective series of 18 patients evaluated abdominal wall function in patients with DIEP flaps compared to free TRAM reconstructions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/29/39386/abstract/152\">",
"     152",
"    </a>",
"    ]. The TRAM group appeared to have significantly lower trunk flexion torque compared to the DIEP group.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H48\">",
"    <span class=\"h1\">",
"     POSTTREATMENT SURVEILLANCE OF THE RECONSTRUCTED BREAST",
"    </span>",
"    &nbsp;&mdash;&nbsp;Following mastectomy, the reconstructed breast is at risk for a chest wall recurrence and less often, a second primary breast cancer. Even after the most aggressive mastectomies, some small amount of normal residual breast tissue remains and presents a risk for a subsequent new primary breast cancer. Thus, several authors have suggested that screening might be of value [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/29/39386/abstract/153\">",
"     153",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Guidelines from expert groups for the follow-up of breast cancer patients recommend annual mammography, but these recommendations do not apply to women who have undergone breast reconstruction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/29/39386/abstract/129\">",
"     129",
"    </a>",
"    ]. Postmastectomy surveillance for reconstructed breasts has usually been performed by physical examination. Routine mammographic imaging is technically limited in patients who have prosthetic implants and has generally not been advocated. However, mammography is technically feasible following autogenous myocutaneous flap reconstruction, particularly following TRAM or perforator flap reconstruction, because abdominal adipose tissue forms the bulk of the reconstructed breast. (See",
"    <a class=\"local\" href=\"#H20\">",
"     'Autogenous tissue reconstruction'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Although the data are sparse and there is no consensus on this issue, some institutions image TRAM-reconstructed breasts mammographically (sometimes referred to as a \"TRAMogram\"). While \"TRAMograms\" are possible, they are generally not recommended as recurrent breast cancer cannot occur in TRAM tissue. In addition, fat necrosis can appear radiographically as calcifications in reconstructed breast tissue, leading to unnecessary biopsy procedures. Because of the low detection rate for nonpalpable recurrent breast cancer, mammography on reconstructed breasts is not routinely recommended [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/29/39386/abstract/154\">",
"     154",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The only place where cancer can occur is either right below the skin in the subcutaneous tissue or just over the pectoralis muscle. Given that most surgeons remove the pectoralis fascia with the mastectomy specimen, recurrence on the chest wall is less common than subcutaneous tissue recurrence [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/29/39386/abstract/155\">",
"     155",
"    </a>",
"    ]. Physical examination remains the cornerstone of detection of recurrent breast cancer after reconstruction and other modalities such as mammogram, ultrasound, or MRI are used as adjuncts to clarify any physical findings [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/29/39386/abstract/156\">",
"     156",
"    </a>",
"    ]. Detection rates of chest wall recurrence and outcomes are not significantly affected by reconstruction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/29/39386/abstract/156\">",
"     156",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/45/30426?source=see_link&amp;anchor=H8#H8\">",
"     \"Management of locoregional recurrence of breast cancer after mastectomy\", section on 'Findings on imaging'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/12/5322?source=see_link\">",
"     \"Approach to the long-term survivor of breast cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H49\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      All women undergoing mastectomy for breast cancer should be counseled regarding their reconstructive options before surgery. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There are two general types of reconstructive procedures: prosthetic devices (eg, tissue expanders, saline implants, silicone implants) and autogenous tissue reconstruction, which involves the transfer of a flap of tissue from a donor site to the anterior chest wall. The choice of the reconstructive option is dependent on a variety of factors including body habitus, associated comorbidity (eg, obesity, history of diabetes, smoking), the size and configuration of the contralateral breast, prior surgical procedures, the quality of the chest wall skin, and patient choice. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Prosthetic devices'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H20\">",
"       'Autogenous tissue reconstruction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Breast reconstruction is often performed immediately after mastectomy. The advantages of immediate reconstruction include streamlined care, reduced cost, superior cosmetic results, and psychosocial benefits. Immediate reconstruction may be considered in patients who are undergoing mastectomy for prophylaxis, ductal carcinoma in situ, or for invasive breast cancers less than 5 cm in size that are clinically axillary node-negative, with a negative premastectomy sentinel node biopsy. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Immediate versus delayed reconstruction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For women who are likely to need postmastectomy RT (breast tumor size &ge;5 cm, positive lymph nodes), delayed reconstruction may be considered. Autologous tissue is typically preferred rather than an implant following radiation treatments since this approach provides an acceptable outcome with fewer post-radiation complications. (See",
"      <a class=\"local\" href=\"#H2464271\">",
"       'Selecting patients likely to need postmastectomy RT'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/29/39386/abstract/1\">",
"      Harcourt DM, Rumsey NJ, Ambler NR, et al. The psychological effect of mastectomy with or without breast reconstruction: a prospective, multicenter study. Plast Reconstr Surg 2003; 111:1060.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/29/39386/abstract/2\">",
"      Magistrato R, Di Paola M, Ruffolo F, et al. [Psychological effects of breast reconstruction after radical mastectomy]. Minerva Med 1982; 73:1711.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/29/39386/abstract/3\">",
"      Hopwood P, Maguire GP. Body image problems in cancer patients. Br J Psychiatry Suppl 1988; :47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/29/39386/abstract/4\">",
"      Bransfield DD. Breast cancer and sexual functioning: a review of the literature and implications for future research. Int J Psychiatry Med 1982; 12:197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/29/39386/abstract/5\">",
"      Teimourian B, Adham MN. Survey of patients' responses to breast reconstruction. Ann Plast Surg 1982; 9:321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/29/39386/abstract/6\">",
"      Anderson SG, Rodin J, Ariyan S. Treatment considerations in postmastectomy reconstruction: their relative importance and relationship to patient satisfaction. Ann Plast Surg 1994; 33:263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/29/39386/abstract/7\">",
"      Rowland JH, Desmond KA, Meyerowitz BE, et al. Role of breast reconstructive surgery in physical and emotional outcomes among breast cancer survivors. J Natl Cancer Inst 2000; 92:1422.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/29/39386/abstract/8\">",
"      Dean C, Chetty U, Forrest AP. Effects of immediate breast reconstruction on psychosocial morbidity after mastectomy. Lancet 1983; 1:459.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/29/39386/abstract/9\">",
"      Slavin SA, Love SM, Goldwyn RM. Recurrent breast cancer following immediate reconstruction with myocutaneous flaps. Plast Reconstr Surg 1994; 93:1191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/29/39386/abstract/10\">",
"      Cederna PS, Yates WR, Chang P, et al. Postmastectomy reconstruction: comparative analysis of the psychosocial, functional, and cosmetic effects of transverse rectus abdominis musculocutaneous flap versus breast implant reconstruction. Ann Plast Surg 1995; 35:458.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/29/39386/abstract/11\">",
"      Stevens LA, McGrath MH, Druss RG, et al. The psychological impact of immediate breast reconstruction for women with early breast cancer. Plast Reconstr Surg 1984; 73:619.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/29/39386/abstract/12\">",
"      Schain WS. Breast reconstruction. Update of psychosocial and pragmatic concerns. Cancer 1991; 68:1170.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/29/39386/abstract/13\">",
"      Medina-Franco H, Vasconez LO, Fix RJ, et al. Factors associated with local recurrence after skin-sparing mastectomy and immediate breast reconstruction for invasive breast cancer. Ann Surg 2002; 235:814.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/29/39386/abstract/14\">",
"      Greenberg PA, Hortobagyi GN, Smith TL, et al. Long-term follow-up of patients with complete remission following combination chemotherapy for metastatic breast cancer. J Clin Oncol 1996; 14:2197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/29/39386/abstract/15\">",
"      Kroll SS, Khoo A, Singletary SE, et al. Local recurrence risk after skin-sparing and conventional mastectomy: a 6-year follow-up. Plast Reconstr Surg 1999; 104:421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/29/39386/abstract/16\">",
"      Brandberg Y, Malm M, Blomqvist L. A prospective and randomized study, \"SVEA,\" comparing effects of three methods for delayed breast reconstruction on quality of life, patient-defined problem areas of life, and cosmetic result. Plast Reconstr Surg 2000; 105:66.",
"     </a>",
"    </li>",
"    <li>",
"     Data from the American Society of Plastic Surgeons (ASPS) National Plastic Surgery Statistics Clearinghouse www.plasticsurgery.org/media/statistics/index.cfm (Accessed on September 10, 2007).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/29/39386/abstract/18\">",
"      Alderman AK, Wei Y, Birkmeyer JD. Use of breast reconstruction after mastectomy following the Women's Health and Cancer Rights Act. JAMA 2006; 295:387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/29/39386/abstract/19\">",
"      Christian CK, Niland J, Edge SB, et al. A multi-institutional analysis of the socioeconomic determinants of breast reconstruction: a study of the National Comprehensive Cancer Network. Ann Surg 2006; 243:241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/29/39386/abstract/20\">",
"      Tseng JF, Kronowitz SJ, Sun CC, et al. The effect of ethnicity on immediate reconstruction rates after mastectomy for breast cancer. Cancer 2004; 101:1514.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/29/39386/abstract/21\">",
"      Alderman AK, Hawley ST, Waljee J, et al. Correlates of referral practices of general surgeons to plastic surgeons for mastectomy reconstruction. Cancer 2007; 109:1715.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/29/39386/abstract/22\">",
"      Morrow M, Mujahid M, Lantz PM, et al. Correlates of breast reconstruction: results from a population-based study. Cancer 2005; 104:2340.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/29/39386/abstract/23\">",
"      Lee CN, Belkora J, Chang Y, et al. Are patients making high-quality decisions about breast reconstruction after mastectomy? [outcomes article]. Plast Reconstr Surg 2011; 127:18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/29/39386/abstract/24\">",
"      Meretoja T, Suominen E. Demand for plastic surgical operations after primary breast cancer surgery. Scand J Surg 2005; 94:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/29/39386/abstract/25\">",
"      Joslyn SA. Patterns of care for immediate and early delayed breast reconstruction following mastectomy. Plast Reconstr Surg 2005; 115:1289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/29/39386/abstract/26\">",
"      Alderman AK, McMahon L Jr, Wilkins EG. The national utilization of immediate and early delayed breast reconstruction and the effect of sociodemographic factors. Plast Reconstr Surg 2003; 111:695.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/29/39386/abstract/27\">",
"      Chung KC, Hamill JB, Kim HM, et al. Predictors of patient satisfaction in an outpatient plastic surgery clinic. Ann Plast Surg 1999; 42:56.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/29/39386/abstract/28\">",
"      Lin KY, Johns FR, Gibson J, et al. An outcome study of breast reconstruction: presurgical identification of risk factors for complications. Ann Surg Oncol 2001; 8:586.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/29/39386/abstract/29\">",
"      Chang DW, Reece GP, Wang B, et al. Effect of smoking on complications in patients undergoing free TRAM flap breast reconstruction. Plast Reconstr Surg 2000; 105:2374.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/29/39386/abstract/30\">",
"      Spear SL, Ducic I, Cuoco F, Hannan C. The effect of smoking on flap and donor-site complications in pedicled TRAM breast reconstruction. Plast Reconstr Surg 2005; 116:1873.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/29/39386/abstract/31\">",
"      Goodwin SJ, McCarthy CM, Pusic AL, et al. Complications in smokers after postmastectomy tissue expander/implant breast reconstruction. Ann Plast Surg 2005; 55:16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/29/39386/abstract/32\">",
"      Kroll SS, Netscher DT. Complications of TRAM flap breast reconstruction in obese patients. Plast Reconstr Surg 1989; 84:886.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/29/39386/abstract/33\">",
"      Spear SL, Ducic I, Cuoco F, Taylor N. Effect of obesity on flap and donor-site complications in pedicled TRAM flap breast reconstruction. Plast Reconstr Surg 2007; 119:788.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/29/39386/abstract/34\">",
"      Paige KT, Bostwick J 3rd, Bried JT, Jones G. A comparison of morbidity from bilateral, unipedicled and unilateral, unipedicled TRAM flap breast reconstructions. Plast Reconstr Surg 1998; 101:1819.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/29/39386/abstract/35\">",
"      Beahm EK, Walton RL, Chang DW. Breast reconstruction in the obese patient. Plast Reconstr Surg 2006; 118:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/29/39386/abstract/36\">",
"      Alderman AK, Wilkins EG, Kim HM, Lowery JC. Complications in postmastectomy breast reconstruction: two-year results of the Michigan Breast Reconstruction Outcome Study. Plast Reconstr Surg 2002; 109:2265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/29/39386/abstract/37\">",
"      Atisha DM, Alderman AK, Kuhn LE, Wilkins EG. The impact of obesity on patient satisfaction with breast reconstruction. Plast Reconstr Surg 2008; 121:1893.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/29/39386/abstract/38\">",
"      Greco JA 3rd, Castaldo ET, Nanney LB, et al. Autologous breast reconstruction: the Vanderbilt experience (1998 to 2005) of independent predictors of displeasing outcomes. J Am Coll Surg 2008; 207:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/29/39386/abstract/39\">",
"      Khoo A, Kroll SS, Reece GP, et al. A comparison of resource costs of immediate and delayed breast reconstruction. Plast Reconstr Surg 1998; 101:964.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/29/39386/abstract/40\">",
"      Al-Ghazal SK, Sully L, Fallowfield L, Blamey RW. The psychological impact of immediate rather than delayed breast reconstruction. Eur J Surg Oncol 2000; 26:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/29/39386/abstract/41\">",
"      Wilkins EG, Cederna PS, Lowery JC, et al. Prospective analysis of psychosocial outcomes in breast reconstruction: one-year postoperative results from the Michigan Breast Reconstruction Outcome Study. Plast Reconstr Surg 2000; 106:1014.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/29/39386/abstract/42\">",
"      Al-Ghazal SK, Fallowfield L, Blamey RW. Comparison of psychological aspects and patient satisfaction following breast conserving surgery, simple mastectomy and breast reconstruction. Eur J Cancer 2000; 36:1938.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/29/39386/abstract/43\">",
"      Fung KW, Lau Y, Fielding R, et al. The impact of mastectomy, breast-conserving treatment and immediate breast reconstruction on the quality of life of Chinese women. ANZ J Surg 2001; 71:202.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/29/39386/abstract/44\">",
"      Mock V. Body image in women treated for breast cancer. Nurs Res 1993; 42:153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/29/39386/abstract/45\">",
"      Pusic A, Thompson TA, Kerrigan CL, et al. Surgical options for the early-stage breast cancer: factors associated with patient choice and postoperative quality of life. Plast Reconstr Surg 1999; 104:1325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/29/39386/abstract/46\">",
"      Nano MT, Gill PG, Kollias J, et al. Psychological impact and cosmetic outcome of surgical breast cancer strategies. ANZ J Surg 2005; 75:940.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/29/39386/abstract/47\">",
"      Chawla AK, Kachnic LA, Taghian AG, et al. Radiotherapy and breast reconstruction: complications and cosmesis with TRAM versus tissue expander/implant. Int J Radiat Oncol Biol Phys 2002; 54:520.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/29/39386/abstract/48\">",
"      Slavin SA, Schnitt SJ, Duda RB, et al. Skin-sparing mastectomy and immediate reconstruction: oncologic risks and aesthetic results in patients with early-stage breast cancer. Plast Reconstr Surg 1998; 102:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/29/39386/abstract/49\">",
"      Ramon Y, Ullmann Y, Moscona R, et al. Aesthetic results and patient satisfaction with immediate breast reconstruction using tissue expansion: a follow-up study. Plast Reconstr Surg 1997; 99:686.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/29/39386/abstract/50\">",
"      Sullivan SR, Fletcher DR, Isom CD, Isik FF. True incidence of all complications following immediate and delayed breast reconstruction. Plast Reconstr Surg 2008; 122:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/29/39386/abstract/51\">",
"      Kronowitz SJ, Kuerer HM. Advances and surgical decision-making for breast reconstruction. Cancer 2006; 107:893.",
"     </a>",
"    </li>",
"    <li>",
"     Spear SL, Boehmler J. Immediate two-stage breast reconstruction utilizing a tissue expander and implant. In: Surgery of the Breast: Principles and Art, Spear SL (Ed), Lippincott, Williams and Wilkins, Philadelphia 2006. p.463.",
"    </li>",
"    <li>",
"     Beasley ME. Delayed two-stage expander/implant reconstruction. In: Surgery of the Breast: Principles and Art, Spear SL (Ed), Lippincott, Williams and Wilkins, 489 2006. p.489.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/29/39386/abstract/54\">",
"      Kroll SS, Baldwin B. A comparison of outcomes using three different methods of breast reconstruction. Plast Reconstr Surg 1992; 90:455.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/29/39386/abstract/55\">",
"      Eberlein TJ, Crespo LD, Smith BL, et al. Prospective evaluation of immediate reconstruction after mastectomy. Ann Surg 1993; 218:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/29/39386/abstract/56\">",
"      Kroll SS, Coffey JA Jr, Winn RJ, Schusterman MA. A comparison of factors affecting aesthetic outcomes of TRAM flap breast reconstructions. Plast Reconstr Surg 1995; 96:860.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/29/39386/abstract/57\">",
"      Hidalgo DA. Aesthetic refinement in breast reconstruction: complete skin-sparing mastectomy with autogenous tissue transfer. Plast Reconstr Surg 1998; 102:63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/29/39386/abstract/58\">",
"      Alderman AK, Wilkins EG, Lowery JC, et al. Determinants of patient satisfaction in postmastectomy breast reconstruction. Plast Reconstr Surg 2000; 106:769.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/29/39386/abstract/59\">",
"      Alderman AK, Kuhn LE, Lowery JC, Wilkins EG. Does patient satisfaction with breast reconstruction change over time? Two-year results of the Michigan Breast Reconstruction Outcomes Study. J Am Coll Surg 2007; 204:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/29/39386/abstract/60\">",
"      Spear SL, Parikh PM, Reisin E, Menon NG. Acellular dermis-assisted breast reconstruction. Aesthetic Plast Surg 2008; 32:418.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/29/39386/abstract/61\">",
"      Salzberg CA. Nonexpansive immediate breast reconstruction using human acellular tissue matrix graft (AlloDerm). Ann Plast Surg 2006; 57:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/29/39386/abstract/62\">",
"      Nahabedian MY. AlloDerm performance in the setting of prosthetic breast surgery, infection, and irradiation. Plast Reconstr Surg 2009; 124:1743.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/29/39386/abstract/63\">",
"      Nahabedian MY, Tsangaris T, Momen B, Manson PN. Infectious complications following breast reconstruction with expanders and implants. Plast Reconstr Surg 2003; 112:467.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/29/39386/abstract/64\">",
"      Spear SL, Onyewu C. Staged breast reconstruction with saline-filled implants in the irradiated breast: recent trends and therapeutic implications. Plast Reconstr Surg 2000; 105:930.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/29/39386/abstract/65\">",
"      Krueger EA, Wilkins EG, Strawderman M, et al. Complications and patient satisfaction following expander/implant breast reconstruction with and without radiotherapy. Int J Radiat Oncol Biol Phys 2001; 49:713.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/29/39386/abstract/66\">",
"      Spear SL, Majidian A. Immediate breast reconstruction in two stages using textured, integrated-valve tissue expanders and breast implants: a retrospective review of 171 consecutive breast reconstructions from 1989 to 1996. Plast Reconstr Surg 1998; 101:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/29/39386/abstract/67\">",
"      Clough KB, O'Donoghue JM, Fitoussi AD, et al. Prospective evaluation of late cosmetic results following breast reconstruction: I. Implant reconstruction. Plast Reconstr Surg 2001; 107:1702.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/29/39386/abstract/68\">",
"      Burns CJ, Laing TJ, Gillespie BW, et al. The epidemiology of scleroderma among women: assessment of risk from exposure to silicone and silica. J Rheumatol 1996; 23:1904.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/29/39386/abstract/69\">",
"      Edworthy SM, Martin L, Barr SG, et al. A clinical study of the relationship between silicone breast implants and connective tissue disease. J Rheumatol 1998; 25:254.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/29/39386/abstract/70\">",
"      Gabriel SE, Woods JE, O'Fallon WM, et al. Complications leading to surgery after breast implantation. N Engl J Med 1997; 336:677.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/29/39386/abstract/71\">",
"      Hochberg MC, Perlmutter DL, Medsger TA Jr, et al. Lack of association between augmentation mammoplasty and systemic sclerosis (scleroderma). Arthritis Rheum 1996; 39:1125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/29/39386/abstract/72\">",
"      Hennekens CH, Lee IM, Cook NR, et al. Self-reported breast implants and connective-tissue diseases in female health professionals. A retrospective cohort study. JAMA 1996; 275:616.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/29/39386/abstract/73\">",
"      Janowsky EC, Kupper LL, Hulka BS. Meta-analyses of the relation between silicone breast implants and the risk of connective-tissue diseases. N Engl J Med 2000; 342:781.",
"     </a>",
"    </li>",
"    <li>",
"     Information on silicone gel breast implants www.fda.gov/cdrh/breastimplants/ (Accessed on January 17, 2008).",
"    </li>",
"    <li>",
"     www.fda.gov/cdrh/pdf2/P020056d.pdf (Accessed on February 13, 2009).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/29/39386/abstract/76\">",
"      McCarthy CM, Pusic AL, Kerrigan CL. Silicone breast implants and magnetic resonance imaging screening for rupture: do U.S. Food and Drug Administration recommendations reflect an evidence-based practice approach to patient care? Plast Reconstr Surg 2008; 121:1127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/29/39386/abstract/77\">",
"      Cher DJ, Conwell JA, Mandel JS. MRI for detecting silicone breast implant rupture: meta-analysis and implications. Ann Plast Surg 2001; 47:367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/29/39386/abstract/78\">",
"      de Jong D, Vasmel WL, de Boer JP, et al. Anaplastic large-cell lymphoma in women with breast implants. JAMA 2008; 300:2030.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm241101.htm.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/29/39386/abstract/80\">",
"      Lin SJ, Nguyen MD, Chen C, et al. Tissue oximetry monitoring in microsurgical breast reconstruction decreases flap loss and improves rate of flap salvage. Plast Reconstr Surg 2011; 127:1080.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/29/39386/abstract/81\">",
"      Hartrampf CR Jr, Bennett GK. Autogenous tissue reconstruction in the mastectomy patient. A critical review of 300 patients. Ann Surg 1987; 205:508.",
"     </a>",
"    </li>",
"    <li>",
"     Shestak KC. Bipedicle TRAM flap reconstruction. In: Surgery of the Breast: Principles and Art, Spear SL (Ed), Lippincott, Williams and Wilkins, Philadelphia 2006. p.719.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/29/39386/abstract/83\">",
"      Codner MA, Bostwick J 3rd. The delayed TRAM flap. Clin Plast Surg 1998; 25:183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/29/39386/abstract/84\">",
"      Ascherman JA, Seruya M, Bartsich SA. Abdominal wall morbidity following unilateral and bilateral breast reconstruction with pedicled TRAM flaps: an outcomes analysis of 117 consecutive patients. Plast Reconstr Surg 2008; 121:1.",
"     </a>",
"    </li>",
"    <li>",
"     Grotting JC, Anderson ED. Free TRAM flap breast reconstruction. In: Surgery of the Breast: Principles and Art, Spear SL (Ed), Lippincott, Williams and Wilkins, Philadelphia 2006. p.757.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/29/39386/abstract/86\">",
"      Spear SL, Boehmler JH, Taylor NS, Prada C. The role of the latissimus dorsi flap in reconstruction of the irradiated breast. Plast Reconstr Surg 2007; 119:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/29/39386/abstract/87\">",
"      Menke H, Erkens M, Olbrisch RR. Evolving concepts in breast reconstruction with latissimus dorsi flaps: results and follow-up of 121 consecutive patients. Ann Plast Surg 2001; 47:107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/29/39386/abstract/88\">",
"      Tarantino I, Banic A, Fischer T. Evaluation of late results in breast reconstruction by latissimus dorsi flap and prosthesis implantation. Plast Reconstr Surg 2006; 117:1387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/29/39386/abstract/89\">",
"      Tomita K, Yano K, Masuoka T, et al. Postoperative seroma formation in breast reconstruction with latissimus dorsi flaps: a retrospective study of 174 consecutive cases. Ann Plast Surg 2007; 59:149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/29/39386/abstract/90\">",
"      Munhoz AM, Aldrighi C, Montag E, et al. Periareolar skin-sparing mastectomy and latissimus dorsi flap with biodimensional expander implant reconstruction: surgical planning, outcome, and complications. Plast Reconstr Surg 2007; 119:1637.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/29/39386/abstract/91\">",
"      Fraulin FO, Louie G, Zorrilla L, Tilley W. Functional evaluation of the shoulder following latissimus dorsi muscle transfer. Ann Plast Surg 1995; 35:349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/29/39386/abstract/92\">",
"      Granzow JW, Levine JL, Chiu ES, Allen RJ. Breast reconstruction using perforator flaps. J Surg Oncol 2006; 94:441.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/29/39386/abstract/93\">",
"      Dayhim F, Wilkins EG. The impact of Pfannenstiel scars on TRAM flap complications. Ann Plast Surg 2004; 53:432.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/29/39386/abstract/94\">",
"      Ghattaura A, Henton J, Jallali N, et al. One hundred cases of abdominal-based free flaps in breast reconstruction. The impact of preoperative computed tomographic angiography. J Plast Reconstr Aesthet Surg 2010; 63:1597.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/29/39386/abstract/95\">",
"      Pacifico MD, See MS, Cavale N, et al. Preoperative planning for DIEP breast reconstruction: early experience of the use of computerised tomography angiography with VoNavix 3D software for perforator navigation. J Plast Reconstr Aesthet Surg 2009; 62:1464.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/29/39386/abstract/96\">",
"      Smit JM, Klein S, Werker PM. An overview of methods for vascular mapping in the planning of free flaps. J Plast Reconstr Aesthet Surg 2010; 63:e674.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/29/39386/abstract/97\">",
"      Gill PS, Hunt JP, Guerra AB, et al. A 10-year retrospective review of 758 DIEP flaps for breast reconstruction. Plast Reconstr Surg 2004; 113:1153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/29/39386/abstract/98\">",
"      Bajaj AK, Chevray PM, Chang DW. Comparison of donor-site complications and functional outcomes in free muscle-sparing TRAM flap and free DIEP flap breast reconstruction. Plast Reconstr Surg 2006; 117:737.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/29/39386/abstract/99\">",
"      Futter CM, Webster MH, Hagen S, Mitchell SL. A retrospective comparison of abdominal muscle strength following breast reconstruction with a free TRAM or DIEP flap. Br J Plast Surg 2000; 53:578.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/29/39386/abstract/100\">",
"      Kroll SS, Sharma S, Koutz C, et al. Postoperative morphine requirements of free TRAM and DIEP flaps. Plast Reconstr Surg 2001; 107:338.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/29/39386/abstract/101\">",
"      Nahabedian MY, Momen B, Galdino G, Manson PN. Breast Reconstruction with the free TRAM or DIEP flap: patient selection, choice of flap, and outcome. Plast Reconstr Surg 2002; 110:466.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/29/39386/abstract/102\">",
"      Futter CM, Weiler-Mithoff E, Hagen S, et al. Do pre-operative abdominal exercises prevent post-operative donor site complications for women undergoing DIEP flap breast reconstruction? A two-centre, prospective randomised controlled trial. Br J Plast Surg 2003; 56:674.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/29/39386/abstract/103\">",
"      Vyas RM, Dickinson BP, Fastekjian JH, et al. Risk factors for abdominal donor-site morbidity in free flap breast reconstruction. Plast Reconstr Surg 2008; 121:1519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/29/39386/abstract/104\">",
"      Kroll SS. Fat necrosis in free transverse rectus abdominis myocutaneous and deep inferior epigastric perforator flaps. Plast Reconstr Surg 2000; 106:576.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/29/39386/abstract/105\">",
"      Chun YS, Sinha I, Turko A, et al. Comparison of morbidity, functional outcome, and satisfaction following bilateral TRAM versus bilateral DIEP flap breast reconstruction. Plast Reconstr Surg 2010; 126:1133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/29/39386/abstract/106\">",
"      Garvey PB, Buchel EW, Pockaj BA, et al. DIEP and pedicled TRAM flaps: a comparison of outcomes. Plast Reconstr Surg 2006; 117:1711.",
"     </a>",
"    </li>",
"    <li>",
"     Hamdi M, Blondeel PN. The superficial inferior epigastic artery flap in breast reconstruction. In: Surgery of the Breast: Principles and Art, Spear SL (Ed), Lippincott, Williams and Wilkins, Philadelphia 2006. p.873.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/29/39386/abstract/108\">",
"      Guerra AB, Metzinger SE, Bidros RS, et al. Breast reconstruction with gluteal artery perforator (GAP) flaps: a critical analysis of 142 cases. Ann Plast Surg 2004; 52:118.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/29/39386/abstract/109\">",
"      Granzow JW, Levine JL, Chiu ES, Allen RJ. Breast reconstruction with gluteal artery perforator flaps. J Plast Reconstr Aesthet Surg 2006; 59:614.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/29/39386/abstract/110\">",
"      Fansa H, Schirmer S, Warnecke IC, et al. The transverse myocutaneous gracilis muscle flap: a fast and reliable method for breast reconstruction. Plast Reconstr Surg 2008; 122:1326.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/29/39386/abstract/111\">",
"      Arnez ZM, Pogorelec D, Planinsek F, Ahcan U. Breast reconstruction by the free transverse gracilis (TUG) flap. Br J Plast Surg 2004; 57:20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/29/39386/abstract/112\">",
"      Gart MS, Smetona JT, Hanwright PJ, et al. Autologous options for postmastectomy breast reconstruction: a comparison of outcomes based on the American College of Surgeons National Surgical Quality Improvement Program. J Am Coll Surg 2013; 216:229.",
"     </a>",
"    </li>",
"    <li>",
"     Namnoun JD. Options for the contralateral breast in breast reconstruction. In: Surgery of the Breast: Principles and Art, Spear SL (Ed), Lippincott, Williams and Wilkins, Philadelphia 2006. p.888.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/29/39386/abstract/114\">",
"      Pomahac B, Recht A, May JW, et al. New trends in breast cancer management: is the era of immediate breast reconstruction changing? Ann Surg 2006; 244:282.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/29/39386/abstract/115\">",
"      Motwani SB, Strom EA, Schechter NR, et al. The impact of immediate breast reconstruction on the technical delivery of postmastectomy radiotherapy. Int J Radiat Oncol Biol Phys 2006; 66:76.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/29/39386/abstract/116\">",
"      Schechter NR, Strom EA, Perkins GH, et al. Immediate breast reconstruction can impact postmastectomy irradiation. Am J Clin Oncol 2005; 28:485.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/29/39386/abstract/117\">",
"      Buchholz TA, Kronowitz SJ, Kuerer HM. Immediate breast reconstruction after skin-sparing mastectomy for the treatment of advanced breast cancer: radiation oncology considerations. Ann Surg Oncol 2002; 9:820.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/29/39386/abstract/118\">",
"      Nahabedian MY, Momen B. The impact of breast reconstruction on the oncologic efficacy of radiation therapy: a retrospective analysis. Ann Plast Surg 2008; 60:244.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/29/39386/abstract/119\">",
"      Wright JL, Cordeiro PG, Ben-Porat L, et al. Mastectomy with immediate expander-implant reconstruction, adjuvant chemotherapy, and radiation for stage II-III breast cancer: treatment intervals and clinical outcomes. Int J Radiat Oncol Biol Phys 2008; 70:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/29/39386/abstract/120\">",
"      Classen J, Nitzsche S, Wallwiener D, et al. Fibrotic changes after postmastectomy radiotherapy and reconstructive surgery in breast cancer. A retrospective analysis in 109 patients. Strahlenther Onkol 2010; 186:630.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/29/39386/abstract/121\">",
"      Adesiyun TA, Lee BT, Yueh JH, et al. Impact of sequencing of postmastectomy radiotherapy and breast reconstruction on timing and rate of complications and patient satisfaction. Int J Radiat Oncol Biol Phys 2011; 80:392.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/29/39386/abstract/122\">",
"      Contant CM, van Geel AN, van der Holt B, et al. Morbidity of immediate breast reconstruction (IBR) after mastectomy by a subpectorally placed silicone prosthesis: the adverse effect of radiotherapy. Eur J Surg Oncol 2000; 26:344.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/29/39386/abstract/123\">",
"      Tallet AV, Salem N, Moutardier V, et al. Radiotherapy and immediate two-stage breast reconstruction with a tissue expander and implant: complications and esthetic results. Int J Radiat Oncol Biol Phys 2003; 57:136.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/29/39386/abstract/124\">",
"      Ascherman JA, Hanasono MM, Newman MI, Hughes DB. Implant reconstruction in breast cancer patients treated with radiation therapy. Plast Reconstr Surg 2006; 117:359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/29/39386/abstract/125\">",
"      Vandeweyer E, Deraemaecker R. Radiation therapy after immediate breast reconstruction with implants. Plast Reconstr Surg 2000; 106:56.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/29/39386/abstract/126\">",
"      Anderson PR, Hanlon AL, Fowble BL, et al. Low complication rates are achievable after postmastectomy breast reconstruction and radiation therapy. Int J Radiat Oncol Biol Phys 2004; 59:1080.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/29/39386/abstract/127\">",
"      Cordeiro PG, Pusic AL, Disa JJ, et al. Irradiation after immediate tissue expander/implant breast reconstruction: outcomes, complications, aesthetic results, and satisfaction among 156 patients. Plast Reconstr Surg 2004; 113:877.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/29/39386/abstract/128\">",
"      McCarthy CM, Pusic AL, Disa JJ, et al. Unilateral postoperative chest wall radiotherapy in bilateral tissue expander/implant reconstruction patients: a prospective outcomes analysis. Plast Reconstr Surg 2005; 116:1642.",
"     </a>",
"    </li>",
"    <li>",
"     National Comprehensive Cancer Network (NCCN) guidelines. Available at: www.nccn.org (Accessed on May 15, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/29/39386/abstract/130\">",
"      Huang CJ, Hou MF, Lin SD, et al. Comparison of local recurrence and distant metastases between breast cancer patients after postmastectomy radiotherapy with and without immediate TRAM flap reconstruction. Plast Reconstr Surg 2006; 118:1079.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/29/39386/abstract/131\">",
"      Jhaveri JD, Rush SC, Kostroff K, et al. Clinical outcomes of postmastectomy radiation therapy after immediate breast reconstruction. Int J Radiat Oncol Biol Phys 2008; 72:859.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/29/39386/abstract/132\">",
"      Williams JK, Carlson GW, Bostwick J 3rd, et al. The effects of radiation treatment after TRAM flap breast reconstruction. Plast Reconstr Surg 1997; 100:1153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/29/39386/abstract/133\">",
"      Rogers NE, Allen RJ. Radiation effects on breast reconstruction with the deep inferior epigastric perforator flap. Plast Reconstr Surg 2002; 109:1919.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/29/39386/abstract/134\">",
"      Schrenk P, Woelfl S, Bogner S, et al. The use of sentinel node biopsy in breast cancer patients undergoing skin sparing mastectomy and immediate autologous reconstruction. Plast Reconstr Surg 2005; 116:1278.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/29/39386/abstract/135\">",
"      Kronowitz SJ, Chang DW, Robb GL, et al. Implications of axillary sentinel lymph node biopsy in immediate autologous breast reconstruction. Plast Reconstr Surg 2002; 109:1888.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/29/39386/abstract/136\">",
"      Chagpar AB, Scoggins CR, Martin RC 2nd, et al. Predicting patients at low probability of requiring postmastectomy radiation therapy. Ann Surg Oncol 2007; 14:670.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/29/39386/abstract/137\">",
"      Kronowitz SJ, Hunt KK, Kuerer HM, et al. Delayed-immediate breast reconstruction. Plast Reconstr Surg 2004; 113:1617.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/29/39386/abstract/138\">",
"      Metcalfe KA, Semple J, Quan ML, et al. Changes in psychosocial functioning 1 year after mastectomy alone, delayed breast reconstruction, or immediate breast reconstruction. Ann Surg Oncol 2012; 19:233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/29/39386/abstract/139\">",
"      Elder EE, Brandberg Y, Bj&ouml;rklund T, et al. Quality of life and patient satisfaction in breast cancer patients after immediate breast reconstruction: a prospective study. Breast 2005; 14:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/29/39386/abstract/140\">",
"      Atisha D, Alderman AK, Lowery JC, et al. Prospective analysis of long-term psychosocial outcomes in breast reconstruction: two-year postoperative results from the Michigan Breast Reconstruction Outcomes Study. Ann Surg 2008; 247:1019.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/29/39386/abstract/141\">",
"      Brandberg Y, Wickman M. Quality of life, patients' satisfaction, and aesthetic outcome after pedicled or free TRAM flap breast surgery. Plast Reconstr Surg 2001; 107:1142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/29/39386/abstract/142\">",
"      Nahabedian MY, Tsangaris T, Momen B. Breast reconstruction with the DIEP flap or the muscle-sparing (MS-2) free TRAM flap: is there a difference? Plast Reconstr Surg 2005; 115:436.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/29/39386/abstract/143\">",
"      Man LX, Selber JC, Serletti JM. Abdominal wall following free TRAM or DIEP flap reconstruction: a meta-analysis and critical review. Plast Reconstr Surg 2009; 124:752.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/29/39386/abstract/144\">",
"      Suominen S, Asko-Seljavaara S, Kinnunen J, et al. Abdominal wall competence after free transverse rectus abdominis musculocutaneous flap harvest: a prospective study. Ann Plast Surg 1997; 39:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/29/39386/abstract/145\">",
"      Kind GM, Rademaker AW, Mustoe TA. Abdominal-wall recovery following TRAM flap: a functional outcome study. Plast Reconstr Surg 1997; 99:417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/29/39386/abstract/146\">",
"      Alderman AK, Kuzon WM Jr, Wilkins EG. A two-year prospective analysis of trunk function in TRAM breast reconstructions. Plast Reconstr Surg 2006; 117:2131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/29/39386/abstract/147\">",
"      Kroll SS, Marchi M. Comparison of strategies for preventing abdominal-wall weakness after TRAM flap breast reconstruction. Plast Reconstr Surg 1992; 89:1045.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/29/39386/abstract/148\">",
"      Lejour M, Dome M. Abdominal wall function after rectus abdominis transfer. Plast Reconstr Surg 1991; 87:1054.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/29/39386/abstract/149\">",
"      Dulin WA, Avila RA, Verheyden CN, Grossman L. Evaluation of abdominal wall strength after TRAM flap surgery. Plast Reconstr Surg 2004; 113:1662.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/29/39386/abstract/150\">",
"      Atisha D, Alderman AK. A systematic review of abdominal wall function following abdominal flaps for postmastectomy breast reconstruction. Ann Plast Surg 2009; 63:222.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/29/39386/abstract/151\">",
"      Hamdi M, Weiler-Mithoff EM, Webster MH. Deep inferior epigastric perforator flap in breast reconstruction: experience with the first 50 flaps. Plast Reconstr Surg 1999; 103:86.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/29/39386/abstract/152\">",
"      Blondeel N, Vanderstraeten GG, Monstrey SJ, et al. The donor site morbidity of free DIEP flaps and free TRAM flaps for breast reconstruction. Br J Plast Surg 1997; 50:322.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/29/39386/abstract/153\">",
"      Helvie MA, Bailey JE, Roubidoux MA, et al. Mammographic screening of TRAM flap breast reconstructions for detection of nonpalpable recurrent cancer. Radiology 2002; 224:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/29/39386/abstract/154\">",
"      Lee JM, Georgian-Smith D, Gazelle GS, et al. Detecting nonpalpable recurrent breast cancer: the role of routine mammographic screening of transverse rectus abdominis myocutaneous flap reconstructions. Radiology 2008; 248:398.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/29/39386/abstract/155\">",
"      Langstein HN, Cheng MH, Singletary SE, et al. Breast cancer recurrence after immediate reconstruction: patterns and significance. Plast Reconstr Surg 2003; 111:712.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/29/39386/abstract/156\">",
"      Chagpar A, Langstein HN, Kronowitz SJ, et al. Treatment and outcome of patients with chest wall recurrence after mastectomy and breast reconstruction. Am J Surg 2004; 187:164.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 801 Version 17.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-118.195.65.244-820E8C5BBF-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_29_39386=[""].join("\n");
var outline_f38_29_39386=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H49\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      UTILIZATION AND PATTERNS OF CARE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      INITIAL RECONSTRUCTIVE EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      History and physical examination",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Physical examination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Immediate versus delayed reconstruction",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H173461702\">",
"      - Immediate reconstruction",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H173461709\">",
"      - Delayed reconstruction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      RECONSTRUCTIVE OPTIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      PROSTHETIC DEVICES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5976686\">",
"      Implants",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Advantages and disadvantages",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Patient selection",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5611043\">",
"      - One stage implant reconstruction",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5611050\">",
"      - Two stage implant reconstruction",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5611057\">",
"      - Acellular dermal matrices and implant reconstruction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5611116\">",
"      Tissue expanders",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Complications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Silicone and breast reconstruction",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H46564970\">",
"      - Association of breast implants with lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      AUTOGENOUS TISSUE RECONSTRUCTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Pedicled TRAM flap",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Free TRAM flap",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Latissimus dorsi reconstruction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      Perforator flaps",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H895837\">",
"      - DIEP perforator flaps",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H37\">",
"      - SEIA perforator flaps",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H38\">",
"      - GAP perforator flaps",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4082052\">",
"      - TUG flaps",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10133119\">",
"      Postoperative morbidity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H39\">",
"      OPTIONS FOR THE CONTRALATERAL NORMAL BREAST (SYMMETRY PROCEDURES)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H40\">",
"      RECONSTRUCTION OF THE NIPPLE/AREOLAR COMPLEX",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2464163\">",
"      RADIATION THERAPY AND RECONSTRUCTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2464250\">",
"      Impact of RT on implants",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2464257\">",
"      Impact of RT on flap reconstruction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2464271\">",
"      Selecting patients likely to need postmastectomy RT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H41\">",
"      OUTCOMES ASSOCIATED WITH BREAST RECONSTRUCTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H42\">",
"      Psychosocial function and quality of life",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H44\">",
"      Patient satisfaction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H45\">",
"      Physical functioning",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H46\">",
"      - TRAM procedures",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H47\">",
"      - Perforator flaps",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H48\">",
"      POSTTREATMENT SURVEILLANCE OF THE RECONSTRUCTED BREAST",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H49\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"SURG/801\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/801|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?29/57/30608\" title=\"figure 1\">",
"      Implant breast reconstruction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?21/25/21909\" title=\"figure 2\">",
"      Pedicled TRAM flap reconstruction after mastectomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?40/44/41669\" title=\"figure 3\">",
"      Free TRAM flap reconstruction after skin sparing mastectomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?42/6/43107\" title=\"figure 4\">",
"      Latissimus flap breast reconstruction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?14/44/15045\" title=\"figure 5\">",
"      DIEP flap breast reconstruction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?5/44/5826\" title=\"figure 6\">",
"      GAP flap breast reconstruction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?0/49/788\" title=\"figure 7\">",
"      TUG flap breast reconstruction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/801|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?27/7/27763\" title=\"picture 1\">",
"      Single stage breast reconstruct",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?10/21/10580\" title=\"picture 2\">",
"      TRAM breast reconstruction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?2/5/2130\" title=\"picture 3\">",
"      Bilateral TRAM reconstruction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?8/52/9026\" title=\"picture 4\">",
"      Latissimus dorsi reconstruction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?9/58/10147\" title=\"picture 5\">",
"      Contralateral breast management",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?0/28/448\" title=\"picture 6\">",
"      Nipple areola reconstruction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?35/62/36834\" title=\"picture 7\">",
"      Delayed TRAM reconstruction",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/12/5322?source=related_link\">",
"      Approach to the long-term survivor of breast cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/42/31402?source=related_link\">",
"      Breast conserving therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/43/42678?source=related_link\">",
"      Breast implant infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/19/36150?source=related_link\">",
"      Breast lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/49/10009?source=related_link\">",
"      Clinical features, diagnosis, and staging of newly diagnosed breast cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/29/23002?source=related_link\">",
"      MRI of the breast and emerging technologies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/0/17418?source=related_link\">",
"      Management of hereditary breast and ovarian cancer syndrome and patients with BRCA mutations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/45/30426?source=related_link\">",
"      Management of locoregional recurrence of breast cancer after mastectomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/18/12586?source=related_link\">",
"      Mastectomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/22/19817?source=related_link\">",
"      Overview of anesthesia and anesthetic choices",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/3/41017?source=related_link\">",
"      Postmastectomy chest wall irradiation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/33/11799?source=related_link\">",
"      Reconstructive materials used in surgery: Classification and host response",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/47/36602?source=related_link\">",
"      Sentinel lymph node dissection for breast cancer: Indications and outcomes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/45/24278?source=related_link\">",
"      Tumor node metastasis (TNM) staging classification for breast cancer",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f38_29_39387="Dx liver disease pregnancy";
var content_f38_29_39387=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F50080&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F50080&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Evaluation of liver disease in pregnancy",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle2_left\">",
"       History and review of systems",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       History of pruritus during previous pregnancies or while using oral contraceptives, abdominal pain, nausea or vomiting, polyuria and polydipsia, drugs, travel, exposure to viral hepatitis, history of gallstones. Note trimester of pregnancy.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\">",
"       Physical examination",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Temperature, blood pressure, proteinuria, liver examination (difficult during late pregnancy)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\">",
"       Blood tests",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Complete blood count including platelets",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Routine liver function tests including prothrombin time (see table on liver function tests in normal pregnancy)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Serum creatinine, electrolytes, glucose and uric acid levels",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Serology for viral hepatitis (A, B, C) and cytomegalovirus",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Test for hepatitis E if suspected (especially in endemic countries less commonly in non-endemic countries)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Measure serum total bile acids if cholestasis is suspected and not otherwise apparent (not a routine test)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\">",
"       Urinalysis and culture",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\">",
"       Ultrasonography of the liver and bile ducts",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\">",
"       Monitor evolution of symptoms and liver function tests before and after delivery",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_29_39387=[""].join("\n");
var outline_f38_29_39387=null;
var title_f38_29_39388="Clinical features of vaginitis";
var content_f38_29_39388=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F68759&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F68759&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Clinical findings in women with vaginitis",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"5\" width=\"20%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Parameter",
"       </td>",
"       <td class=\"subtitle1\">",
"        Normal findings",
"       </td>",
"       <td class=\"subtitle1\">",
"        Vulovaginal candidiasis",
"       </td>",
"       <td class=\"subtitle1\">",
"        Bacterial vaginosis",
"       </td>",
"       <td class=\"subtitle1\">",
"        Trichomoniasis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Symptoms",
"       </td>",
"       <td>",
"        None or mild, transient",
"       </td>",
"       <td>",
"        Pruritus, soreness, dyspareunia",
"       </td>",
"       <td>",
"        Malodorous discharge, no dyspareunia",
"       </td>",
"       <td>",
"        Malodorous discharge, burning, postcoital bleeding, dyspareunia, dysuria",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Signs",
"       </td>",
"       <td>",
"        Normal vaginal discharge consists of 1 to 4 mL fluid (per 24 hours), which is white or transparent, thin or thick, and mostly odorless",
"       </td>",
"       <td>",
"        Vulvar erythema and/or edema. Discharge may be white and clumpy and may or may not adhere to vagina.",
"       </td>",
"       <td>",
"        Off-white/gray thin discharge that coats the vagina",
"       </td>",
"       <td>",
"        Thin green-yellow discharge, vulvovaginal erythema",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Vaginal pH",
"       </td>",
"       <td>",
"        4.0-4.5",
"       </td>",
"       <td>",
"        4.0-4.5",
"       </td>",
"       <td>",
"        &gt;4.5",
"       </td>",
"       <td>",
"        5.0-6.0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Amine test",
"       </td>",
"       <td>",
"        Negative",
"       </td>",
"       <td>",
"        Negative",
"       </td>",
"       <td>",
"        Positive (in 70-80 percent of patients)",
"       </td>",
"       <td>",
"        Often positive",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Saline microscopy",
"       </td>",
"       <td>",
"        PMN:EC ratio &lt;1; rods dominate; squames +++",
"       </td>",
"       <td>",
"        PMN:EC ratio &lt;1; rods dominate; squames +++; pseudohyphae (present in about 40 percent of patients); budding yeast for nonalbicans Candida",
"       </td>",
"       <td>",
"        PMN:EC &lt;1; loss of rods; increased coccobacilli; clue cells comprise at least 20 percent of epithelial cells (present in &gt;90 percent of patients)",
"       </td>",
"       <td>",
"        PMN ++++; mixed flora; motile trichomonads (present in about 60 percent of patients)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        10 percent potassium hydroxide microscopy",
"       </td>",
"       <td>",
"        Negative",
"       </td>",
"       <td>",
"        Pseudohyphae (in about 70 percent of patients)",
"       </td>",
"       <td>",
"        Negative",
"       </td>",
"       <td>",
"        Negative",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Other tests",
"       </td>",
"       <td>",
"        &ndash;",
"       </td>",
"       <td>",
"        Culture if microscopy nondiagnostic",
"       </td>",
"       <td>",
"        Culture of no value",
"       </td>",
"       <td>",
"        Culture or rapid antigen/nucleic acid amplification tests if microscopy nondiagnostic",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Differential diagnosis",
"       </td>",
"       <td>",
"        Physiologic leukorrhea",
"       </td>",
"       <td>",
"        Contact irritant or allergic vulvar dermatitis, chemical irritation, focal vulvitis (vulvodynia)",
"       </td>",
"       <td>",
"        Elevated pH in trichomoniasis, atrophic vaginitis, and desquamative inflammatory vaginitis",
"       </td>",
"       <td>",
"        Purulent vaginitis, desquamative inflammatory vaginitis, atrophic vaginitis, erosive lichen planus",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     PMN: polymorphonuclear leukocytes; EC: vaginal epithelial cells.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_29_39388=[""].join("\n");
var outline_f38_29_39388=null;
var title_f38_29_39389="Pre-transplant mortality among adults wait-listed for HT";
var content_f38_29_39389=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F83826&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=12\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F83826&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=12\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Pre-transplant mortality rates among adult patients wait-listed for a heart transplant",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\">",
"        18 to 34",
"       </td>",
"       <td class=\"subtitle1\">",
"        35 to 49",
"       </td>",
"       <td class=\"subtitle1\">",
"        50 to 64",
"       </td>",
"       <td class=\"subtitle1\">",
"        65+",
"       </td>",
"       <td class=\"subtitle1\">",
"        Male",
"       </td>",
"       <td class=\"subtitle1\">",
"        Female",
"       </td>",
"       <td class=\"subtitle1\">",
"        All",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         1998",
"        </strong>",
"       </td>",
"       <td class=\"centered\">",
"        24.7",
"       </td>",
"       <td class=\"centered\">",
"        17.5",
"       </td>",
"       <td class=\"centered\">",
"        20.7",
"       </td>",
"       <td class=\"centered\">",
"        28.8",
"       </td>",
"       <td class=\"centered\">",
"        21.0",
"       </td>",
"       <td class=\"centered\">",
"        19.6",
"       </td>",
"       <td class=\"centered\">",
"        20.7",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         1999",
"        </strong>",
"       </td>",
"       <td class=\"centered\">",
"        21.7",
"       </td>",
"       <td class=\"centered\">",
"        18.2",
"       </td>",
"       <td class=\"centered\">",
"        17.7",
"       </td>",
"       <td class=\"centered\">",
"        23.7",
"       </td>",
"       <td class=\"centered\">",
"        19.0",
"       </td>",
"       <td class=\"centered\">",
"        17.2",
"       </td>",
"       <td class=\"centered\">",
"        18.6",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         2000",
"        </strong>",
"       </td>",
"       <td class=\"centered\">",
"        22.0",
"       </td>",
"       <td class=\"centered\">",
"        14.0",
"       </td>",
"       <td class=\"centered\">",
"        16.7",
"       </td>",
"       <td class=\"centered\">",
"        19.1",
"       </td>",
"       <td class=\"centered\">",
"        16.5",
"       </td>",
"       <td class=\"centered\">",
"        16.9",
"       </td>",
"       <td class=\"centered\">",
"        16.6",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         2001",
"        </strong>",
"       </td>",
"       <td class=\"centered\">",
"        20.9",
"       </td>",
"       <td class=\"centered\">",
"        15.2",
"       </td>",
"       <td class=\"centered\">",
"        16.9",
"       </td>",
"       <td class=\"centered\">",
"        20.0",
"       </td>",
"       <td class=\"centered\">",
"        16.7",
"       </td>",
"       <td class=\"centered\">",
"        18.3",
"       </td>",
"       <td class=\"centered\">",
"        17.1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         2002",
"        </strong>",
"       </td>",
"       <td class=\"centered\">",
"        21.5",
"       </td>",
"       <td class=\"centered\">",
"        14.1",
"       </td>",
"       <td class=\"centered\">",
"        14.9",
"       </td>",
"       <td class=\"centered\">",
"        14.3",
"       </td>",
"       <td class=\"centered\">",
"        15.3",
"       </td>",
"       <td class=\"centered\">",
"        14.6",
"       </td>",
"       <td class=\"centered\">",
"        15.2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         2003",
"        </strong>",
"       </td>",
"       <td class=\"centered\">",
"        16.4",
"       </td>",
"       <td class=\"centered\">",
"        12.2",
"       </td>",
"       <td class=\"centered\">",
"        15.9",
"       </td>",
"       <td class=\"centered\">",
"        17.0",
"       </td>",
"       <td class=\"centered\">",
"        15.4",
"       </td>",
"       <td class=\"centered\">",
"        14.2",
"       </td>",
"       <td class=\"centered\">",
"        15.2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         2004",
"        </strong>",
"       </td>",
"       <td class=\"centered\">",
"        15.4",
"       </td>",
"       <td class=\"centered\">",
"        13.8",
"       </td>",
"       <td class=\"centered\">",
"        14.1",
"       </td>",
"       <td class=\"centered\">",
"        20.0",
"       </td>",
"       <td class=\"centered\">",
"        14.7",
"       </td>",
"       <td class=\"centered\">",
"        15.6",
"       </td>",
"       <td class=\"centered\">",
"        14.9",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         2005",
"        </strong>",
"       </td>",
"       <td class=\"centered\">",
"        15.9",
"       </td>",
"       <td class=\"centered\">",
"        13.6",
"       </td>",
"       <td class=\"centered\">",
"        13.6",
"       </td>",
"       <td class=\"centered\">",
"        15.0",
"       </td>",
"       <td class=\"centered\">",
"        13.8",
"       </td>",
"       <td class=\"centered\">",
"        14.7",
"       </td>",
"       <td class=\"centered\">",
"        14.0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         2006",
"        </strong>",
"       </td>",
"       <td class=\"centered\">",
"        15.5",
"       </td>",
"       <td class=\"centered\">",
"        13.7",
"       </td>",
"       <td class=\"centered\">",
"        14.6",
"       </td>",
"       <td class=\"centered\">",
"        16.9",
"       </td>",
"       <td class=\"centered\">",
"        14.9",
"       </td>",
"       <td class=\"centered\">",
"        14.6",
"       </td>",
"       <td class=\"centered\">",
"        14.8",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         2007",
"        </strong>",
"       </td>",
"       <td class=\"centered\">",
"        12.3",
"       </td>",
"       <td class=\"centered\">",
"        13.2",
"       </td>",
"       <td class=\"centered\">",
"        13.1",
"       </td>",
"       <td class=\"centered\">",
"        16.2",
"       </td>",
"       <td class=\"centered\">",
"        13.7",
"       </td>",
"       <td class=\"centered\">",
"        12.6",
"       </td>",
"       <td class=\"centered\">",
"        13.5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         2008",
"        </strong>",
"       </td>",
"       <td class=\"centered\">",
"        16.2",
"       </td>",
"       <td class=\"centered\">",
"        13.3",
"       </td>",
"       <td class=\"centered\">",
"        14.6",
"       </td>",
"       <td class=\"centered\">",
"        18.2",
"       </td>",
"       <td class=\"centered\">",
"        15.0",
"       </td>",
"       <td class=\"centered\">",
"        14.8",
"       </td>",
"       <td class=\"centered\">",
"        15.0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         2009",
"        </strong>",
"       </td>",
"       <td class=\"centered\">",
"        12.6",
"       </td>",
"       <td class=\"centered\">",
"        13.1",
"       </td>",
"       <td class=\"centered\">",
"        13.1",
"       </td>",
"       <td class=\"centered\">",
"        17.3",
"       </td>",
"       <td class=\"centered\">",
"        13.8",
"       </td>",
"       <td class=\"centered\">",
"        13.4",
"       </td>",
"       <td class=\"centered\">",
"        13.7",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <p>",
"     Mortality rates listed as deaths per 100 wait-list years.",
"    </p>",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Organ Procurement and Transplantation Network (OPTN) and Scientific Registry of Transplant Recipients (SRTR). OPTN / SRTR 2010 Annual Data Report. Department of Health and Human Services, Health Resources and Services Administration, Healthcare Systems Bureau, Division of Transplantation, Rockville, MD: 2011.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_29_39389=[""].join("\n");
var outline_f38_29_39389=null;
var title_f38_29_39390="Microbiology CAP comprehensive testing";
var content_f38_29_39390=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F54365&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F54365&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 576px\">",
"   <div class=\"ttl\">",
"    Microbial etiology of community-acquired pneumonia in patients who underwent comprehensive testing",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 556px; height: 427px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Percentage of patients with complete samples collected (n = 38) whose case of infection was etiologically determined.",
"    <div class=\"footnotes\">",
"     <em>",
"      H. influenzae",
"     </em>",
"     :",
"     <em>",
"      Haemophilus influenzae",
"     </em>",
"     ;",
"     <em>",
"      M. catarrhalis",
"     </em>",
"     :",
"     <em>",
"      Moraxella catarrhalis",
"     </em>",
"     ;",
"     <em>",
"      M. pneumoniae",
"     </em>",
"     :",
"     <em>",
"      Mycoplasma pneumoniae",
"     </em>",
"     ;",
"     <em>",
"      N. cyriacigeorgica",
"     </em>",
"     :",
"     <em>",
"      Nocardia cyriacigeorgica",
"     </em>",
"     ; RSV: respiratory syncytial virus;",
"     <em>",
"      S. pneumoniae",
"     </em>",
"     :",
"     <em>",
"      Streptococcus pneumoniae",
"     </em>",
"     .",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: Johansson N, Kalin M, Tiveljung-Lindell A, et al. Etiology of Community-Acquired Pneumonia: Increased Microbiological Yield with new Diagnostic Methods. Clin Infect Dis 2010; 50:202, by permission of Oxford University Press. Copyright &copy; 2010.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_29_39390=[""].join("\n");
var outline_f38_29_39390=null;
var title_f38_29_39391="Abdom incisions PI";
var content_f38_29_39391=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F55363&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F55363&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 515px\">",
"   <div class=\"ttl\">",
"    Incisions for abdominal hysterectomy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 495px; height: 361px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_29_39391=[""].join("\n");
var outline_f38_29_39391=null;
